
<html lang="en"     class="pb-page"  data-request-id="6c8f3318-c35e-4f62-952e-8a0ee3453eef"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm400463q;issue:issue:10.1021/jmcmar.2013.56.issue-11;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer" /></meta><meta name="dc.Creator" content="Chun  Han" /></meta><meta name="dc.Creator" content="Zhangjian  Huang" /></meta><meta name="dc.Creator" content="Chao  Zheng" /></meta><meta name="dc.Creator" content="Ledong  Wan" /></meta><meta name="dc.Creator" content="Lianwen  Zhang" /></meta><meta name="dc.Creator" content="Sixun  Peng" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Creator" content="Hongbin  Ji" /></meta><meta name="dc.Creator" content="Jide  Tian" /></meta><meta name="dc.Creator" content="Yihua  Zhang" /></meta><meta name="dc.Description" content="A series of hybrids (12a–k) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of ..." /></meta><meta name="Description" content="A series of hybrids (12a–k) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 24, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400463q" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400463q" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400463q" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400463q" /></link>
        
    
    

<title>Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400463q" /></meta><meta property="og:title" content="Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0007.jpeg" /></meta><meta property="og:description" content="A series of hybrids (12a–k) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of non-small-cell lung cancer (NSCLC). Compound 12k exhibited strong and selective EGFR L858R/T790M inhibitory activity (IC50 = 0.047 μM) and displayed antiproliferative effects on EGFR mutation NSCLC cell lines HCC827 (del E746_A750) and H1975 (L858R/T790M) with IC50 values of 0.007 and 0.029 μM, respectively. Additionally, 12k released high levels of NO in H1975 cells but not in normal human cells, and its activity was diminished by pretreatment with a NO scavenger. Furthermore, 12k induced apoptosis of H1975 and HCC827 cells more strongly than WZ4002 (1), inhibited EGFR downstream signaling in H1975 cells, and suppressed the nuclear factor-κB activation in H1975 cells, while 1 had no significant effects under the same conditions. Finally, 12k substantially inhibited tumor growth in an H1975 xenograft mouse model. Overall, 12k might be a promising candidate for the treatment of NSCLC." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400463q"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400463q">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400463q&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400463q&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400463q&amp;href=/doi/10.1021/jm400463q" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4738-4748</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400458q" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm400479p" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun++Han">Chun Han</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhangjian++Huang">Zhangjian Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Zheng">Chao Zheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ledong++Wan">Ledong Wan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lianwen++Zhang">Lianwen Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sixun++Peng">Sixun Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hongbin++Ji">Hongbin Ji</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jide++Tian">Jide Tian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yihua++Zhang">Yihua Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>State Key Laboratory of Natural Medicines and <sup>‡</sup>Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, People’s Republic of China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, People’s Republic of China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∥</span> <span class="aff-text">Key Laboratory of Regenerative Biology and Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, People’s Republic of China</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">⊥</span> <span class="aff-text">Department of Molecular and Medical Pharmacology, University of California—Los Angeles, Los Angeles, California 90095, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +86-25-83271015 (Y.Z.); +86-21-54921108 (H.J.); +86-20-32015276 (K.D.). Fax: +86-25-83271015 (Y.Z.); +86-21-54921101 (H.J.); +86-20-32015299 (K.D.). E-mail: <a href="/cdn-cgi/l/email-protection#52282b3a263536126364617c313d3f"><span class="__cf_email__" data-cfemail="d2a8abbaa6b5b692e3e4e1fcb1bdbf">[email protected]</span></a> (Y.Z.); <a href="/cdn-cgi/l/email-protection#6a020800032a19030819440b09440904"><span class="__cf_email__" data-cfemail="0169636b6841726863722f60622f626f">[email protected]</span></a> (H.J.); <a href="/cdn-cgi/l/email-protection#2b4f42454c74404e6b4c424943054a48054845"><span class="__cf_email__" data-cfemail="c3a7aaada49ca8a683a4aaa1abeda2a0eda0ad">[email protected]</span></a> (K.D.).</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400463q&amp;href=/doi/10.1021%2Fjm400463q" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4738–4748</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 13, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 March 2013</li><li><span class="item_label"><b>Published</b> online</span>24 May 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 June 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400463q" title="DOI URL">https://doi.org/10.1021/jm400463q</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4738%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChun%2BHan%252C%2BZhangjian%2BHuang%252C%2BChao%2BZheng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D11%26contentID%3Djm400463q%26title%3DNovel%2BHybrids%2Bof%2B%2528Phenylsulfonyl%2529furoxan%2Band%2BAnilinopyrimidine%2Bas%2BPotent%2Band%2BSelective%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitors%2Bfor%2BIntervention%2Bof%2BNon-Small-Cell%2BLung%2BCancer%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4748%26publicationDate%3DJune%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400463q"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2919</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">42</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400463q" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chun&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Zhangjian&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Ledong&quot;,&quot;last_name&quot;:&quot;Wan&quot;},{&quot;first_name&quot;:&quot;Lianwen&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Sixun&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Hongbin&quot;,&quot;last_name&quot;:&quot;Ji&quot;},{&quot;first_name&quot;:&quot;Jide&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Yihua&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;4738-4748&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400463q&quot;},&quot;abstract&quot;:&quot;A series of hybrids (12a–k) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of non-small-cell lung cancer (NSCLC). Compound 12k exhibited strong and selective EGFR L858R/T790M inhibitory activity (IC50 = 0.047 μM) and displayed antiproliferative effects on EGFR mutation NSCLC cell lines HCC827 (del E746_A750) and H1975 (L858R/T790M) with IC50 values of 0.007 and 0.029 μM, respectively. Additionally, 12k released high levels of NO in H1975 cells but not in normal human cells, and its activity was diminished by pretreatment with a NO scavenger. Furthermore, 12k induced apoptosis of H1975 and HCC827 cells more strongly than WZ4002 (1), inhibited EGFR downstream signaling in H1975 cells, and suppressed the nuclear factor-κB activation in H1975 cells, while 1 had no significant effects under the same conditions. Finally, 12k substantially inhibited tumor growth in an H1975 xenograft mouse model. Ov&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400463q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400463q" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400463q&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400463q" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400463q&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400463q" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400463q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400463q&amp;href=/doi/10.1021/jm400463q" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400463q" /></input><a href="/doi/pdf/10.1021/jm400463q" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400463q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400463q%26sid%3Dliteratum%253Aachs%26pmid%3D23668441%26genre%3Darticle%26aulast%3DHan%26date%3D2013%26atitle%3DNovel%2BHybrids%2Bof%2B%2528Phenylsulfonyl%2529furoxan%2Band%2BAnilinopyrimidine%2Bas%2BPotent%2Band%2BSelective%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitors%2Bfor%2BIntervention%2Bof%2BNon-Small-Cell%2BLung%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D11%26spage%3D4738%26epage%3D4748%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jmcmar.2013.56.issue-11/production/jmcmar.2013.56.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of hybrids (<b>12a</b>–<b>k</b>) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of non-small-cell lung cancer (NSCLC). Compound <b>12k</b> exhibited strong and selective EGFR L858R/T790M inhibitory activity (IC<sub>50</sub> = 0.047 μM) and displayed antiproliferative effects on EGFR mutation NSCLC cell lines HCC827 (del E746_A750) and H1975 (L858R/T790M) with IC<sub>50</sub> values of 0.007 and 0.029 μM, respectively. Additionally, <b>12k</b> released high levels of NO in H1975 cells but not in normal human cells, and its activity was diminished by pretreatment with a NO scavenger. Furthermore, <b>12k</b> induced apoptosis of H1975 and HCC827 cells more strongly than WZ4002 (<b>1</b>), inhibited EGFR downstream signaling in H1975 cells, and suppressed the nuclear factor-κB activation in H1975 cells, while <b>1</b> had no significant effects under the same conditions. Finally, <b>12k</b> substantially inhibited tumor growth in an H1975 xenograft mouse model. Overall, <b>12k</b> might be a promising candidate for the treatment of NSCLC.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The epidermal growth factor receptor (EGFR) is an important mediator responsible for cell proliferation, survival, adhesion, migration, and differentiation through downstream signaling pathway activation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Dysregulation of EGFR caused by overexpression or mutation contributes to malignant transformation<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and is correlated with poor prognosis in a number of cancers, including lung cancer,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> anal cancer,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and glioblastoma multiforme.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These features make EGFR a good target for intervention of tumor.</div><div class="NLM_p">Lung cancer is the leading cause of death from cancer worldwide, with five-year survival of less than 15%.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Non-small-cell lung cancer (NSCLC) accounts for approximately 80–85% of lung cancers.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Overexpression of EGFR is found in the majority of NSCLCs,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and EGFR mutations occur in about 10% of NSCLC patients in the Caucasian population and 30–50% of NSCLC patients from East Asian populations.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Therefore, inhibition of EGFR has been recognized as an attractive strategy for the treatment of NSCLC and validated in preclinical and clinical trials.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">Gefitinib<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and erlotinib<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), as first-generation ATP-competitive and reversible EGFR inhibitors, were effective for NSCLC patients harboring somatic EGFR mutations L858R and delE746_A750, which account for 90% of all EGFR mutations in NSCLC.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Unfortunately, due to acquired secondary mutations such as T790M missense in EGFR, leading to drug resistance in roughly 50% NSCLC patients, the ability of these EGFR inhibitors to effectively treat NSCLC patients is short-lived to subsequent treatments.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> EGFR T790M mutation restores the affinity for ATP similar to that of wild-type (WT) EGFR and prevents the reversible inhibitors from binding at higher ATP concentrations.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative reversible and irreversible EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Second-generation EGFR inhibitors such as canertinib,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> afatinib,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> neratinib,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and dacomitinib<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) have been developed with the intent to overcome T790M mutation related resistance.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The molecules of these inhibitors are built on the basis of a quinazoline or quinoline core scaffold such as gefitinib and erlotinib, but contain an electrophilic functionality that can undergo a Micheal addition reaction with a conserved cysteine residue present in EGFR (Cys797) to achieve occupancy greater than that of the reversible inhibitors.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> However, since the ATP affinity of EGFR T790M is similar to that of WT EGFR, these EGFR inhibitors at the concentrations required to inhibit EGFR T790M will also effectively inhibit WT EGFR, leading to dose-limiting toxicity such as diarrhea and skin rash. Therefore, the clinical application of these inhibitors has been limited, especially in patients with gefitinib- or erlotinib-resistant NSCLC.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20">(17-20)</a></div><div class="NLM_p">Recently, Gray et al. documented a novel series of substituted anilinopyrimidines as irreversible EGFR inhibitors, which display good selectivity against the EGFR T790M mutant over the WT EGFR.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The representative compound WZ4002<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (<b>1</b>) shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a> is 30–100-fold more potent against EGFR T790M but up to 100-fold less potent against WT EGFR than irreversible quinazoline-based inhibitors in vitro and efficacious in murine cancer models of T790M. Accordingly, the anilinopyrimidine is supposed to be an attracting scaffold for the design of small-molecule inhibitors against EGFR mutants.</div><div class="NLM_p">Nitric oxide (NO) as a signaling and/or effector molecule plays a pivotal role in diverse physiological and pathophysiological processes.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> It is well-known that high levels of NO generated from NO donors can not only induce apoptosis and inhibit metastasis of tumor cells, but also sensitize tumor cells to chemotherapy, radiation, and immunotherapy in vitro and in vivo<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> by inhibiting nuclear factor-κB (NF-κB), hypoxia-inducible factor-1α (HIF-1α), DNA repair enzymes, and drug efflux transporters, etc.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> As reported, NF-κB activation can suppress the apoptotic potential of chemotherapeutic agents and contributes to resistance,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> whereas NO exerts negative feedback on iNOS expression by inhibiting the degradation of IκB (also known as NFKBIA), thus preventing NF-κB activation.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> It has also been reported that suppressing NF-κB can improve the response of NSCLC harboring EGFR mutations to EGFR inhibitors.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p last">As an important class of NO donors, furoxans are able to produce high levels of NO in vitro and inhibit the growth of tumors in vivo.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Our group has developed a variety of (phenylsulfonyl)furoxan-based NO-releasing compounds that exhibited selective antitumor activity in vitro and in vivo.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33-35)</a> On the basis of these investigations, we hypothesized that hybridization of such furoxan with anilinopyrimidine may release high levels of NO to exert synergistic anti-NSCLC effects with anilinopyrimidine. To test this hypothesis, a series of hybrids (<b>12a</b>–<b>k</b>) from (phenylsulfonyl)furoxan and anilinopyrimidine were designed and synthesized. Their EGFR kinase inhibitory activity, in vitro anti-NSCLC and apoptosis inductive activities, NO-releasing ability, in vivo antitumor activity, and mechanism of action underlying their anticancer activities were biologically evaluated.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76661" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76661" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">Synthesis of compounds <b>12a</b>–<b>k</b> is illustrated in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Phenylpiperazine <b>2</b> was prepared by amination at the 5-position of 5-fluoro-2-nitrophenyl methyl ether according to ref <a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">36</a>, followed by treatment with ethyl bromoacetate to give ester <b>3</b>. Then the nitro group of <b>3</b> was reduced to yield arylamine <b>4</b>. Meanwhile, aryl ether <b>6</b> was obtained by regioselective coupling of 3-nitrophenol (<b>5</b>) to the 4-position of 2,4,5-trichloropyrimidine. Subsequent reduction of the nitro group of <b>6</b> afforded arylamine <b>7</b>. Acylation of the amino group of <b>7</b> led to acrylamide <b>8</b>. Coupling of <b>4</b> with <b>8</b> in the presence of trifluoroacetic acid offered anilinopyrimidine <b>9</b>, which was converted to the corresponding acid <b>10</b> by hydrolysis. Finally, condensation of <b>10</b> with various mono(phenylsulfonyl)furoxans <b>11a</b>–<b>k</b>, synthesized in a four-step sequence as described previously by us,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> provided the target compounds <b>12a</b>–<b>k</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of <b>12a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) piperazine, dioxane, reflux, overnight, 97%; (b) ethyl bromoacetate, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 4 h, 90%; (c) iron powder, NH<sub>4</sub>Cl, THF/H<sub>2</sub>O (1:1, v/v), reflux, 3 h, 99% for <b>4</b>, 80% for <b>7</b>; (d) 2,4,5-trichloropyrimidine, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h, 95%; (e) acryloyl chloride, Et<sub>3</sub>N, anhydrous CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 1 h, 90%; (f) TFA, 2-BuOH, reflux, 3 h, 80%; (g) LiOH, THF/H<sub>2</sub>O (1:1, v/v), 0 °C, 1 h, 98%; (h) <b>11a</b>–<b>k</b>, DCC/DMAP, anhydrous CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight, 70%–85%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Kinase Inhibitory Activity</h3><div class="NLM_p">The inhibitory activity of the target compounds <b>12a</b>–<b>k</b> against two mutant EGFRs (L858R and L858R/T790M) and WT EGFR were evaluated using a well-established FRET-based Z’-Lyte assay,<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> with gefitinib and <b>1</b> employed as positive controls. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, all compounds, as <b>1</b> did, suppressed EGFR L858R/T790M more selectively (IC<sub>50</sub> = 0.006–0.047 μM) relative to WT EGFR (IC<sub>50</sub> = 0.039–0.292 μM) and EGFR L858R (IC<sub>50</sub> = 0.040–0.305 μM). Although less potent than <b>1</b> (IC<sub>50</sub> = 0.0008 μM), these compounds were more active than gefitinib (IC<sub>50</sub> = 0.941 μM) against EGFR L858R/T790M.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Enzymatic Inhibitory Activities of <b>12a</b>–<b>k</b> against Different Statuses of EGFR</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">EGFR IC<sub>50</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">L858R</th><th class="colsep0 rowsep0" align="center" char="±">L858R/T790M</th><th class="colsep0 rowsep0" align="center" char="±">WT</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="char" char="±">0.0002 ± 0.0001</td><td class="colsep0 rowsep0" align="char" char="±">0.941 ± 0.073</td><td class="colsep0 rowsep0" align="char" char="±">0.0001 ± 0.0002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">0.0054 ± 0.0008</td><td class="colsep0 rowsep0" align="char" char="±">0.0008 ± 0.0001</td><td class="colsep0 rowsep0" align="char" char="±">0.0032 ± 0.0006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.063 ± 0.009</td><td class="colsep0 rowsep0" align="char" char="±">0.014 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">0.051 ± 0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.068 ± 0.014</td><td class="colsep0 rowsep0" align="char" char="±">0.013 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.059 ± 0.022</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.040 ± 0.0004</td><td class="colsep0 rowsep0" align="char" char="±">0.006 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.039 ± 0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.066 ± 0.013</td><td class="colsep0 rowsep0" align="char" char="±">0.013 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.042 ± 0.013</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.099 ± 0.004</td><td class="colsep0 rowsep0" align="char" char="±">0.020 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.073 ± 0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.083 ± 0.035</td><td class="colsep0 rowsep0" align="char" char="±">0.017 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.059 ± 0.016</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12g</b></td><td class="colsep0 rowsep0" align="char" char="±">0.098 ± 0.010</td><td class="colsep0 rowsep0" align="char" char="±">0.023 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">0.099 ± 0.007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12h</b></td><td class="colsep0 rowsep0" align="char" char="±">0.189 ± 0.011</td><td class="colsep0 rowsep0" align="char" char="±">0.038 ± 0.001</td><td class="colsep0 rowsep0" align="char" char="±">0.174 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12i</b></td><td class="colsep0 rowsep0" align="char" char="±">0.064 ± 0.009</td><td class="colsep0 rowsep0" align="char" char="±">0.016 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">0.052 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12j</b></td><td class="colsep0 rowsep0" align="char" char="±">0.113 ± 0.005</td><td class="colsep0 rowsep0" align="char" char="±">0.030 ± 0.004</td><td class="colsep0 rowsep0" align="char" char="±">0.101 ± 0.013</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.305 ± 0.008</td><td class="colsep0 rowsep0" align="char" char="±">0.047 ± 0.006</td><td class="colsep0 rowsep0" align="char" char="±">0.292 ± 0.018</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">EGFR activity assays were performed using the FRET-based Z’-Lyte assay according to the manufacturer’s instructions. The compounds were incubated with the kinase reaction mixture for 1.5 h before measurement. The data are the mean ± SD of three independent experiments.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Inhibitory Activity on Gefitinib-Sensitive HCC827 and Gefitinib-Resistant H1975 Cells</h3><div class="NLM_p">The antiproliferative effects of <b>12a</b>–<b>k</b> on EGFR mutation NSCLC cell lines, gefitinib-sensitive HCC827 bearing EGFR del E746_A750, and gefitinib-resistant H1975 harboring EGFR L858R/T790M were next determined by an MTT assay with gefitinib and <b>1</b> as controls. As can be seen in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, all the compounds except <b>12c</b> (IC<sub>50</sub> = 0.291 μM) were potent in inhibition of HCC827 cells (IC<sub>50</sub> = 0.006–0.041 μM). Compounds <b>12a</b>, <b>12f</b>, <b>12h</b>, <b>12i</b>, and <b>12k</b> (IC<sub>50</sub> = 0.009, 0.007, 0.006, 0.010, and 0.007 μM, respectively) showed inhibition comparable to those of gefitinib (IC<sub>50</sub> = 0.006 μM) and <b>1</b> (IC<sub>50</sub> = 0.008 μM) on HCC827 cells. Additionally, consistent with their kinase inhibition, most of these compounds displayed higher antiproliferative activity on H1975 cells (IC<sub>50</sub> = 0.029–2.017 μM) than gefitinib (IC<sub>50</sub> = 6.917 μM). In general, esters <b>12f</b>–<b>k</b> exhibited better inhibitory effects than amides <b>12a</b>–<b>e</b> against H1975 cells, among which <b>12f</b>, <b>12h</b>, <b>12i</b>, and <b>12k</b> (IC<sub>50</sub> = 0.063, 0.069, 0.043, and 0.029 μM, respectively) were as potent as <b>1</b> (IC<sub>50</sub> = 0.046 μM). Taken together, compounds <b>12f</b>, <b>12h</b>, <b>12i</b>, and <b>12k</b> were potent to inhibit both gefitinib-sensitive HCC827 and gefitinib-resistant H1975 cell lines.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferative Activities of <b>12a</b>–<b>k</b> against Cells Harboring a Different Status of EGFR</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char="±">IC<sub>50</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">HCC827<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">H1975<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">A549<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">A431<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">BEAS-2B<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char="±">16HBE<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="char" char="±">0.006 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">6.917 ± 0.657</td><td class="colsep0 rowsep0" align="left">15.58 ± 2.143</td><td class="colsep0 rowsep0" align="left">4.485 ± 0.295</td><td class="colsep0 rowsep0" align="left">13.94 ± 1.992</td><td class="colsep0 rowsep0" align="char" char="±">12.71 ± 3.675</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">0.008 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.046 ± 0.011</td><td class="colsep0 rowsep0" align="left">2.102 ± 0.584</td><td class="colsep0 rowsep0" align="left">1.108 ± 0.213</td><td class="colsep0 rowsep0" align="left">1.811 ± 0.253</td><td class="colsep0 rowsep0" align="char" char="±">1.355 ± 0.321</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="char" char="±">0.009 ± 0.005</td><td class="colsep0 rowsep0" align="char" char="±">2.017 ± 0.283</td><td class="colsep0 rowsep0" align="left">2.259 ± 0.681</td><td class="colsep0 rowsep0" align="left">0.736 ± 0.088</td><td class="colsep0 rowsep0" align="left">1.531 ± 0.129</td><td class="colsep0 rowsep0" align="char" char="±">1.551 ± 0.573</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.021 ± 0.011</td><td class="colsep0 rowsep0" align="char" char="±">1.027 ± 0.375</td><td class="colsep0 rowsep0" align="left">2.484 ± 0.795</td><td class="colsep0 rowsep0" align="left">0.357 ± 0.067</td><td class="colsep0 rowsep0" align="left">2.445 ± 0.302</td><td class="colsep0 rowsep0" align="char" char="±">2.275 ± 0.990</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.291 ± 0.014</td><td class="colsep0 rowsep0" align="char" char="±">0.311 ± 0.136</td><td class="colsep0 rowsep0" align="left">2.118 ± 0.485</td><td class="colsep0 rowsep0" align="left">0.609 ± 0.153</td><td class="colsep0 rowsep0" align="left">1.893 ± 0.213</td><td class="colsep0 rowsep0" align="char" char="±">1.480 ± 0.742</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.033 ± 0.012</td><td class="colsep0 rowsep0" align="char" char="±">0.855 ± 0.218</td><td class="colsep0 rowsep0" align="left">4.249 ± 1.020</td><td class="colsep0 rowsep0" align="left">0.701 ± 0.098</td><td class="colsep0 rowsep0" align="left">2.200 ± 0.322</td><td class="colsep0 rowsep0" align="char" char="±">1.800 ± 0.593</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="char" char="±">0.038 ± 0.006</td><td class="colsep0 rowsep0" align="char" char="±">0.245 ± 0.182</td><td class="colsep0 rowsep0" align="left">1.793 ± 0.256</td><td class="colsep0 rowsep0" align="left">0.660 ± 0.050</td><td class="colsep0 rowsep0" align="left">0.988 ± 0.126</td><td class="colsep0 rowsep0" align="char" char="±">1.851 ± 0.922</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12f</b></td><td class="colsep0 rowsep0" align="char" char="±">0.007 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">0.063 ± 0.015</td><td class="colsep0 rowsep0" align="left">2.562 ± 0.082</td><td class="colsep0 rowsep0" align="left">1.232 ± 0.275</td><td class="colsep0 rowsep0" align="left">1.349 ± 0.349</td><td class="colsep0 rowsep0" align="char" char="±">2.043 ± 0.379</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12g</b></td><td class="colsep0 rowsep0" align="char" char="±">0.022 ± 0.005</td><td class="colsep0 rowsep0" align="char" char="±">0.396 ± 0.029</td><td class="colsep0 rowsep0" align="left">2.927 ± 0.265</td><td class="colsep0 rowsep0" align="left">1.059 ± 0.364</td><td class="colsep0 rowsep0" align="left">2.982 ± 0.622</td><td class="colsep0 rowsep0" align="char" char="±">2.584 ± 0.290</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12h</b></td><td class="colsep0 rowsep0" align="char" char="±">0.006 ± 0.004</td><td class="colsep0 rowsep0" align="char" char="±">0.069 ± 0.014</td><td class="colsep0 rowsep0" align="left">17.23 ± 1.123</td><td class="colsep0 rowsep0" align="left">4.067 ± 0.986</td><td class="colsep0 rowsep0" align="left">2.561 ± 0.528</td><td class="colsep0 rowsep0" align="char" char="±">4.153 ± 1.533</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12i</b></td><td class="colsep0 rowsep0" align="char" char="±">0.010 ± 0.002</td><td class="colsep0 rowsep0" align="char" char="±">0.043 ± 0.008</td><td class="colsep0 rowsep0" align="left">5.528 ± 0.561</td><td class="colsep0 rowsep0" align="left">3.500 ± 1.310</td><td class="colsep0 rowsep0" align="left">0.959 ± 0.152</td><td class="colsep0 rowsep0" align="char" char="±">2.615 ± 1.112</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12j</b></td><td class="colsep0 rowsep0" align="char" char="±">0.041 ± 0.018</td><td class="colsep0 rowsep0" align="char" char="±">0.471 ± 0.165</td><td class="colsep0 rowsep0" align="left">4.447 ± 1.280</td><td class="colsep0 rowsep0" align="left">3.023 ± 1.203</td><td class="colsep0 rowsep0" align="left">2.944 ± 1.226</td><td class="colsep0 rowsep0" align="char" char="±">3.155 ± 1.905</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12k</b></td><td class="colsep0 rowsep0" align="char" char="±">0.007 ± 0.004</td><td class="colsep0 rowsep0" align="char" char="±">0.029 ± 0.006</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">5.666 ± 0.336</td><td class="colsep0 rowsep0" align="left">44.65 ± 3.221</td><td class="colsep0 rowsep0" align="char" char="±">23.86 ± 2.098</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11k</b></td><td class="colsep0 rowsep0" align="char" char="±">4.294 ± 0.980</td><td class="colsep0 rowsep0" align="char" char="±">5.931 ± 0.488</td><td class="colsep0 rowsep0" align="left">23.56 ± 3.119</td><td class="colsep0 rowsep0" align="left">3.378 ± 0.558</td><td class="colsep0 rowsep0" align="left">1.240 ± 0.405</td><td class="colsep0 rowsep0" align="char" char="±">3.401 ± 0.796</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char="±">0.100 ± 0.027</td><td class="colsep0 rowsep0" align="char" char="±">1.514 ± 0.197</td><td class="colsep0 rowsep0" align="left">1.451 ± 0.173</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="char" char="±">0.707 ± 0.097</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The inhibitory effects of individual compounds on the proliferation of cancer cell lines were determined by the MTT assay. The data are the mean ± SD from at least three independent experiments.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">HCC827 is a human lung cancer cell line (EGFR del E746_A750).</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">H1975 is a human lung cancer cell line (EGFR L858R/T790M).</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">A549 is a human lung cancer cell line (WT EGFR/k-RAS-dependent).</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">A431 is a human epithelial carcinoma cell line (overexpressed WT EGFR).</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">BEAS-2B and 16HBE are normal human bronchial epithelial cell lines.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Effects on the Cell Lines Harboring WT EGFR</h3><div class="NLM_p last">To examine how the target compounds affected WT EGFR, we investigated the effects of these compounds on the cell lines harboring WT EGFR, including NSCLC cells A549 possessing WT EGFR and k-Ras mutation, human epithelial carcinoma cells A431 with overexpressed WT EGFR, and human normal bronchial epithelial cell lines BEAS-2B and 16HBE harboring WT EGFR. It can be seen from Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> that compounds <b>12a</b>–<b>k</b> displayed much less inhibition on the growth of the cell lines harboring WT EGFR than inhibition on H1975 and HCC827 cells. For instance, the active compounds <b>12h</b> and <b>12k</b> exhibited 60–7200-fold weaker antiproliferative activity on A549 cells (IC<sub>50</sub> = 17.23 and >50 μM) and A431 cells (IC<sub>50</sub> = 4.067 and 5.666 μM), respectively, than their inhibition against the H1975 and HCC827 cells, suggesting that these compounds might possess a good selectivity against NSCLC cells with EGFR mutants over the other cancer cells. In addition, <b>12h</b> and <b>12k</b> also showed 40–6400-fold less inhibition on human normal cells BEAS-2B (IC<sub>50</sub> = 2.561 and 44.65 μM) and 16HBE (IC<sub>50</sub> = 4.153 and 23.86 μM), respectively, than inhibition on the H1975 and HCC827 cells, suggesting the safety profile of these compounds. Notably, <b>12k</b> was 5–25-fold less active against the cell lines harboring WT EGFR than <b>1</b>, suggesting <b>12k</b> might be a potent and selective inhibitor for EGFR mutations.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Effects of NO on Antiproliferative Activity</h3><div class="NLM_p">Compounds <b>9</b> and <b>11k</b> are anilinopyrimidine and furoxan moieties of <b>12k</b>, and their inhibitory effects on HCC827 and H1975 cells were examined, respectively. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, both <b>9</b> (IC<sub>50</sub> = 0.100 and 1.514 μM) and <b>11k</b> (IC<sub>50</sub> = 4.294 and 5.931 μM) exhibited inhibitory activity but were much less potent than <b>12k</b> (IC<sub>50</sub> = 0.007 and 0.029 μM), respectively. These results suggest that the antiproliferative activity of <b>12k</b> might be attributed to the synergic effects of anilinopyrimidine and NO donor moieties.</div><div class="NLM_p">To verify the contribution of NO to the inhibitory activity, the levels of NO released by the tested compounds in vitro were detected. NSCLC cells H1975 and normal human bronchial epithelial cells 16HBE were respectively exposed to 100 μM <b>12a</b>, <b>12c</b>, <b>12e</b>, <b>12i</b>–<b>k</b>, <b>11k</b>, and <b>1</b> for the same incubation time. The levels of NO generated in the cell lysates were determined and presented as that of nitrite (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A) using a Griess assay.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> As expected, treatment with <b>1</b> resulted in little nitrite in both H1975 and 16HBE cells. In contrast, treatment with the tested compounds generated variable levels of nitrite in H1975 cells. Interestingly, treatment with more active compounds such as <b>12i</b> and <b>12k</b> produced higher levels of nitrite in the cells, whereas less active compounds <b>12a</b> and <b>11k</b> produced lower levels of nitrite, indicating that the amounts of NO released by these compounds were positively correlated with their inhibitions on H1975 cells in vitro (<i>R</i> = 0.816, <i>p</i> < 0.05, determined by Pearson’s correlation analysis). It was also observed that compounds <b>12i</b>–<b>k</b> linked by an ester bond to anilinopyrimidine released higher levels of NO and exhibited better inhibitory effects than amides <b>12a</b>, <b>12c</b>, and <b>12e</b> against H1975 cells. Additionally, the ester compounds, especially <b>12k</b>, which exerted high selectivity toward EGFR L858R/T790M over WT EGFR, might have a better ability to penetrate H1975 cells harboring EGFR L858R/T790M, leading to high levels of NO released in H1975 cells but not in normal human cells 16HBE bearing WT EGFR, which is in agreement with their strong selective inhibition on proliferation of NSCLC cells harboring EGFR mutations in vitro.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of NO production by the target compounds on NSCLC cell proliferation. (A) Variable levels of NO (presented as nitrite) produced by the indicated compounds. H1975 and 16HBE cells were treated with individual compounds at 100 μM for 150 min, and the concentrations of nitrite in the cell lysates were determined by Griess assay. The individual values were determined by measuring the absorbance at 540 nm and calculated according to the standard curve. Data are expressed as the mean ± SD of each compound in individual types of cells from three experiments. Key: (**) <i>p</i> < 0.01, (***) <i>p</i> < 0.001 vs 16HBE group. (B) Effects of hemoglobin on the antiproliferative effect of <b>12k</b>. H1975 and HCC827 cells were pretreated with the indicated concentrations of hemoglobin (Hb) (0, 1, 5, 10, or 20 μM) for 1 h and treated with 1 μM <b>12k</b> for 24 h. The results are expressed as the percentage of cell growth inhibition relative to control cells. Data are the mean value ± SD obtained from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Next, <b>12k</b> was tested on its antiproliferative effects in the presence or absence of a NO scavenger, hemoglobin. H1975 and HCC827 cells were pretreated with various concentrations of hemoglobin for 1 h and then treated with 1 μM <b>12k</b>. The effects of different treatments on the growth of H1975 and HCC827 cells were determined by the MTT assay (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B). It was observed that treatment with <b>12k</b> alone remarkably inhibited the growth of H1975 and HCC827 cells and this inhibitory effect was diminished by pretreatment with hemoglobin in a dose-dependent manner. These results demonstrated that NO produced by <b>12k</b> substantially contributed to its inhibition on NSCLC cell proliferation in vitro.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Induction of Apoptosis in Vitro</h3><div class="NLM_p">Since high levels of NO act as a tumor cell apoptosis inducer,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> the ability of <b>12k</b> as a NO donor to induce tumor cell apoptosis was tested and compared with that of anilinopyrimidine compound <b>1</b>. EGFR mutant H1975 and HCC827 cells, as well as EGFR-independent H460 cells, were treated with a variable level of <b>12k</b>, <b>1</b>, or vehicle for 24 h, respectively. The cells were harvested and stained with 7-aminoactinomycin D (7-AAD) and annexin-V, and the percentages of apoptotic cells were determined by flow cytometry analysis. It was found that treatment with <b>12k</b> or <b>1</b> induced apoptosis in both H1975 and HCC827 cells in a dose-dependent manner (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), but did not induce apoptosis of the cell line H460 with little EGFR expression (see Figure S1 in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Notably, the ability of <b>12k</b> to induce apoptosis was stronger than that of <b>1</b> in both H1975 and HCC827 cells, which may be attributed to high levels of NO released by <b>12k</b>.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>12k</b> and <b>1</b> induced H1975 (A) and HCC827 (B) cell apoptosis in vitro. The cells were incubated with the indicated concentrations of <b>12k</b> or <b>1</b> for 24 h, and the cells were stained with 7-AAD and annexin-V, followed by flow cytometry analysis. The quantitative data are expressed as the mean ± SD of the percentages of apoptotic cells from three independent experiments. Key: (**) <i>p</i> < 0.01, (***) <i>p</i> < 0.001 vs <b>1</b> group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Effects on EGFR Activation and Downstream Signaling</h3><div class="NLM_p">To gain insight into the mechanisms underlying the activity of these NO-releasing EGFR inhibitors, we subsequently examined the inhibitory effects of the active compound <b>12k</b> on the EGFR activation and downstream signaling in H1975 cells harboring EGFR L858R/T790M using <b>1</b> as a control. The cells were treated with various concentrations of <b>12k</b> and <b>1</b>. The expression and activation of EGFR-related signal events AKT, ERK, and NF-κB were determined by immunoblotting, and the results are summarized in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. It was observed that treatment with <b>12k</b> significantly inhibited the phosphorylation of EGFR, AKT, and ERK in a dose-dependent manner but was less potent than <b>1</b> in H1975 cells. However, <b>12k</b> displayed obvious inhibition on phospho-NF-κB in H1975 cells, while <b>1</b> had no significant change at increased concentrations, suggesting that inhibition of NF-κB activation by <b>12k</b> partially compensated its lower inhibition on EGFR as compared to <b>1</b>, resulting in the significant activity of <b>12k</b> in the growth inhibition and apoptosis induction of the cell lines harboring EGFR mutations.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compounds <b>12k</b> and <b>1</b> inhibited the activation of EGFR and downstream signaling in H1975 NSCLC cells harboring EGFR L858R/T790M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In Vivo Antitumor Activity</h3><div class="NLM_p">Compound <b>12k</b> was further evaluated for its in vivo antitumor efficacy in an EGFR L858R/T790M-driven human NSCLC xenograft mouse model of H1975 (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Nude mice bearing established H1975 tumor xenografts were dosed intraperitoneally with <b>12k</b> (14 mg/kg) over a 14 day period. Gefitinib (16 mg/kg) and <b>1</b> (8 mg/kg) were employed as reference drugs. Relative to the vehicle controls, 14 mg/kg <b>12k</b> was well tolerated, displayed significant in vivo antitumor efficacy (<i>p</i> < 0.05), and inhibited tumor growth by 60%. Treatment with gefitinib produced only a marginal effect on tumor growth, while <b>1</b> had an inhibition rate of 69%. During the experimental period, no significant body mass loss of mice treated with <b>12k</b> was observed relative to that of the vehicle controls.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vivo antitumor effect of compound <b>12k</b> in a human NSCLC (H1975) xenograft nude mouse model. The H1975 model was resistant to gefitinib and sensitive to <b>1</b>. Tumor volumes were measured every other day. Data are shown as the mean ± SD from each group of mice (<i>n</i> = 6). Statistical significance (<i>p</i> < 0.05) for antitumor efficacy, based upon tumor growth relative to the vehicle controls.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a series of hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine (<b>12a</b>–<b>k</b>) were synthesized and biologically evaluated. All of the compounds showed strong and selective inhibitory effects toward EGFR mutant L858R/T790M as <b>1</b> did and were superior to gefitinib. These compounds also exhibited strong antiproliferative activity against HCC827 cells bearing EGFR del E746_A750 and H1975 cells harboring EGFR L858R/T790M. Among them, compounds <b>12f</b>, <b>12h</b>, <b>12i</b>, and <b>12k</b> showed inhibition on HCC827 cells comparable with those of gefitinib and <b>1</b> and were similar to <b>1</b> in the inhibition of H1975 cells. Importantly, these compounds showed lower to moderate inhibition on the cancer and normal cells with WT EGFR (A549, A431, BEAS-2B, and 16HBE cells); especially <b>12k</b> exhibited much less activity against these cell lines harboring WT EGFR than <b>1</b>. Interestingly, <b>12k</b> released much higher levels of NO in H1975 cells than that in the normal human 16HBE cells, and its antiproliferative activity in H1975 and HCC827 cells was diminished by a NO scavenger, hemoglobin, in a dose-dependent manner. In addition, <b>12k</b> induced cell apoptosis of H1975 and HCC827 cells more potently than <b>1</b>. Furthermore, <b>12k</b> inhibited EGFR activation and downstream signaling in H1975 cells and displayed considerable suppression of the NF-κB activation in H1975 cells, while <b>1</b> had no such effects under the same conditions. Moreover, <b>12k</b> exhibited significant tumor inhibition in the EGFR L858R/T790M-driven human NSCLC xenograft mouse model of H1975. All these results indicate that <b>12k</b> showed certain advantages over <b>1</b> owing to hybridization of the NO donor moiety to the anilinopyrimidine scaffold, including selectivity against the cell lines harboring mutant EGFR, and significant induction of apoptosis and inhibition of NF-κB in H1975 cells. Therefore, our novel findings provide a proof of principle in design of NO-releasing compounds as potent and selective inhibitors of EGFR for intervention of NSCLC.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26844" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26844" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p last">Melting points were measured on a Mel-TEMP II melting point apparatus without correction. <sup>1</sup>H and <sup>13</sup>C NMR spectral data were recorded with a Bruker Avance 300 MHz spectrometer at 303 K using TMS as an internal standard. MS spectra were recorded on a Mariner mass spectrometer (ESI) and HRMS spectra on an Agilent Technologies LC/MSD TOF instrument. Analytical and preparative TLC was performed on silica gel GF/UV 254. The chromatograms were conducted on silica gel (100–200 mesh) and visualized under UV light at 254 and 365 nm. The purities of the synthesized compounds were confirmed to be higher than 95% by HPLC analysis performed with a dual-pump Shimadzu LC-20AT system, an SIL-20A autosampler, an SPD-20A UV/vis detector, a CTO-20A column oven, and an ODS-C18 column (5 μm, 4.6 × 150 mm) and eluted with acetonitrile–water (60:40 to 70:30). Compounds <b>11a</b>–<b>k</b> were synthesized as previously described.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Ethyl 2-(4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl)acetate (<b>3</b>)</h3><div class="NLM_p last">Compound <b>2</b><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (0.5 g, 2.1 mmol), potassium carbonate (0.58 g, 4.2 mmol), and ethyl bromoacetate (0.23 mL, 2.1 mmol) were added to 20 mL of acetone, and the resulting mixture was heated to reflux for 4 h. The reaction mixture was cooled to room temperature and filtered. The filtrate was collected and concentrated in vacuo. A 0.61 g (90%) yield of the resulting yellow solid was obtained after purification by flash chromatography with 1:1 (v/v) petroleum ether–ethyl acetate (mp 76–77 °C). Analytical data for <b>3</b>: ESI-MS <i>m</i>/<i>z</i> 324 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.21 (t, 3H, OCH<sub>2</sub>C<i>H</i><sub>3</sub>, <i>J</i> = 7.11 Hz), 2.67 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.65 Hz), 3.21 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.39 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.74 Hz), 3.87 (s, 3H, OC<i>H</i><sub>3</sub>), 4.13 (q, 2H, OC<i>H</i><sub>2</sub>CH<sub>3</sub>, <i>J</i> = 7.08 Hz), 6.25 (d, 1H, ArH, <i>J</i> = 2.0 Hz), 6.33 (dd, 1H, ArH, <i>J</i> = 1.9, 9.3 Hz), 7.88 (d, 1H, ArH, <i>J</i> = 9.3 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 169.95, 156.28, 155.54, 129.39, 128.91, 105.42, 97.02, 60.72, 59.03, 56.17, 52.24, 46.94, 14.20; ESI-HRMS (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub> 324.1559, obsd 324.1563, ppm error 1.2.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Ethyl 2-(4-(4-Amino-3-methoxyphenyl)piperazin-1-yl)acetate (<b>4</b>)</h3><div class="NLM_p last">Compound <b>3</b> (0.469 g, 1.68 mmol) was dissolved in THF (50 mL) and water (50 mL). Iron powder (0.47 g, 8.4 mmol) and ammonium chloride (0.45 g, 8.4 mmol) were then added, and the resulting mixture was heated to 65 °C and stirred for 3 h. The reaction mixture was cooled to room temperature and filtered through Celite. The THF was removed in vacuo, and the resulting residue was basified with sodium bicarbonate and extracted with ethyl acetate (20 mL) three times. The organic layer was separated, dried using anhydrous sodium sulfate, concentrated, and used without further purification (yellow oil, 99% yield). Analytical data for <b>4</b>: ESI-MS <i>m</i>/<i>z</i> 294 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, <i>d</i><sub>6</sub>-DMSO) δ 2.01 (t, 3H, OCH<sub>2</sub>C<i>H</i><sub>3</sub>, <i>J</i> = 6.9 Hz), 3.45 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.5 Hz), 3.76 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.5 Hz), 4.07 (s, 2H, NC<i>H</i><sub>2</sub>CO), 4.56 (s, 3H, OC<i>H</i><sub>3</sub>), 4.92 (q, 2H, OC<i>H</i><sub>2</sub>CH<sub>3</sub>, <i>J</i> = 6.9 Hz), 5.01 (s, 2H, ArNH<sub>2</sub>), 7.11 (dd, 1H, ArH, <i>J</i> = 1.8, 8.4 Hz), 7.31 (d, 1H, ArH, <i>J</i> = 2.1 Hz), 7.36 (d, 1H, ArH, <i>J</i> = 8.4 Hz); <sup>13</sup>C NMR (75 MHz, <i>d</i><sub>6</sub>-DMSO) δ 170.36, 147.48, 143.79, 131.51, 114.70, 109.23, 102.50, 60.28, 59.01, 55.69, 52.74, 50.86, 14.59; ESI-HRMS (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> 294.1818, obsd 294.1822, ppm error 1.4.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 3-((2,5-Dichloropyrimidin-4-yl)oxy)aniline (<b>7</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>6</b>,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and the synthetic method was the same as that of compound <b>4</b> (pale yellow solid, 80% yield, mp 103–105 °C). Analytical data for <b>7</b>: ESI-MS <i>m</i>/<i>z</i> 256 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.48 (s, 1H, ArH), 6.54 (d, 1H, ArH, <i>J</i> = 8.1 Hz), 6.60 (d, 1H, ArH, <i>J</i> = 8.04 Hz), 7.20 (t, 1H, ArH, <i>J</i> = 8.07 Hz), 8.44 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, <i>d</i><sub>6</sub>-DMSO) δ 165.38, 159.34, 156.79, 152.81, 149.55, 130.53, 117.08, 113.16, 109.45, 107.43; ESI-HRMS (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup> calcd for C<sub>10</sub>H<sub>7</sub>N<sub>3</sub>OCl<sub>2</sub> 256.0044, obsd 256.0048, ppm error 1.6.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>N</i>-(3-((2,5-Dichloropyrimidin-4-yl)oxy)phenyl)acrylamide (<b>8</b>)</h3><div class="NLM_p last">Acryloyl chloride (0.257 mL, 3.18 mmol) was added dropwise to a solution of compound <b>7</b> (0.814 g, 3.18 mmol) and diisopropyethylamine (0.56 mL, 3.18 mmol) in methylene chloride (30 mL) at 0 °C. The reaction was stirred for 1 h. A 0.89 g (90%) yield of the resulting white solid was obtained after purification by flash chromatography with 2:1 (v/v) petroleum ether–ethyl acetate (mp 199–201 °C). Analytical data for <b>8</b>: ESI-MS <i>m</i>/<i>z</i> 310 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 5.79 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 10.23 Hz), 6.21 (dd, 1H, COC<i>H</i>═CH<sub>2</sub>, <i>J</i> = 10.17, 16.77 Hz), 6.44 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 16.8 Hz), 6.94 (d, 1H, ArH, <i>J</i> = 8.04 Hz), 7.30 (d, 1H, ArH, <i>J</i> = 8.16 Hz), 7.38 (t, 1H, ArH, <i>J</i> = 8.07 Hz), 7.42 (s, 1H, ArH), 7.74 (s, 1H, ArNHCO), 8.48 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, <i>d</i><sub>6</sub>-DMSO) δ 165.28, 163.85, 159.51, 156.68, 151.96, 140.89, 132.03, 130.50, 127.84, 117.66, 117.16, 116.92, 112.72; ESI-HRMS (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub>Cl<sub>2</sub> 310.0150, obsd 310.0155, ppm error 1.6.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Ethyl 2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetate (<b>9</b>)</h3><div class="NLM_p last">A flask was charged with compound <b>4</b> (196 mg, 0.70 mmol), <b>8</b> (217 mg, 0.70 mmol), TFA (0.08 mL, 1.05 mmol), and 2-BuOH (10 mL). The slurry was heated to 100 °C for 3 h. The reaction mixture was allowed to cool to room temperature and was neutralized with a saturated aqueous sodium bicarbonate solution. The aqueous mixture was then extracted with CH<sub>2</sub>Cl<sub>2</sub> (20 mL) three times. The crude product was purified using flash chromatography with 1:1 (v/v) petroleum ether–ethyl acetate to afford 260 mg of a white solid (80%) (mp 168–170 °C). Analytical data for <b>9</b>: ESI-MS <i>m</i>/<i>z</i> 565 [M – H]<sup>−</sup>, 601 [M + Cl]<sup>−</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.29 (t, 3H, OCH<sub>2</sub>C<i>H</i><sub>3</sub>, <i>J</i> = 7.14 Hz), 2.75 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.59 Hz), 3.14 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.92 Hz), 3.27 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.81 (s, 3H, OC<i>H</i><sub>3</sub>), 4.21 (q, 2H, OC<i>H</i><sub>2</sub>CH<sub>3</sub>, <i>J</i> = 7.11 Hz), 5.77 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 10.14 Hz), 6.24 (dd, 2H, COC<i>H</i>═CH<sub>2</sub> and ArH, <i>J</i> = 10.14, 16.80 Hz), 6.43 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 16.02 Hz), 6.97 (d, 1H, ArH, <i>J</i> = 8.1 Hz), 7.39–7.47 (m, 4H, 3 × ArH and ArNH), 7.63 (d, 2H, ArH and ArNHCO, <i>J</i> = 7.71 Hz), 8.22 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.27, 164.45, 163.48, 157.71, 157.47, 152.82, 148.69, 147.13, 139.02, 130.94, 129.84, 128.22, 121.76, 119.30, 118.17, 117.10, 113.90, 108.04, 100.30, 60.73, 59.46, 55.58, 53.04, 49.93, 14.26; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>28</sub>H<sub>31</sub>ClN<sub>6</sub>O<sub>5</sub> 589.1942, obsd 589.1948, ppm error 1.0.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetic Acid (<b>10</b>)</h3><div class="NLM_p last">To a solution of ethyl ester <b>9</b> (1 g, 1.76 mmol) in THF (15 mL) and water (15 mL) was added LiOH (0.723 g, 17.6 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 1 h, then cooled to 0 °C, and acidified to subacidity (pH 6–7) with dilute hydrochloric acid. The precipitate was collected and used without further purification (yellow solid, 98% yield, mp 205–207 °C). Analytical data for <b>10</b>: ESI-MS <i>m</i>/<i>z</i> 539.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, <i>d</i><sub>6</sub>-DMSO) δ 2.85 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.69 Hz), 3.15 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.52 Hz), 3.33 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.74 (s, 3H, OC<i>H</i><sub>3</sub>), 4.66 (s, 1H, ArNH), 5.77 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 9.9 Hz), 6.25 (dd, 2H, COC<i>H</i>═CH<sub>2</sub> and ArH, <i>J</i> = 10.14, 17.40 Hz), 6.49 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 15.02 Hz), 6.54 (s, 1H, ArH), 6.97 (d, 1H, ArH, <i>J</i> = 6.9 Hz), 7.28 (d, 1H, ArH, <i>J</i> = 7.5 Hz), 7.42 (t, 1H, ArH, <i>J</i> = 6.9 Hz), 7.60 (d, 1H, ArH, <i>J</i> = 6 Hz), 7.68 (s, 1H, ArNHCO), 8.08 (s, 1H, ArH), 8.34 (s, 1H, ArH), 10.50 (s, 1H, COOH); <sup>13</sup>C NMR (75 MHz, <i>d</i><sub>6</sub>-DMSO) δ 170.01, 164.02, 163.85, 158.22, 158.01, 152.18, 147.94, 140.33, 131.74, 129.81, 127.23, 122.82, 119.93, 116.76, 116.57, 112.85, 106.64, 104.06, 100.13, 58.36, 55.60, 51.83, 47.92; ESI-HRMS (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>27</sub>N<sub>6</sub>O<sub>5</sub>Cl 539.1810, obsd 539.1814, ppm error 0.7.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure for the Preparation of <b>12a</b>–<b>k</b></h3><div class="NLM_p last">To a solution of compound <b>10</b> (4.54 g, 8.43 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were added dicyclohexylcarbodiimide (DCC) (1.74 g, 8.43 mmol), <b>11a</b>–<b>k</b> (8.43 mmol), and 4-(dimethylamino)pyridine (DMAP) (catalytic amount), and the mixture was stirred at room temperature for 12 h. After filtration, the filtrate was evaporated to dryness in vacuo, and the crude product was purified by column chromatography with 1:1 (v/v) petroleum ether–ethyl acetate.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 4-(2-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetamido)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12a</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11a</b> and <b>10</b> (yellow solid, 83% yield, mp 194–196 °C). Analytical data for <b>12a</b>: ESI-MS <i>m</i>/<i>z</i> 806 [M + H]<sup>+</sup>, 828 [M + Na]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.75 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.61 Hz), 3.14 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.83 Hz), 3.16 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.77 (s, 3H, OC<i>H</i><sub>3</sub>), 3.82 (t, 2H, NHC<i>H</i><sub>2</sub>CH<sub>2</sub>O <i>J</i> = 5.19 Hz), 4.58 (t, 2H, NHCH<sub>2</sub>C<i>H</i><sub>2</sub>O, <i>J</i> = 4.77 Hz), 5.74 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 9.96 Hz), 6.17 (d, 1H, ArH, <i>J</i> = 8.31 Hz), 6.25 (dd, 1H, COC<i>H</i>═CH<sub>2</sub>, <i>J</i> = 9.99, 16.83 Hz), 6.41 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 17.25 Hz), 6.95 (d, 1H, ArH, <i>J</i> = 8.07 Hz), 7.37 (t, 1H, ArH, <i>J</i> = 8.07 Hz), 7.47 (s, 1H, ArNH), 7.50 (d, 1H, ArH, <i>J</i> = 8.19 Hz), 7.60 (t, 4H, 3 × ArH and ArNHCO, <i>J</i> = 7.61 Hz), 7.74 (t, 3H, 2 × ArH and NHCO, <i>J</i> = 7.02 Hz), 8.04 (d, 2H, ArH, <i>J</i> = 7.77 Hz), 8.21 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.76, 164.54, 163.70, 158.76, 157.73, 157.41, 152.87, 148.59, 146.85, 139.16, 137.67, 135.87, 131.02, 129.80, 129.74, 128.51, 128.09, 121.99, 119.06, 118.15, 116.93, 114.00, 108.07, 100.56, 70.16, 61.46, 59.34, 55.59, 53.69, 50.30, 37.82; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>36</sub>H<sub>36</sub>ClN<sub>9</sub>O<sub>9</sub>S 828.1943, obsd 828.1950, ppm error 0.8.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 4-(3-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetamido)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12b</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11b</b> and <b>10</b> (yellow solid, 80% yield, mp 141–143 °C). Analytical data for <b>12b</b>: ESI-MS <i>m</i>/<i>z</i> 820 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.16 (quint, 2H, C<i>H</i><sub>2</sub>, <i>J</i> = 6.33 Hz), 2.73 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.51 Hz), 3.12 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.73 Hz), 3.13 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.53 (q, 2H, NHC<i>H</i><sub>2</sub>, <i>J</i> = 6.27 Hz), 3.81 (s, 3H, OC<i>H</i><sub>3</sub>), 4.51 (t, 2H, OC<i>H</i><sub>2</sub>, <i>J</i> = 6.06 Hz), 5.75 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 9.63 Hz), 6.21 (d, 1H, ArH, <i>J</i> = 8.31 Hz), 6.25 (dd, 1H, COC<i>H</i>═CH<sub>2</sub>, <i>J</i> = 10.11, 16.86 Hz), 6.42 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 16.38 Hz), 6.99 (d, 1H, ArH, <i>J</i> = 8.16 Hz), 7.35–7.47 (m, 4H, 3 × ArH and ArNH), 7.57–7.66 (m, 5H, 3 × ArH, ArNHCO and NHCO), 7.76 (t, 1H, ArH, <i>J</i> = 7.47 Hz), 8.07 (d, 2H, ArH, <i>J</i> = 7.47 Hz), 8.23 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.56, 163.81, 162.83, 158.76, 157.75, 157.38, 152.84, 148.65, 146.84, 138.72, 137.55, 135.75, 131.03, 129.84, 129.76, 128.57, 128.12, 122.03, 119.10, 118.19, 116.97, 111.64, 108.05, 100.50, 69.24, 61.56, 55.62, 53.62, 50.25, 35.62, 28.81; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>37</sub>H<sub>38</sub>ClN<sub>9</sub>O<sub>9</sub>S 842.2099, obsd 842.2106, ppm error 0.8.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 4-(2-(4-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetyl)piperazin-1-yl)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12c</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11c</b> and <b>10</b> (yellow solid, 78% yield, mp 130–132 °C). Analytical data for <b>12c</b>: ESI-MS <i>m</i>/<i>z</i> 875 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.56 (t, 2H, NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.33 Hz), 2.65 (t, 6H, 3 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.56 Hz), 2.88 (t, 2H, NC<i>H</i><sub>2</sub>, <i>J</i> = 5.07 Hz), 3.09 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.73 Hz), 3.25 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.64 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.65 Hz), 3.79 (s, 3H, OC<i>H</i><sub>3</sub>), 4.57 (t, 2H, OC<i>H</i><sub>2</sub>, <i>J</i> = 5.01 Hz), 5.75 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 9.99 Hz), 6.18 (d, 1H, ArH, <i>J</i> = 8.31 Hz), 6.27 (dd, 1H, COC<i>H</i>═CH<sub>2</sub>, <i>J</i> = 9.99, 16.8 Hz), 6.42 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 16.47 Hz), 6.98 (d, 1H, ArH, <i>J</i> = 7.98 Hz), 7.41 (t, 1H, ArH, <i>J</i> = 7.77 Hz), 7.43 (s, 1H, ArNH), 7.48 (s, 1H, ArH), 7.59 (t, 3H, 2 × ArH and ArNHCO, <i>J</i> = 7.74 Hz), 7.68 (d, 1H, ArH, <i>J</i> = 8.07 Hz), 7.74 (t, 2H, ArH, <i>J</i> = 7.2 Hz), 8.02 (d, 2H, ArH, <i>J</i> = 7.71 Hz), 8.22 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 167.83, 164.14, 163.82, 159.39, 158.72, 158.48, 152.62, 152.31, 148.75, 140.70, 137.79, 136.59, 132.20, 130.44, 130.27, 128.71, 127.64, 120.17, 117.17, 116.93, 113.24, 110.95, 107.01, 100.42, 69.83, 56.05, 53.57, 53.19, 52.90, 49.10, 45.99, 45.60; ESI-HRMS (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>43</sub>ClN<sub>10</sub>O<sub>9</sub>S 875.2702, obsd 875.2710, ppm error 0.9.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-((1-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetyl)piperidin-4-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12d</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11d</b> and <b>10</b> (yellow solid, 80% yield, mp 128–130 °C). Analytical data for <b>12d</b>: ESI-MS <i>m</i>/<i>z</i> 846 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.97–2.04 (m, 4H, C<i>H</i><sub>2</sub>CC<i>H</i><sub>2</sub>), 2.69 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.56 Hz), 3.11 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.73 Hz), 3.29 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.80 (s, 3H, OC<i>H</i><sub>3</sub>), 3.7–3.9 (m, 4H, C<i>H</i><sub>2</sub>NC<i>H</i><sub>2</sub>), 5.17 (m, 1H, OCH), 5.76 (dd, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 9.96, 1.11 Hz), 6.19 (d, 1H, ArH, <i>J</i> = 8.31 Hz), 6.27 (dd, 1H, COC<i>H</i>═CH<sub>2</sub>, <i>J</i> = 9.96, 16.8 Hz), 6.43 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 16.47 Hz), 6.98 (dd, 1H, ArH, <i>J</i> = 7.98, 1.32 Hz), 7.41 (t, 1H, ArH, <i>J</i> = 8.25 Hz), 7.45 (s, 1H, ArNH), 7.50 (s, 1H, ArH), 7.62 (t, 4H, 2 × ArH and ArNHCO, <i>J</i> = 7.89 Hz), 7.76 (t, 1H, ArH, <i>J</i> = 7.44 Hz), 7.80 (s, 1H, ArH), 8.05 (d, 2H, ArH, <i>J</i> = 7.35 Hz), 8.22 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 168.05, 164.48, 163.64, 157.90, 157.70, 157.44, 152.80, 148.68, 146.97, 139.21, 137.96, 135.76, 131.09, 129.74, 128.48, 128.06, 121.84, 119.20, 118.08, 117.13, 113.92, 110.46, 107.94, 100.39, 61.44, 55.62, 53.18, 50.12,42.12, 38.35, 30.84, 29.99; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>39</sub>H<sub>40</sub>ClN<sub>9</sub>O<sub>9</sub>S 868.2256, obsd 868.2265, ppm error 1.0.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-((1-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetamido)propan-2-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12e</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11e</b> and <b>10</b> (yellow solid, 85% yield, mp 105–107 °C). Analytical data for <b>12e</b>: ESI-MS <i>m</i>/<i>z</i> 820 [M + H]<sup>+</sup>, 842 [M + Na]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.47 (d, 3H, CHC<i>H</i><sub>3</sub>, <i>J</i> = 6.24 Hz), 2.65 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.56 Hz), 3.08 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.73 Hz), 3.10 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.50 (t, 1H, NHC<i>H</i><sub>2</sub>, <i>J</i> = 6.63 Hz), 3.79 (s, 3H, OC<i>H</i><sub>3</sub>), 4.52 (t, 1H, NHC<i>H</i><sub>2</sub>, <i>J</i> = 6.56 Hz), 5.15 (m, 1H, C<i>H</i>CH<sub>3</sub>), 5.72 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 9.96 Hz), 6.16 (d, 1H, ArH, <i>J</i> = 7.02 Hz), 6.25 (dd, 1H, COC<i>H</i>═CH<sub>2</sub>, <i>J</i> = 10.11, 16.74 Hz), 6.41 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 16.47 Hz), 6.95 (d, 1H, ArH, <i>J</i> = 8.25 Hz), 7.37 (t, 1H, ArH, <i>J</i> = 8.43 Hz), 7.45 (s, 1H, ArNH), 7.58 (m, 5H, 3 × ArH, ArNHCO and NHCO), 7.71 (d, 1H, ArH, <i>J</i> = 6.36 Hz), 7.68 (t, 1H, ArH, <i>J</i> = 6.27 Hz), 8.03 (d, 3H, ArH, <i>J</i> = 7.23 Hz), 8.20 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.73, 164.53, 163.37, 158.74, 157.74, 157.41, 152.89, 148.68, 146.82, 139.11, 137.80, 135.82, 130..98, 129.78, 128.46, 128.12, 122.01, 119.02, 118.17, 116.93, 113.91, 110.46, 108.14, 100.58, 78.78, 61.47, 55.60, 53.72, 53.62, 50.22, 43.12, 17.20; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>37</sub>H<sub>38</sub>ClN<sub>9</sub>O<sub>9</sub>S 842.2099, obsd 842.2106, ppm error 0.8.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-(2-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12f</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11f</b> and <b>10</b> (yellow solid, 75% yield, mp 123–125 °C). Analytical data for <b>12f</b>: ESI-MS <i>m</i>/<i>z</i> 807 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.80 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.59 Hz), 3.16 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.77 Hz), 3.38 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.79 (s, 3H, OC<i>H</i><sub>3</sub>), 4.58 (t, 2H, OC<i>H</i><sub>2</sub>CH<sub>2</sub>O <i>J</i> = 3.66 Hz), 4.68 (t, 2H, OCH<sub>2</sub>C<i>H</i><sub>2</sub>O, <i>J</i> = 3.03 Hz), 5.74 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 9.99 Hz), 6.27 (dd, 2H, COC<i>H</i>═CH<sub>2</sub> and ArH, <i>J</i> = 9.99, 16.8 Hz), 6.42 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 17.07 Hz), 6.96 (d, 1H, ArH, <i>J</i> = 7.14 Hz), 7.39 (t, 1H, ArH, <i>J</i> = 8.55 Hz), 7.45 (s, 1H, ArNH), 7.58 (d, 3H, 2 × ArH and ArNHCO, <i>J</i> = 6.54 Hz), 7.63 (t, 2H, ArH, <i>J</i> = 7.59 Hz), 7.76 (t, 1H, ArH <i>J</i> = 7.59 Hz), 7.79 (s, 1H, ArH), 8.07 (d, 2H, ArH, <i>J</i> = 7.71 Hz), 8.22 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.05, 164.49, 163.61, 158.65, 157.69, 157.44, 152.82, 148.71, 147.02, 139.11, 137.83, 135.79, 130.98, 129.78, 129.74, 128.63, 128.18, 121.78, 119.33, 118.12, 117.09, 114.01, 108.01, 100.35, 68.81, 61.34, 59.20, 55.60, 52.98, 49.94; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>36</sub>H<sub>35</sub>ClN<sub>8</sub>O<sub>10</sub>S 829.1783, obsd 829.1790, ppm error 0.8.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4-(3-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)propoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12g</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11g</b> and <b>10</b> (yellow solid, 72% yield, mp 102–104 °C). Analytical data for <b>12g</b>: ESI-MS <i>m</i>/<i>z</i> 821 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.25 (t, 2H, OCH<sub>2</sub>C<i>H</i><sub>2</sub>CH<sub>2</sub>O, <i>J</i> = 5.67 Hz), 2.73 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.60 Hz), 3.12 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.76 Hz), 3.31 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.79 (s, 3H, OC<i>H</i><sub>3</sub>), 4.35 (t, 2H, OC<i>H</i><sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>O <i>J</i> = 5.49 Hz), 4.53 (t, 2H, OCH<sub>2</sub>CH<sub>2</sub>C<i>H</i><sub>2</sub>O, <i>J</i> = 5.52 Hz), 5.75 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 10.05 Hz), 6.25 (dd, 2H, COC<i>H</i>═CH<sub>2</sub>, ArH, <i>J</i> = 9.99, 17.4 Hz), 6.41 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 17.07 Hz), 6.97 (d, 1H, ArH, <i>J</i> = 7.35 Hz), 7.40 (t, 1H, ArH, <i>J</i> = 7.92 Hz), 7.43 (s, 1H, ArNH), 7.49 (s, 1H, ArH), 7.63–7.66 (t, 4H, 3 × ArH and ArNHCO, <i>J</i> = 7.08 Hz), 7.76 (t, 2H, ArH, <i>J</i> = 7.59 Hz), 8.06 (d, 2H, ArH, <i>J</i> = 7.5 Hz), 8.21 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.21, 164.46, 163.68, 158.83, 157.66, 157.45, 152.77, 148.72, 147.07, 139.15, 137.91, 135.76, 131.00, 129.77, 128.53, 128.14, 121.73, 119.37, 118.08, 117.19, 113.96, 108.03, 100.30, 68.00, 60.58, 59.18, 55.59, 53.00, 49.90, 27.89; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>37</sub>H<sub>37</sub>ClN<sub>8</sub>O<sub>10</sub>S 843.1940, obsd 843.1947, ppm error 0.8.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 4-(4-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)butoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12h</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11h</b> and <b>10</b> (yellow solid, 78% yield, mp 98–100 °C). Analytical data for <b>12h</b>: ESI-MS <i>m</i>/<i>z</i> 835 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.88 (quint, 2H, CH<sub>2</sub>, <i>J</i> = 5.88, 7.2 Hz), 1.97 (quint, 2H, CH<sub>2</sub>, <i>J</i> = 5.67, 6.72 Hz), 2.74 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.59 Hz), 3.13 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.77 Hz), 3.30 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.79 (s, 3H, OC<i>H</i><sub>3</sub>), 4.25 (t, 2H, OC<i>H</i><sub>2</sub>, <i>J</i> = 6.18 Hz), 4.47 (t, 2H, OC<i>H</i><sub>2</sub>, <i>J</i> = 6.15 Hz), 5.75 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 10.17 Hz), 6.25 (dd, 2H, COC<i>H</i>═CH<sub>2</sub>, ArH, <i>J</i> = 10.08, 16.92 Hz), 6.42 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 16.14 Hz), 6.97 (d, 1H, ArH, <i>J</i> = 8.07 Hz), 7.40 (t, 1H, ArH, <i>J</i> = 8.13 Hz), 7.43 (s, 1H, ArNH), 7.49 (s, 1H, ArH), 7.62 (t, 4H, 3 × ArH and ArNHCO, <i>J</i> = 7.8 Hz), 7.76 (t, 2H, ArH, <i>J</i> = 7.83 Hz), 8.05 (d, 2H, ArH, <i>J</i> = 7.56 Hz), 8.21 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.31, 164.46, 163.66, 158.96, 157.68, 157.45, 152.79, 148.72, 147.08, 139.12, 137.95, 135.70, 130.98, 129.80, 129.71, 128.53, 128.16, 121.75, 119.36, 118.11, 117.19, 113.96, 108.04, 100.32, 70.94, 63.91, 59.31, 55.60, 53.03, 49.92, 25.26, 25.04; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>38</sub>H<sub>39</sub>ClN<sub>8</sub>O<sub>10</sub>S 857.2096, obsd 857.2104, ppm error 0.9.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 4-((4-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)but-2-yn-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12i</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11i</b> and <b>10</b> (yellow solid, 83% yield, mp 185–187 °C). Analytical data for <b>12i</b>: ESI-MS <i>m</i>/<i>z</i> 831 [M + H]<sup>+</sup>, 853 [M + Na]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.75 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.59 Hz), 3.13 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.77 Hz), 3.34 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.80 (s, 3H, OC<i>H</i><sub>3</sub>), 4.81 (s, 2H, OC<i>H</i><sub>2</sub>), 5.10 (s, 2H, OC<i>H</i><sub>2</sub>), 5.76 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 10.05 Hz), 6.25 (dd, 2H, COC<i>H</i>═CH<sub>2</sub>, ArH, <i>J</i> = 10.11, 16.98 Hz), 6.43 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 16.14 Hz), 6.98 (d, 1H, ArH, <i>J</i> = 7.68 Hz), 7.41 (t, 1H, ArH, <i>J</i> = 8.07 Hz), 7.43 (s, 1H, ArNH), 7.49 (s, 1H, ArH), 7.64 (t, 4H, 3 × ArH and ArNHCO, <i>J</i> = 7.47 Hz), 7.77 (t, 2H, ArH, <i>J</i> = 7.32 Hz), 8.07 (d, 2H, ArH, <i>J</i> = 7.71 Hz), 8.22 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 169.41, 164.37, 163.48, 158.06, 157.72, 157.46, 152.84, 148.68, 147.02, 139.01, 137.95, 135.71, 130.97, 129.83, 129.75, 128.63, 128.21, 121.79, 119.27, 118.17, 117.06, 113.88, 108.02, 100.27, 83.77, 78.81, 59.08, 58.58, 55.60, 52.93, 51.97, 49.89; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>38</sub>H<sub>35</sub>ClN<sub>8</sub>O<sub>10</sub>S 853.1783, obsd 853.1790, ppm error 0.8.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 4-(2-(2-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)ethoxy)ethoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12j</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11j</b> and <b>10</b> (yellow solid, 68% yield, mp 91–93 °C). Analytical data for <b>12j</b>: ESI-MS <i>m</i>/<i>z</i> 851 [M + H]<sup>+</sup>, 873 [M + Na]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.73 (m, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N), 3.11 (m, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N), 3.32 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.78 (s, 3H, OC<i>H</i><sub>3</sub>), 3.82 (m, 2H, OC<i>H</i><sub>2</sub>), 3.92 (m, 2H, OC<i>H</i><sub>2</sub>), 4.34 (m, 2H, OC<i>H</i><sub>2</sub>), 4.57 (m, 2H, OC<i>H</i><sub>2</sub>), 5.74 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 9.84 Hz), 6.26 (dd, 2H, COC<i>H</i>═CH<sub>2</sub>, ArH, <i>J</i> = 9.99, 16.77 Hz), 6.41 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 16.14 Hz), 6.96 (d, 1H, ArH, <i>J</i> = 7.29 Hz), 7.39 (t, 1H, ArH, <i>J</i> = 7.89 Hz), 7.43 (s, 1H, ArNH), 7.51 (s, 1H, ArH), 7.64 (t, 4H, 3 × ArH and ArNHCO, <i>J</i> = 7.17 Hz), 7.76 (t, 1H, ArH, <i>J</i> = 6.96 Hz), 7.91 (s, 1H, ArH), 8.07 (d, 2H, ArH, <i>J</i> = 7.38 Hz), 8.20 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.23, 164.47, 163.58, 159.03, 157.72, 157.47, 152.82, 148.71, 147.06, 139.04, 135.69, 130.96, 129.82, 129.70, 128.60, 128.22, 121.77, 119.33, 118.16, 113.90, 108.02, 100.30, 70.54, 69.37, 68.35, 63.46, 59.17, 55.60, 52.95, 49.91; ESI-HRMS (<i>m</i>/<i>z</i>) [M + Na]<sup>+</sup> calcd for C<sub>38</sub>H<sub>39</sub>ClN<sub>8</sub>O<sub>11</sub>S 873.2045, obsd 873.2053, ppm error 0.9.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 4-((6-(2-(4-(4-((4-(3-Acrylamidophenoxy)-5-chloropyrimidin-2-yl)amino)-3-methoxyphenyl)piperazin-1-yl)acetoxy)hexyl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-Oxide (<b>12k</b>)</h3><div class="NLM_p last">The title compound was obtained starting from <b>11k</b> and <b>10</b> (yellow solid, 70% yield, mp 84–86 °C). Analytical data for <b>12k</b>: ESI-MS <i>m</i>/<i>z</i> 863 [M + H]<sup>+</sup>, 885 [M + Na]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.47 (quint, 4H, 2 × CH<sub>2</sub>, <i>J</i> = 6.39 Hz), 1.71 (quint, 2H, CH<sub>2</sub>, <i>J</i> = 6.66 Hz), 1.89 (quint, 2H, CH<sub>2</sub>, <i>J</i> = 6.27 Hz), 2.74 (t, 4H, 2 × NC<i>H</i><sub>2</sub>CH<sub>2</sub>N, <i>J</i> = 4.57 Hz), 3.13 (t, 4H, 2 × NCH<sub>2</sub>C<i>H</i><sub>2</sub>N, <i>J</i> = 4.75 Hz), 3.29 (s, 2H, NC<i>H</i><sub>2</sub>CO), 3.79 (s, 3H, OC<i>H</i><sub>3</sub>), 4.17 (t, 2H, OC<i>H</i><sub>2</sub>, <i>J</i> = 6.57 Hz), 4.42 (t, 2H, OC<i>H</i><sub>2</sub>, <i>J</i> = 6.42 Hz), 5.76 (d, 1H, COCH═C<i>H</i><sub>2</sub>, <i>J</i> = 10.14 Hz), 6.25 (dd, 2H, COC<i>H</i>═CH<sub>2</sub>, ArH, <i>J</i> = 10.08, 16.86 Hz), 6.43 (d, 2H, COCH═C<i>H</i><sub>2</sub> and ArH, <i>J</i> = 15.93 Hz), 6.98 (d, 1H, ArH, <i>J</i> = 7.95 Hz), 7.40 (t, 1H, ArH, <i>J</i> = 8.13 Hz), 7.43 (s, 1H, ArNH), 7.48 (s, 1H, ArH), 7.62 (t, 4H, 3 × ArH and ArNHCO, <i>J</i> = 7.59 Hz), 7.76 (t, 2H, ArH, <i>J</i> = 7.2 Hz), 8.05 (d, 2H, ArH, <i>J</i> = 7.53 Hz), 8.21 (s, 1H, ArH); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 170.37, 164.55, 163.58, 159.03, 157.71, 157.45, 152.81, 148.70, 147.10, 139.04, 135.65, 130.96, 129.83, 129.67, 128.53, 128.22, 121.76, 119.30, 118.15, 117.10, 108.02, 100.28, 71.42, 64.52, 59.37, 55.59, 53.03, 49.93, 28.49, 28.32, 25.49, 25.29; ESI-HRMS (<i>m</i>/<i>z</i>) [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>43</sub>ClN<sub>8</sub>O<sub>10</sub>S 863.2590, obsd 863.2597, ppm error 0.8.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Cell Lines and Reagents</h3><div class="NLM_p last">H1975 (NSCLC, EGFRL858R/T790M), HCC827 (NSCLC, EGFR del E746_A750), A549 (NSCLC, EGFR wild type), H460 (NSCLC, EGFR independent), A431 (epidermoid carcinoma, EGFR overexpression), HLF-1 (diploid human lung fibroblasts), and BEAS-2B and 16HBE (human bronchial epithelial) cells were obtained from ATCC. The cells were maintained at 37 °C in a 5% CO<sub>2</sub> incubator in DMEM or RPMI 1640 (Hyclone) containing 8% fetal bovine serum (FBS; Biochrom, AG).</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> In Vitro Enzymatic Activity Assay</h3><div class="NLM_p last">WT and EGFR mutants (L858R, L858R/T790M) and the Z’-Lyte Kinase Kit were purchased from Invitrogen. The experiments were performed according to the instructions of the manufacturer. Briefly, the respective concentrations of different kinases determined by optimization experiments were as follows: EGFR (PV3872, Invitrogen), 0.287 μg/μL; EGFR-L858R (PV4128, Invitrogen), 0.054 μg/μL; EGFR-L858R/T790M (PV4879, Invitrogen), 0.055 μg/μL. Ten concentration gradients were set for all the tested compounds from 5.1 × 10<sup>–9</sup> to 1 × 10<sup>–4</sup> M in DMSO, and a 4× compound solution was prepared. An ATP solution and a kinase/peptide mixture were prepared right before use. The 10 μL kinase reaction consisted of 2.5 μL of compound solution, 5 μL of kinase/peptide mixture, and 2.5 μL of ATP solution. A 100% phosphorylation control was provided by 5 μL of phosphopeptide solution instead of the kinase/peptide mixture. A 100% inhibition control was prepared using 2.5 μL of kinase buffer instead of the ATP solution, and 2.5 μL of 4% DMSO instead of the compound solution was used as a 0% inhibition control. The solutions on the plate were mixed thoroughly, and the plate was incubated for 1 h at room temperature. After 5 μL of development solution was added to each well, the plate was incubated for 1 h at room temperature; the non-phosphopeptides were cleaved in this time. Finally, 5 μL of stop reagent was added to stop the reaction. The activity was measured with an EnVision multilabel reader (Perkin-Elmer). Curve fitting and data presentations were performed using Graph Pad Prism version 5.0. Every experiment was repeated at least three times.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> MTT Assay</h3><div class="NLM_p last">A total of 1000 cells/well of H1975 and 2000 cells/well of HCC827, A549, A431, H460, BEAS-2B, and 16HBE were cultured in 8% FBS respective growth medium in 96-well microplates overnight. Seven concentrations (0.0001–10 μM) were set for the compounds. The cells were then treated in triplicate with various concentrations of each compound and cultured in 5% FBS medium for 72 h. Control cells were treated with vehicle alone. During the last 4 h of incubation, tetrazolium dye (MTT) solution (5 mg/mL, 20 μL/well) was added to each well. After the supernatant was discarded completely, the generated formazan crystals were dissolved in 100 μL of dimethyl sulfoxide (DMSO), and the absorbance was read spectrophotometrically at a test wavelength of 570 nm and a reference wavelength of 630 nm using an enzyme-linked immunosorbent assay plate reader. The data were calculated using Graph Pad Prism version 5.0. The IC<sub>50</sub> values were fitted using a nonlinear regression model with a sigmodial dose response.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Nitrite Measurement in Vitro</h3><div class="NLM_p last">The levels of NO generated by individual compounds in the cells are presented as that of nitrite and were determined by the colorimetric assay using the nitrite colorimetric assay kit (Beyotime, China), according to the manufacturer’s instructions. Briefly, H1975 or 16HBE cells (1 × 10<sup>6</sup>/well) were treated with a 100 μM concentration of each compound for 150 min. Subsequently, the cells were harvested, and their cell lysates were prepared and then mixed with Griess for 10 min at 37 °C, followed by measurement at 540 nm by an enzyme-linked immunosorbent assay plate reader. The cells treated with DMSO were used as negative controls for the background levels of nitrite production, while sodium nitrite at different concentrations was prepared as the positive control for the standard curve.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Cell Apoptosis Assay</h3><div class="NLM_p last">H1975 (1 × 10<sup>5</sup>), HCC827 (1.5 × 10<sup>5</sup>), or H460 (1.5 × 10<sup>5</sup>) cells were seeded into six-well plates for 24 h. Fresh growth medium with <b>12k</b>, <b>1</b>, or paclitaxel (0.1 and 1 μM for H1975 and HCC827; 1 and 5 μM for H460 cells) was added. Medium with 1‰ DMSO was used as the control. After 24 h, the growth medium was collected, and the cells were trypsined and collected with the corresponding medium. After centrifugation at 300<i>g</i> at 4 °C for 10 min, the supernatant was removed completely, and the cells were washed twice with precold PBS. A 200 μL volume of 1× binding buffer, 2.5 μL of 7-AAD, and 2.5 μL of annexin-V were added (PE-Annexin V Kit, BD Pharmingen). The cells were gently vortex-mixed and incubated for 15 min at 25 °C in the dark. Using cells stained with 7-AAD and annexin-V alone as the positive control, the samples were detected and performed with an FACS Calibur flow cytometer (Becton Dickinson).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Western Blotting Analysis</h3><div class="NLM_p last">A total of 1 ×10<sup>6</sup> cells of H1975 were plated in 6 cm dishes to incubate for 24 h. Then the cells were treated with a 0.01, 0.1, or 1 μM concentration of the compounds or vehicle control (0.1% DMSO) for 24 h. Meanwhile, H460, HLF-1, and A431 cells were incubated for 24 h without pretreatment by drugs. Then the cells were harvested and lysed. After protein quantification using the BCA protein assay kit (Beyotime, China), the cell lysates (20 μL/lane) were loaded and separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (7.5% gel) and transferred to PVDF membranes. After they were blocked in 5% fat-free milk for 1 h, the target proteins were probed with anti-EGFR, anti-phospho-EGFR (Tyr1068), anti-AKT, anti-phospho-AKT (Ser473), anti-ERK, anti-phospho-ERK (Thr202/Tyr204), anti-NF-κB p65, anti-phoshpo-NF-κB p65, and anti-β-actin antibodies (Cell Signaling, Boston, MA). The bound antibodies were detected using horseradish peroxidase (HRP)-conjugated second antibodies and visualized by the enhanced chemiluminescent reagent.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Mouse Tumor Xenograft Efficacy Study</h3><div class="NLM_p last">The efficacy study was conducted in strict accordance with protocols approved by the Institutional Animal Care and Use Committee of the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. Athymic nude male mice (BALB/c) 3–5 weeks old were obtained from Shanghai Slac Laboratory Animal Co. Ltd. and housed in an individual ventilated cage under controlled environmental conditions in an AAALAC-accredited facility. The mice were inoculated subcutaneously with H1975 NSCLC cells (2 × 10<sup>6</sup>/mouse) in the right flank when they were 6–8 weeks old. Upon reaching an average tumor volume of 180–200 mm<sup>3</sup> (9–11 days postimplantation), the animals were randomized into treatment groups (<i>n</i> = 6 mice/group) and treated intraperitoneally for 14 days with 0.2 mL of vehicle only/20 g of body mass, <b>12k</b> at 14 mg/kg, <b>1</b> at 8 mg/kg, and gefitinib at 16 mg/kg daily (qd). Tumor volumes were measured every other day using vernier calipers and calculated using the following formula: tumor volume (mm<sup>3</sup>) = <i>W</i><sup>2</sup>(<i>L</i>/2), where <i>W</i> = width and <i>L</i> = length (mm).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42"><a href="/doi/suppl/10.1021/jm400463q">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Description of the induction of apoptosis in H460 cells and compound purity measured by HPLC. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400463q/suppl_file/jm400463q_si_001.pdf">jm400463q_si_001.pdf (548.13 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm400463q" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86315" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86315" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of Regenerative Biology and
Institute of Chemical Biology, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, Guangzhou 510530, People’s Republic of China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#542e2d3c203330146562677a373b39743c363e3d14273d36277a35377a373a74303d3a330b3f3114333d363c7a35377a373a"><span class="__cf_email__" data-cfemail="e09a9988948784a0d1d6d3ce838f8d">[email protected]</span> <span class="__cf_email__" data-cfemail="1e767c74775e6d777c6d307f7d307d70">[email protected]</span> <span class="__cf_email__" data-cfemail="6004090e073f0b0520070902084e01034e030e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongbin Ji</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Cell Biology, Institute of
Biochemistry and Cell Biology, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences,
Shanghai 200031, People’s Republic of China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6e1417061a090a2e5f585d400d01034e060c04072e1d070c1d400f0d400d004e0a07000931050b2e09070c06400f0d400d00"><span class="__cf_email__" data-cfemail="3d474455495a597d0c0b0e135e5250">[email protected]</span> <span class="__cf_email__" data-cfemail="c7afa5adae87b4aea5b4e9a6a4e9a4a9">[email protected]</span> <span class="__cf_email__" data-cfemail="fc9895929ba39799bc9b959e94d29d9fd29f92">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yihua Zhang</span> - <span class="hlFld-Affiliation affiliation">†State Key Laboratory of Natural Medicines and ‡Center of Drug Discovery, China Pharmaceutical University, Nanjing
210009, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">State Key Laboratory of Cell Biology, Institute of
Biochemistry and Cell Biology, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences,
Shanghai 200031, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Key Laboratory of Regenerative Biology and
Institute of Chemical Biology, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, Guangzhou 510530, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Molecular and Medical
Pharmacology, University of California—Los Angeles, Los Angeles, California 90095, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#502a2938243734106166637e333f3d7038323a3910233932237e31337e333e7034393e370f3b3510373932387e31337e333e"><span class="__cf_email__" data-cfemail="6a1013021e0d0e2a5b5c5944090507">[email protected]</span> <span class="__cf_email__" data-cfemail="e38b81898aa3908a8190cd8280cd808d">[email protected]</span> <span class="__cf_email__" data-cfemail="a2c6cbccc5fdc9c7e2c5cbc0ca8cc3c18cc1cc">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun Han</span> - <span class="hlFld-Affiliation affiliation">†State Key Laboratory of Natural Medicines and ‡Center of Drug Discovery, China Pharmaceutical University, Nanjing
210009, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">State Key Laboratory of Cell Biology, Institute of
Biochemistry and Cell Biology, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences,
Shanghai 200031, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Key Laboratory of Regenerative Biology and
Institute of Chemical Biology, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, Guangzhou 510530, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Molecular and Medical
Pharmacology, University of California—Los Angeles, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhangjian Huang</span> - <span class="hlFld-Affiliation affiliation">†State Key Laboratory of Natural Medicines and ‡Center of Drug Discovery, China Pharmaceutical University, Nanjing
210009, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">State Key Laboratory of Cell Biology, Institute of
Biochemistry and Cell Biology, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences,
Shanghai 200031, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Key Laboratory of Regenerative Biology and
Institute of Chemical Biology, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, Guangzhou 510530, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Molecular and Medical
Pharmacology, University of California—Los Angeles, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Zheng</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory of Cell Biology, Institute of
Biochemistry and Cell Biology, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences,
Shanghai 200031, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ledong Wan</span> - <span class="hlFld-Affiliation affiliation">†State Key Laboratory of Natural Medicines and ‡Center of Drug Discovery, China Pharmaceutical University, Nanjing
210009, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">State Key Laboratory of Cell Biology, Institute of
Biochemistry and Cell Biology, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences,
Shanghai 200031, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Key Laboratory of Regenerative Biology and
Institute of Chemical Biology, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, Guangzhou 510530, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Molecular and Medical
Pharmacology, University of California—Los Angeles, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lianwen Zhang</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of Regenerative Biology and
Institute of Chemical Biology, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, Guangzhou 510530, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sixun Peng</span> - <span class="hlFld-Affiliation affiliation">†State Key Laboratory of Natural Medicines and ‡Center of Drug Discovery, China Pharmaceutical University, Nanjing
210009, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">State Key Laboratory of Cell Biology, Institute of
Biochemistry and Cell Biology, Shanghai Institutes for Biological
Sciences, Chinese Academy of Sciences,
Shanghai 200031, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Key Laboratory of Regenerative Biology and
Institute of Chemical Biology, Guangzhou Institutes of Biomedicine
and Health, Chinese Academy of Sciences, Guangzhou 510530, People’s Republic of China</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Molecular and Medical
Pharmacology, University of California—Los Angeles, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jide Tian</span> - <span class="hlFld-Affiliation affiliation">Department of Molecular and Medical
Pharmacology, University of California—Los Angeles, Los Angeles, California 90095, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.H., Z.H., and C.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i44" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i44"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i45" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i45"> Abbreviations Used</h2><tr><td class="NLM_term">NO</td><td class="NLM_def"><p class="first last">nitric oxide</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor-κB</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">HIF-1α</td><td class="NLM_def"><p class="first last">hypoxia-inducible factor-1α</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">Hb</td><td class="NLM_def"><p class="first last">hemoglobin</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">7-AAD</td><td class="NLM_def"><p class="first last">7-aminoactinomycin D</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-(dimethylamino)pyridine</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0liAC8UbTIypmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Mendelsohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor targeting in cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1053%2Fj.seminoncol.2006.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=16890793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2006&pages=369-385&author=J.+Mendelsohnauthor=J.+Baselga&title=Epidermal+growth+factor+receptor+targeting+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor targeting in cancer</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-385</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family that is abnormally activated in many epithelial tumors.  Several mechanisms lead to the receptor's aberrant activation that is obsd. in cancer, including receptor overexpression, mutation, ligand-dependent receptor dimerization, and ligand-independent activation.  Two classes of anti-EGFR agents are currently approved for the treatment of patients with cancer: cetuximab, a monoclonal antibody directed at the extracellular domain of the receptor, and gefitinib and erlotinib, oral, low-mol.-wt. (MW), ATP-competitive inhibitors of the receptor's tyrosine kinase.  Anti-EGFR monoclonal antibodies have demonstrated activity in the therapy of advanced colorectal carcinoma and in a variety of epithelial tumor types, including head and neck cancer and non-small cell lung cancer (NSCLC).  The development of low MW, anti-EGFR tyrosine kinase inhibitors (TKIs) has been focused until recently on NSCLC, although responses have been reported for other types of cancer.  Erlotinib was the only agent approved based on demonstrating improved survival, which was obsd. in patients with advanced NSCLC who previously had been treated with chemotherapy.  Recent major advances in the EGFR field include the discovery of EGFR somatic mutations in NSCLC that have important implications for biol., treatment, clin. trial design, and methods for mutation detection.  Clin. and survival benefits with anti-EGFR agents have been demonstrated in addnl. tumor types such as head and neck and pancreatic carcinomas.  New agents with clin. activity are entering the clinic and new combinatorial approaches with anti-EGFR agents are being explored.  Major efforts are, belatedly, attempting to identify mol. markers that can predict patients more likely to respond to anti-EGFR therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkawbwoHPfpLVg90H21EOLACvtfcHk0lgla3ZB5AgcRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersLk%253D&md5=68ddafac141c8351630137c8b28ca74e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2006.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2006.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520targeting%2520in%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2006%26volume%3D33%26spage%3D369%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lgla3ZB5AgcRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Le, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chetty, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor expression in anal canal carcinoma</span> <span class="citation_source-journal">Am. J. Clin. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1309%2FX4UADHVN317V2XMW" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15923158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVGnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2005&pages=20-23&author=L.+H.+Leauthor=R.+Chettyauthor=M.+J.+Moore&title=Epidermal+growth+factor+receptor+expression+in+anal+canal+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor expression in anal canal carcinoma</span></div><div class="casAuthors">Le, Lyly H.; Chetty, Runjan; Moore, Malcolm J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-23</span>CODEN:
                <span class="NLM_cas:coden">AJCPAI</span>;
        ISSN:<span class="NLM_cas:issn">0002-9173</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Pathology</span>)
        </div><div class="casAbstract">Most anal canal carcinomas (ACCs) are squamous cell carcinomas (SCCs).  SCCs in other tumor sites strongly express epidermal growth factor receptors (EGFRs), the inhibition of which might result in favorable changes in tumor growth.  A review of the published scientific literature reveals no information regarding the expression of EGFR in ACCs.  Therefore, we obtained archived pathol. samples from ACC biopsies and examd. the frequency and level of expression of EGFR and other cell surface and cell cycle markers.  The 21 samples studied universally and strongly expressed EGFR and were neg. for HER-2.  Clin. studies of EGFR inhibitors in advanced ACC are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9-g7t4797grVg90H21EOLACvtfcHk0lgla3ZB5AgcRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVGnsbY%253D&md5=9e2173f3725ba21f7aab99bc68b15791</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1309%2FX4UADHVN317V2XMW&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1309%252FX4UADHVN317V2XMW%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DL.%2BH.%26aulast%3DChetty%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520expression%2520in%2520anal%2520canal%2520carcinoma%26jtitle%3DAm.%2520J.%2520Clin.%2520Pathol.%26date%3D2005%26volume%3D124%26spage%3D20%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiestler, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Deimling, A.</span><span> </span><span class="NLM_article-title">Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme</span> <span class="citation_source-journal">Brain Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">871</span><span class="NLM_x">–</span> <span class="NLM_lpage">875</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1111%2Fj.1750-3639.1997.tb00890.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=9217972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADyaK2sXks1Skurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=871-875&author=Y.+Hayashiauthor=K.+Uekiauthor=A.+Wahaauthor=O.+D.+Wiestlerauthor=D.+N.+Louisauthor=A.+von+Deimling&title=Association+of+EGFR+gene+amplification+and+CDKN2+%28p16%2FMTS1%29+gene+deletion+in+glioblastoma+multiforme"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Association of EGFR gene amplification and CDKN2 (p 16/MTS 1) gene deletion in glioblastoma multiforme</span></div><div class="casAuthors">Hayashi, Yutaka; Ueki, Keisuke; Waha, Andreas; Wiestler, Otmar D.; Louis, David N.; Von Deimling, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Brain Pathology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">871-875</span>CODEN:
                <span class="NLM_cas:coden">BRPAE7</span>;
        ISSN:<span class="NLM_cas:issn">1015-6305</span>.
    
            (<span class="NLM_cas:orgname">International Society of Neuropathology</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) can be divided into genetic subsets: approx. one-third of GBM, primarily in older adults, have EGFR amplification; another one-third, primarily in younger adults, have TP53 mutation.  The majority of GBM also have homozygous deletions of the CDKN2 (p16/MTS1) gene, resulting in cell cycle deregulation and elevated proliferation indexes.  We evaluated the relationship between CDKN2 deletions and the GBM subsets as defined by EGFR amplification or TP53 mutation in 70 GBM.  Twenty-eight cases (40%) had EGFR amplification, 21 (30%) had TP53 mutation, and 21 (30%) had neither change.  CDKN2 deletions were present in 36 (51%) GBM.  Of the 28 GBM with EGFR amplification, 20 (71%) had CDKN2 deletion (p = 0.0078).  The remaining 16 cases with CDKN2 loss were divided between GBM with TP53 mutations (6 cases) and GBM with neither EGFR amplification nor TP53 mutation (10 cases).  Thus, CDKN2 deletions occur twice as commonly in GBM with EGFR amplification (71%) than in GBM with TP53 mutation (29%).  CDKN2 deletions occurred in GBM from patients somewhat older than those patients with GBM lacking CDKN2 deletion (mean age 53 vs. 48 yr).  Specifically among GBM with EGFR amplification, those with CDKN2 deletions also occurred in patients slightly older than those few GBM without CDKN2 deletions (mean age 55 vs. 51 yr).  The presence of CDKN2 deletions in most GBM with EGFR amplification and in generally older patients may provide one explanation for the potentially more aggressive nature of such tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrsMa5kqhhG7Vg90H21EOLACvtfcHk0ljOPXAEjBFkUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXks1Skurs%253D&md5=b04bf59e302420b06a53bd6385bd7309</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1750-3639.1997.tb00890.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1750-3639.1997.tb00890.x%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DUeki%26aufirst%3DK.%26aulast%3DWaha%26aufirst%3DA.%26aulast%3DWiestler%26aufirst%3DO.%2BD.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26atitle%3DAssociation%2520of%2520EGFR%2520gene%2520amplification%2520and%2520CDKN2%2520%2528p16%252FMTS1%2529%2520gene%2520deletion%2520in%2520glioblastoma%2520multiforme%26jtitle%3DBrain%2520Pathol.%26date%3D1997%26volume%3D7%26spage%3D871%26epage%3D875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naishadham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer statistics, 2013</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.3322%2Fcaac.21166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=23335087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A280%3ADC%252BC3szgvFSqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=11-30&author=R.+Siegelauthor=D.+Naishadhamauthor=A.+Jemal&title=Cancer+statistics%2C+2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2013</span></div><div class="casAuthors">Siegel Rebecca; Naishadham Deepa; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics.  A total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013.  During the most recent 5 years for which there are data (2005-2009), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women.  Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 100,000 population) to 2009 (173.1 per 100,000 population).  Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate).  Over the past 10 years of data (2000-2009), the largest annual declines in death rates were for chronic myeloid leukemia (8.4%), cancers of the stomach (3.1%) and colorectum (3.0%), and non-Hodgkin lymphoma (3.0%).  The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of approximately 1.18 million deaths from cancer, with 152,900 of these deaths averted in 2009 alone.  Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA4Ff_lauq0IkFb3mqPUYDfW6udTcc2eZwksvHbdrG17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szgvFSqsw%253D%253D&md5=1b89010b6bcfc5472f32879085ab4ccc</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21166%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DNaishadham%26aufirst%3DD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202013%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2013%26volume%3D63%26spage%3D11%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippman, S. M.</span><span> </span><span class="NLM_article-title">Lung cancer</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">–</span> <span class="NLM_lpage">1380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1056%2FNEJMra0802714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=18815398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKjt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1367-1380&author=R.+S.+Herbstauthor=J.+V.+Heymachauthor=S.+M.+Lippman&title=Lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular origins of cancer: lung cancer</span></div><div class="casAuthors">Herbst, Roy S.; Heymach, John V.; Lippman, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1367-1380</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The altered mol. genetics of non-small-cell lung cancer is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxvIgLl4BT2LVg90H21EOLACvtfcHk0ljOPXAEjBFkUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKjt7bM&md5=a5968124ab5b0807e9a1b89e5e2dad51</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0802714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0802714%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26atitle%3DLung%2520cancer%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D1367%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, N.</span><span> </span><span class="NLM_article-title">New driver mutations in non-small-cell lung cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1016%2FS1470-2045%2810%2970087-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=21277552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ns74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=175-180&author=W.+Paoauthor=N.+Girard&title=New+driver+mutations+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">New driver mutations in non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Girard, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-180</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Treatment decisions for patients with lung cancer have historically been based on tumor histol.  Some understanding of the mol. compn. of tumors has led to the development of targeted agents, for which initial findings are promising.  Clearer understanding of mutations in relevant genes and their effects on cancer cell proliferation and survival, is, therefore, of substantial interest.  We review current knowledge about mol. subsets in non-small-cell lung cancer that have been identified as potentially having clin. relevance to targeted therapies.  Since mutations in EGFR and KRAS have been extensively reviewed elsewhere, here, we discuss subsets defined by so-called driver mutations in ALK, HER2 (also known as ERBB2), BRAF, PIK3CA, AKT1, MAP2K1, and MET.  The adoption of treatment tailored according to the genetic make-up of individual tumors would involve a paradigm shift, but might lead to substantial therapeutic improvements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplMPwgmZjAT7Vg90H21EOLACvtfcHk0ljOPXAEjBFkUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ns74%253D&md5=3d590b884d4a9827e85781d65d17759f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970087-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970087-5%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DGirard%26aufirst%3DN.%26atitle%3DNew%2520driver%2520mutations%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D175%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Suda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomizawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span> </span><span class="NLM_article-title">Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1007%2Fs10555-010-9209-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=20108024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVOjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=49-60&author=K.+Sudaauthor=K.+Tomizawaauthor=T.+Mitsudomi&title=Biological+and+clinical+significance+of+KRAS+mutations+in+lung+cancer%3A+an+oncogenic+driver+that+contrasts+with+EGFR+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation</span></div><div class="casAuthors">Suda, Kenichi; Tomizawa, Kenji; Mitsudomi, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-60</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  KRAS and epidermal growth factor receptor (EGFR) are the two most frequently mutated proto-oncogenes in adenocarcinoma of the lung.  The occurrence of these two oncogenic mutations is mutually exclusive, and they exhibit many contrasting characteristics such as clin. background, pathol. features of patients harboring each mutation, and prognostic or predictive implications.  Lung cancers harboring the EGFR mutations are remarkably sensitive to EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib.  This discovery has dramatically changed the clin. treatment of lung cancer in that it almost doubled the duration of survival for lung cancer patients with an EGFR mutation.  In this review, we describe the features of KRAS mutations in lung cancer and contrast these with the features of EGFR mutations.  Recent strategies to combat lung cancer harboring KRAS mutations are also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprCfWXTA1K8LVg90H21EOLACvtfcHk0lhlv_TTJk2L-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVOjtL0%253D&md5=dfeb54c1b4a68e501ee652d4b0ab57dc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs10555-010-9209-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-010-9209-4%26sid%3Dliteratum%253Aachs%26aulast%3DSuda%26aufirst%3DK.%26aulast%3DTomizawa%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DBiological%2520and%2520clinical%2520significance%2520of%2520KRAS%2520mutations%2520in%2520lung%2520cancer%253A%2520an%2520oncogenic%2520driver%2520that%2520contrasts%2520with%2520EGFR%2520mutation%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2010%26volume%3D29%26spage%3D49%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Gately, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Flaherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K.</span><span> </span><span class="NLM_article-title">The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC</span> <span class="citation_source-journal">J. Clin. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1136%2Fjclinpath-2011-200275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=22039281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1Chsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2012&pages=1-7&author=K.+Gatelyauthor=J.+O%E2%80%99Flahertyauthor=F.+Cappuzzoauthor=R.+Pirkerauthor=K.+Kerrauthor=K.+O%E2%80%99Byrne&title=The+role+of+the+molecular+footprint+of+EGFR+in+tailoring+treatment+decisions+in+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC</span></div><div class="casAuthors">Gately, Kathy; O'Flaherty, John; Cappuzzo, Frederico; Pirker, Robert; Kerr, Keith; O'Byrne, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">JCPAAK</span>;
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of patients with non-small-cell lung cancer (NSCLC) present with advanced disease, with targeted therapies providing some improvement in clin. outcomes.  The epidermal growth factor receptor (EGFR) tyrosine kinase (TK) plays an important role in the pathogenesis of NSCLC.  Tyrosine kinase inhibitors (TKIs), which target the EGFR TK domain, have proven to be an effective treatment strategy; however, patient responses to treatment vary considerably.  Therefore, the identification of patients most likely to respond to treatment is essential to optimize the benefit of TKIs.  Tumor-assocd. activating mutations in EGFR can identify patients with NSCLC who are likely to have a good response to TKIs.  Nonetheless, the majority of patients relapse within a year of starting treatment.  Studies of tumors at relapse have demonstrated expression of a T790M mutation in exon 20 of the EGFR TK domain in approx. 50% of cases.  Although conferring resistance to reversible TKIs, these patients may remain sensitive to new-generation irreversible/panerb inhibitors.  A no. of techniques have been employed for genotypic assessment of tumor-assocd. DNA to identify EGFR mutations, each of which has advantages and disadvantages.  This review presents an overview of the current methodologies used to identify such mol. markers.  Recent developments in technol. may make the monitoring of changes in patients' tumor genotypes easier in clin. practice, which may enable patients' treatment regimens to be tailored during the course of their disease, potentially leading to improved patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocEi-NA6vfibVg90H21EOLACvtfcHk0lhlv_TTJk2L-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1Chsbg%253D&md5=b19dd64dfc23bfbcaef4ea7f6a5bd3bc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2011-200275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2011-200275%26sid%3Dliteratum%253Aachs%26aulast%3DGately%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Flaherty%26aufirst%3DJ.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DPirker%26aufirst%3DR.%26aulast%3DKerr%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26atitle%3DThe%2520role%2520of%2520the%2520molecular%2520footprint%2520of%2520EGFR%2520in%2520tailoring%2520treatment%2520decisions%2520in%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2012%26volume%3D65%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Sarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28Iressa%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0lhlv_TTJk2L-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DSarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528Iressa%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Orio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neveu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theleman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P.</span><span> </span><span class="NLM_article-title">Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">Caner Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4838</span><span class="NLM_x">–</span> <span class="NLM_lpage">4848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=9354447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4838-4848&author=J.+D.+Moyerauthor=E.+G.+Barbacciauthor=K.+K.+Iwataauthor=L.+Arnoldauthor=B.+Bomanauthor=A.+Cunninghamauthor=C.+Di+Orioauthor=J.+Dotyauthor=M.+J.+Morinauthor=M.+P.+Moyerauthor=M.+Neveuauthor=V.+A.+Pollackauthor=L.+R.+Pustilnickauthor=M.+M.+Reynoldsauthor=D.+Sloanauthor=A.+Thelemanauthor=P.+Miller&title=Induction+of+apoptosis+and+cell+cycle+arrest+by+CP-358%2C774%2C+an+inhibitor+of+epidermal+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Moyer, James D.; Barbacci, Elsa G.; Iwata, Kenneth K.; Arnold, Lee; Boman, Bruce; Cunningham, Ann; Diorio, Catherine; Doty, Jonathan; Morin, Michael J.; Moyer, Mikel P.; Neveu, Mark; Pollack, Vincent A.; Pustilnik, Leslie R.; Reynolds, Margaret M.; Sloan, Don; Theleman, April; Miller, Penny</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4838-4848</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype.  CP-358774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.  This inhibition is selective for EGFR tyrosine kinase relative to other tyrosine kinases we have examd., both in assays of isolated kinases and whole cells.  At doses of 100 mg/kg, CP-358774 completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice.  CP-358774 inhibits the proliferation of DiFi human colon tumor cells at submicromolar concns. in cell culture and blocks cell cycle progression at the G1 phase.  This inhibitor produces a marked accumulation of retinoblastoma protein in its underphosphorylated form and accumulation of p27KIP1 in DiFi cells, which may contribute to the cell cycle block.  Inhibition of the EGFR also triggers apoptosis in these cells as detd. by formation of DNA fragments and other criteria.  These results indicate that CP-358774 has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation or survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghArQOnGlkbVg90H21EOLACvtfcHk0lj0Q4uPfpPwTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D&md5=0a6e9697bf290d8e7c44cbe2a125e0b1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DBoman%26aufirst%3DB.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DDi%2BOrio%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DM.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DNeveu%26aufirst%3DM.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DPustilnick%26aufirst%3DL.%2BR.%26aulast%3DReynolds%26aufirst%3DM.%2BM.%26aulast%3DSloan%26aufirst%3DD.%26aulast%3DTheleman%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DInduction%2520of%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520by%2520CP-358%252C774%252C%2520an%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DCaner%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4838%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">S16</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=S16-22&issue=Suppl+2&author=M.+Ladanyiauthor=W.+Pao&title=Lung+adenocarcinoma%3A+guiding+EGFR-targeted+therapy+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DLung%2520adenocarcinoma%253A%2520guiding%2520EGFR-targeted%2520therapy%2520and%2520beyond%26jtitle%3DMod.%2520Pathol.%26date%3D2008%26volume%3D21%26issue%3DSuppl%25202%26spage%3DS16%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lj0Q4uPfpPwTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lhoWRH74HTsag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butts, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiappori, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dasse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheeran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, P. D.</span><span> </span><span class="NLM_article-title">Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3936</span><span class="NLM_x">–</span> <span class="NLM_lpage">3944</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=3936-3944&author=P.+A.+Janneauthor=J.+von+Pawelauthor=R.+B.+Cohenauthor=L.+Crinoauthor=C.+A.+Buttsauthor=S.+S.+Olsonauthor=I.+A.+Eisemanauthor=A.+A.+Chiapporiauthor=B.+Y.+Yeapauthor=P.+F.+Lenehanauthor=K.+Dasseauthor=M.+Sheeranauthor=P.+D.+Bonomi&title=Multicenter%2C+randomized%2C+phase+II+trial+of+CI-1033%2C+an+irreversible+pan-ERBB+inhibitor%2C+for+previously+treated+advanced+non+small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DButts%26aufirst%3DC.%2BA.%26aulast%3DOlson%26aufirst%3DS.%2BS.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DChiappori%26aufirst%3DA.%2BA.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DDasse%26aufirst%3DK.%26aulast%3DSheeran%26aufirst%3DM.%26aulast%3DBonomi%26aufirst%3DP.%2BD.%26atitle%3DMulticenter%252C%2520randomized%252C%2520phase%2520II%2520trial%2520of%2520CI-1033%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520for%2520previously%2520treated%2520advanced%2520non%2520small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D3936%26epage%3D3944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nokihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarashina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">–</span> <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1007%2Fs00280-011-1738-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=22071596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVCku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=891-899&author=H.+Murakamiauthor=T.+Tamuraauthor=T.+Takahashiauthor=H.+Nokiharaauthor=T.+Naitoauthor=Y.+Nakamuraauthor=K.+Nishioauthor=Y.+Sekiauthor=A.+Sarashinaauthor=M.+Shahidiauthor=N.+Yamamoto&title=Phase+I+study+of+continuous+afatinib+%28BIBW+2992%29+in+patients+with+advanced+non-small+cell+lung+cancer+after+prior+chemotherapy%2Ferlotinib%2Fgefitinib+%28LUX-Lung+4%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)</span></div><div class="casAuthors">Murakami, H.; Tamura, T.; Takahashi, T.; Nokihara, H.; Naito, T.; Nakamura, Y.; Nishio, K.; Seki, Y.; Sarashina, A.; Shahidi, M.; Yamamoto, N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose This Phase I study detd. the max.-tolerated dose (MTD) of afatinib (Afatinib is an investigational compd. and its safety and efficacy have not yet been established) (BIBW 2992; trade name not yet approved by FDA), an irreversible inhibitor of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor (HER)1 and 2, up to a dose of 50 mg/day in advanced non-small cell lung cancer (NSCLC), to establish the recommended dose for Phase II.  Methods Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily.  The MTD was detd. based on dose-limiting toxicities (DLTs); other assessments included safety, pharmacokinetic profile, antitumor activity according to response evaluation criteria in solid tumors and EGFR/HER1 mutation anal. where possible.  Results Twelve evaluable patients were treated at doses of 20-50 mg/day.  One DLT was obsd. at 50 mg/day in Course 1 (Grade 3 mucositis).  The most frequent drug-related adverse events were diarrhoea, dry skin, stomatitis, rash, paronychia and anorexia; most were Grade 1 or 2.  Six out of 12 patients had tumor size redns.; durable stable disease was achieved in three patients including one with EGFR/HER1 exon 19 and T790 M mutations.  Peak plasma concns. of afatinib were reached 3-4 h after administration and declined with a half-life of 30-40 h.  Afatinib 50 mg/day was well tolerated with an acceptable safety profile during Phase I. Conclusion Recommended dose for Phase II was defined as 50 mg/day for Japanese patients; the same as for non-Japanese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW-SUAjXGY-7Vg90H21EOLACvtfcHk0lhoWRH74HTsag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVCku7c%253D&md5=154c8fe17cadb847db769258c29e6643</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1738-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1738-1%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DSarashina%26aufirst%3DA.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DPhase%2520I%2520study%2520of%2520continuous%2520afatinib%2520%2528BIBW%25202992%2529%2520in%2520patients%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520after%2520prior%2520chemotherapy%252Ferlotinib%252Fgefitinib%2520%2528LUX-Lung%25204%2529%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D891%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+irreversible+pan-ErbB+receptor+tyrosine+kinase+inhibitor%3A+results+of+a+phase+II+trial+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0lhoWRH74HTsag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520irreversible%2520pan-ErbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seog Heo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbot, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span> </span><span class="NLM_article-title">Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3337</span><span class="NLM_x">–</span> <span class="NLM_lpage">3344</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1200%2FJCO.2011.40.9433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=22753918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3337-3344&author=S.+S.+Ramalingamauthor=F.+Blackhallauthor=M.+Krzakowskiauthor=C.+H.+Barriosauthor=K.+Parkauthor=I.+Boverauthor=D.+Seog+Heoauthor=R.+Rosellauthor=D.+C.+Talbotauthor=R.+Frankauthor=S.+P.+Letrentauthor=A.+Ruiz-Garciaauthor=I.+Taylorauthor=J.+Q.+Liangauthor=A.+K.+Campbellauthor=J.+O%E2%80%99Connellauthor=M.+Boyer&title=Randomized+phase+II+study+of+dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-human+epidermal+growth+factor+receptor+inhibitor%2C+versus+erlotinib+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of dacomitinib (PF-00299804), and irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Blackhall, Fiona; Krzakowski, Maciej; Barrios, Carlos H.; Park, Keunchil; Bover, Isabel; Heo, Dae Seog; Rosell, Rafael; Talbot, Denis C.; Frank, Richard; Letrent, Stephen P.; Ruiz-Garcia, Ana; Taylor, Ian; Liang, Jane Q.; Campbell, Alicyn K.; O'Connell, Joseph; Boyer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3337-3344</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR1/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).  Patients and Methods Patients with NSCLC, Eastern Cooperative Oncol. Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily.  Results One hundred eighty-eight patients were randomly assigned.  Treatment arms were balanced for most clin. and mol. characteristics.  Median progression-free survival (PFS; primary end point) was 2.86 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (hazard ratio [HR] = 0.66; 95% CI, 0.47 to 0.91; two-sided P = .012); in patients with KRAS wild-type tumors, median PFS was 3.71 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (HR = 0.55; 95% CI, 0.35 to 0.85; two-sided P = .006); and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 mo for patients treated with dacomitinib and 1.84 mo for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37 to 0.99; two-sided P = .043).  Median overall survival was 9.53 mo for patients treated with dacomitinib and 7.44 mo for patients treated with erlotinib (HR = 0.80; 95% CI, 0.56 to 1.13; two-sided P = .205).  Adverse event-related discontinuations were uncommon in both arms.  Common treatment-related adverse events were dermatol. and gastrointestinal, predominantly grade 1 to 2, and more frequent with dacomitinib.  Conclusion Dacomitinib demonstrated significantly improved PFS vs. erlotinib, with acceptable toxicity.  PFS benefit was obsd. in most clin. and mol. subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHl-bReesXsbVg90H21EOLACvtfcHk0limprPc1t-3Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK&md5=bdc76102e0ae37fb3f5307c285f952d4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.9433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.9433%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DKrzakowski%26aufirst%3DM.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DSeog%2BHeo%26aufirst%3DD.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTalbot%26aufirst%3DD.%2BC.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DLetrent%26aufirst%3DS.%2BP.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DJ.%2BQ.%26aulast%3DCampbell%26aufirst%3DA.%2BK.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DM.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-human%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520versus%2520erlotinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3337%26epage%3D3344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">S146</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=S146-149&author=G.+J.+Riely&title=Second-generation+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DSecond-generation%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2008%26volume%3D3%26spage%3DS146%26epage%3D149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0limprPc1t-3Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+J.+Zhouauthor=D.+Ercanauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0li77mdi-YMgSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0li77mdi-YMgSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Fukumura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashiwagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">The role of nitric oxide in tumour progression</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnrc1910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=16794635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=521-534&author=D.+Fukumuraauthor=S.+Kashiwagiauthor=R.+K.+Jain&title=The+role+of+nitric+oxide+in+tumour+progression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The role of nitric oxide in tumour progression</span></div><div class="casAuthors">Fukumura, Dai; Kashiwagi, Satoshi; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">521-534</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) and nitric oxide synthases are ubiquitous in malignant tumors and are known to exert both pro- and anti-tumor effects.  We summarize our current understanding of the role of NO in tumor progression, esp. in relation to angiogenesis and vascular functions.  We also discuss potential strategies for cancer treatment that modulate NO prodn. and/or its downstream signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorTlzSMm-9dbVg90H21EOLACvtfcHk0li77mdi-YMgSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFehu7Y%253D&md5=ee546d1b8e37e216ef373374ba15209c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc1910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1910%26sid%3Dliteratum%253Aachs%26aulast%3DFukumura%26aufirst%3DD.%26aulast%3DKashiwagi%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DThe%2520role%2520of%2520nitric%2520oxide%2520in%2520tumour%2520progression%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D521%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Bonavida, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baritaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huerta-Yepez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.</span><span> </span><span class="NLM_article-title">Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases</span> <span class="citation_source-journal">Nitric Oxide</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=152-157&author=B.+Bonavidaauthor=S.+Baritakiauthor=S.+Huerta-Yepezauthor=M.+I.+Vegaauthor=D.+Chatterjeeauthor=K.+Yeung&title=Novel+therapeutic+applications+of+nitric+oxide+donors+in+cancer%3A+roles+in+chemo-+and+immunosensitization+to+apoptosis+and+inhibition+of+metastases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonavida%26aufirst%3DB.%26aulast%3DBaritaki%26aufirst%3DS.%26aulast%3DHuerta-Yepez%26aufirst%3DS.%26aulast%3DVega%26aufirst%3DM.%2BI.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DYeung%26aufirst%3DK.%26atitle%3DNovel%2520therapeutic%2520applications%2520of%2520nitric%2520oxide%2520donors%2520in%2520cancer%253A%2520roles%2520in%2520chemo-%2520and%2520immunosensitization%2520to%2520apoptosis%2520and%2520inhibition%2520of%2520metastases%26jtitle%3DNitric%2520Oxide%26date%3D2008%26volume%3D19%26spage%3D152%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Riganti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miraglia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viarisio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costamagna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pescarmona, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghigo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosia, A.</span><span> </span><span class="NLM_article-title">Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">525</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15695394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1KqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=516-525&author=C.+Rigantiauthor=E.+Miragliaauthor=D.+Viarisioauthor=C.+Costamagnaauthor=G.+Pescarmonaauthor=D.+Ghigoauthor=A.+Bosia&title=Nitric+oxide+reverts+the+resistance+to+doxorubicin+in+human+colon+cancer+cells+by+inhibiting+the+drug+efflux"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux</span></div><div class="casAuthors">Riganti, Chiara; Miraglia, Erica; Viarisio, Daniele; Costamagna, Costanzo; Pescarmona, Gianpiero; Ghigo, Dario; Bosia, Amalia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">516-525</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is a phenomenon by which cancer cells evade the cytotoxic effects of chemotherapeutic agents.  It may occur through different mechanisms, but it often correlates with the overexpression of integral membrane transporters, such as P-glycoprotein (Pgp) and MDR-assocd. proteins (MRPs), with resulting decrease of drug accumulation and cellular death.  Doxorubicin is a substrate of Pgp; it has been suggested that its ability to induce synthesis of nitric oxide (NO) could explain, at least in part, its cytotoxic effects.  Culturing the human epithelial colon cell line HT29 in the presence of doxorubicin, we obtained a doxorubicin-resistant (HT29-dx) cell population: these cells accumulated less intracellular doxorubicin, were less sensitive to the cytotoxic effects of doxorubicin and cisplatin, overexpressed Pgp and MRP3, and exhibited a lower NO prodn. (both under basal conditions and after doxorubicin stimulation).  The resistance to doxorubicin could be reversed when HT29-dx cells were incubated with inducers of NO synthesis (cytokines mix, atorvastatin).  Some NO donors increased the drug accumulation in HT29-dx cells in a guanosine-3':5'-cyclic monophosphate-independent way; this effect was assocd. with a marked redn. of doxorubicin efflux rate in HT29 and HT29-dx cells, and tyrosine nitration in the MRP3 protein.  Our results suggest that onset of MDR and impairment of NO synthesis are related; this finding could point to a new strategy to reverse doxorubicin resistance in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTu2bqm5O1DbVg90H21EOLACvtfcHk0lh79mnUPSi8jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1KqtQ%253D%253D&md5=e0e7757d954680c9b9eb3470a1758da6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiganti%26aufirst%3DC.%26aulast%3DMiraglia%26aufirst%3DE.%26aulast%3DViarisio%26aufirst%3DD.%26aulast%3DCostamagna%26aufirst%3DC.%26aulast%3DPescarmona%26aufirst%3DG.%26aulast%3DGhigo%26aufirst%3DD.%26aulast%3DBosia%26aufirst%3DA.%26atitle%3DNitric%2520oxide%2520reverts%2520the%2520resistance%2520to%2520doxorubicin%2520in%2520human%2520colon%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520drug%2520efflux%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D516%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Sullivan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, C. H.</span><span> </span><span class="NLM_article-title">Chemosensitization of cancer by nitric oxide</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1113</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.2174%2F138161208784246225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=18473858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslKrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1113-1123&author=R.+Sullivanauthor=C.+H.+Graham&title=Chemosensitization+of+cancer+by+nitric+oxide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Chemosensitization of cancer by nitric oxide</span></div><div class="casAuthors">Sullivan, Richard; Graham, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1113-1123</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent evidence from exptl. and clin. studies links the development of intratumoral hypoxia and oxidative stress with malignant progression.  Cellular adaptation induced by these environmental stresses is also assocd. with the emergence of drug resistant populations.  This adaptation is most likely a multifactorial process involving coordination of various stress-induced signaling pathways, including those regulated by hypoxia-inducible factor-1 (HIF-1) and nuclear factor κB (NF-κB) together with their down-stream targets linked to resistance mechanisms.  Exptl. data suggest that treatment of human cancer cells with nitric oxide (NO) and NO mimetic agents can effectively restore the sensitivity of resistant populations to the cytotoxic effects of chemotherapeutics both in vitro and in vivo.  Furthermore, preliminary results from Phase II clin. trials evaluating NO as an adjuvant to chemotherapy are promising.  The present review highlights the significance of intratumoral hypoxia and oxidative stress in the emergence of multidrug resistance, and summarizes the latest data demonstrating the chemosensitizing ability of NO.  To date, the specific mechanisms through which NO restores sensitivity to anticancer agents are not clearly understood.  However, the data suggest that chemosensitization is likely to involve NO-mediated activities assocd. with both prevention and inhibition of cellular drug resistance mechanisms.  Potential mechanisms contributing to the chemosensitizing activity of NO include vascular changes that promote increased blood delivery and tumor oxygenation, antioxidant effects and down-regulation of the glutathione detoxification/redox buffering system, inhibition of key transcription factors such as HIF-1 and NF-κB, as well as inhibition of drug efflux transporters and DNA repair enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgKEY49it3dbVg90H21EOLACvtfcHk0lh79mnUPSi8jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslKrsrw%253D&md5=e0a4aa6a7c684d5e8cc68e2c88dffe09</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138161208784246225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161208784246225%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DR.%26aulast%3DGraham%26aufirst%3DC.%2BH.%26atitle%3DChemosensitization%2520of%2520cancer%2520by%2520nitric%2520oxide%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2008%26volume%3D14%26spage%3D1113%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Nakanishi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toi, M.</span><span> </span><span class="NLM_article-title">Nuclear factor-κB inhibitors as sensitizers to anticancer drugs</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnrc1588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15803156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=297-309&author=C.+Nakanishiauthor=M.+Toi&title=Nuclear+factor-%CE%BAB+inhibitors+as+sensitizers+to+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear factor-κB inhibitors as sensitizers to anticancer drugs</span></div><div class="casAuthors">Nakanishi, Chikashi; Toi, Masakazu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-309</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytotoxicity of chemotherapeutic agents is attributed to apoptosis.  Acquired resistance to the effects of chemotherapy has emerged as a significant impediment to effective cancer therapy.  One feature that cytotoxic treatments of cancer have in common is their activation of the transcription factor nuclear factor-κB (NF-κB), which regulates cell survival.  NF-κB activation suppresses the apoptotic potential of chemotherapeutic agents and contributes to resistance.  What evidence is there that inhibitors of NF-κB might promote apoptosis in cancer cells and can NF-κB inhibitors be used to overcome resistance to chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsXlm8lIyTbVg90H21EOLACvtfcHk0liz1lMRzfu5Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7Y%253D&md5=4449832c63d81112812502b97d2fdaea</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnrc1588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1588%26sid%3Dliteratum%253Aachs%26aulast%3DNakanishi%26aufirst%3DC.%26aulast%3DToi%26aufirst%3DM.%26atitle%3DNuclear%2520factor-%25CE%25BAB%2520inhibitors%2520as%2520sensitizers%2520to%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D297%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Chang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billiar, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. M.</span><span> </span><span class="NLM_article-title">Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of IκB</span> <span class="citation_source-journal">Exp. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Femm.2004.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15365250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVWmu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=311-324&author=K.+Changauthor=S.+J.+Leeauthor=I.+Cheongauthor=T.+R.+Billiarauthor=H.+T.+Chungauthor=J.+A.+Hanauthor=Y.+G.+Kwonauthor=K.+S.+Haauthor=Y.+M.+Kim&title=Nitric+oxide+suppresses+inducible+nitric+oxide+synthase+expression+by+inhibiting+post-translational+modification+of+I%CE%BAB"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of IκB</span></div><div class="casAuthors">Chang, Kwang; Lee, Seon-Jin; Cheong, Ilyoung; Billiar, Timothy R.; Chung, Hun-Taeg; Han, Jeong-A.; Kwon, Young-Guen; Ha, Kwon-Soo; Kim, Young-Myeong</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-324</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1226-3613</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Medical Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The expression of inducible nitric oxide synthase (iNOS) is a crit. factor in both normal physiol. functions and the pathogenesis of disease.  This study was undertaken to det. the mol. mechanism by which nitric oxide (NO) exerts neg. feedback regulation on iNOS gene expression.  Isolated rat hepatocytes stimulated with cytokines exhibited a marked increase in NO prodn. as well as iNOS mRNA and protein levels, which were significantly reduced by pretreatment of the NO donors S-nitroso-N-acetyl-D,L-penicillamine (SNAP) and V-PYRRO/NO.  This effect of SNAP was inhibited when NO was scavenged using red blood cells.  Pretreatment with oxidized SNAP, 8-Br-cGMP, NO2-, or NO3- did not suppress the cytokine-induced NO prodn.  Moreover, LPS/IFN-γ-stimulated RAW264.7 cells, which produce endogenous NO, expressed lower levels of iNOS, IL-1β, IL-6 and TNF-α mRNAs, without changes in their mRNA half-lives, than those in the presence of the iNOS inhibitor NG-monomethyl-L-arginine.  The iNOS gene transcription rate exhibited an 18-fold increase after cytokine stimulation, which was significantly inhibited by SNAP pretreatment.  SNAP also blocked cytokine-induced increase in NF-κB activation, iNOS promoter activity, nuclear translocation of cytosolic NF-κB p65 subunit, and IκBα degrdn., which correlated with its inhibitory effect on phosphorylation and ubiquitination of IκB.  These data indicate that NO down-regulates iNOS gene expression and NO prodn. by inhibiting the post-translational processes of IκBα thereby preventing NF-κB activation.  These results identify a novel neg. feedback mechanism whereby NO down-regulates iNOS gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5HdSQePfzd7Vg90H21EOLACvtfcHk0liz1lMRzfu5Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVWmu7o%253D&md5=3ee24e7eb89b28c3900285b5ae5d2dec</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Femm.2004.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femm.2004.42%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DCheong%26aufirst%3DI.%26aulast%3DBilliar%26aufirst%3DT.%2BR.%26aulast%3DChung%26aufirst%3DH.%2BT.%26aulast%3DHan%26aufirst%3DJ.%2BA.%26aulast%3DKwon%26aufirst%3DY.%2BG.%26aulast%3DHa%26aufirst%3DK.%2BS.%26aulast%3DKim%26aufirst%3DY.%2BM.%26atitle%3DNitric%2520oxide%2520suppresses%2520inducible%2520nitric%2520oxide%2520synthase%2520expression%2520by%2520inhibiting%2520post-translational%2520modification%2520of%2520I%25CE%25BAB%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2004%26volume%3D36%26spage%3D311%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Bivona, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieronymus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">471</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=471&publication_year=2011&pages=523-526&author=T.+G.+Bivonaauthor=H.+Hieronymusauthor=J.+Parkerauthor=K.+Changauthor=M.+Taronauthor=R.+Rosellauthor=P.+Moonsamyauthor=K.+Dahlmanauthor=V.+A.+Millerauthor=C.+Costaauthor=G.+Hannonauthor=C.+L.+Sawyers&title=FAS+and+NF-%CE%BAB+signalling+modulate+dependence+of+lung+cancers+on+mutant+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DHieronymus%26aufirst%3DH.%26aulast%3DParker%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DDahlman%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DHannon%26aufirst%3DG.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DFAS%2520and%2520NF-%25CE%25BAB%2520signalling%2520modulate%2520dependence%2520of%2520lung%2520cancers%2520on%2520mutant%2520EGFR%26jtitle%3DNature%26date%3D2011%26volume%3D471%26spage%3D523%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Aguirre, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boiani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerecetto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pintos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymondo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arredondo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basombrio, M. A.</span><span> </span><span class="NLM_article-title">Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies</span> <span class="citation_source-journal">Pharmazie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2006&pages=54-59&author=G.+Aguirreauthor=M.+Boianiauthor=H.+Cerecettoauthor=M.+Fernandezauthor=M.+Gonzalezauthor=E.+Leonauthor=C.+Pintosauthor=S.+Raymondoauthor=C.+Arredondoauthor=J.+P.+Pachecoauthor=M.+A.+Basombrio&title=Furoxan+derivatives+as+cytotoxic+agents%3A+preliminary+in+vivo+antitumoral+activity+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAguirre%26aufirst%3DG.%26aulast%3DBoiani%26aufirst%3DM.%26aulast%3DCerecetto%26aufirst%3DH.%26aulast%3DFernandez%26aufirst%3DM.%26aulast%3DGonzalez%26aufirst%3DM.%26aulast%3DLeon%26aufirst%3DE.%26aulast%3DPintos%26aufirst%3DC.%26aulast%3DRaymondo%26aufirst%3DS.%26aulast%3DArredondo%26aufirst%3DC.%26aulast%3DPacheco%26aufirst%3DJ.%2BP.%26aulast%3DBasombrio%26aufirst%3DM.%2BA.%26atitle%3DFuroxan%2520derivatives%2520as%2520cytotoxic%2520agents%253A%2520preliminary%2520in%2520vivo%2520antitumoral%2520activity%2520studies%26jtitle%3DPharmazie%26date%3D2006%26volume%3D61%26spage%3D54%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span> </span><span class="NLM_article-title">Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4834</span><span class="NLM_x">–</span> <span class="NLM_lpage">4838</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800167u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4834-4838&author=L.+Chenauthor=Y.+Zhangauthor=X.+Kongauthor=E.+Lanauthor=Z.+Huangauthor=S.+Pengauthor=D.+L.+Kaufmanauthor=J.+Tian&title=Design%2C+synthesis%2C+and+antihepatocellular+carcinoma+activity+of+nitric+oxide+releasing+derivatives+of+oleanolic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm800167u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800167u%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DLan%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DKaufman%26aufirst%3DD.%2BL.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520antihepatocellular%2520carcinoma%2520activity%2520of%2520nitric%2520oxide%2520releasing%2520derivatives%2520of%2520oleanolic%2520acid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4834%26epage%3D4838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span> </span><span class="NLM_article-title">Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">632</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=632-639&author=Z.+Huangauthor=Y.+Zhangauthor=L.+Zhaoauthor=Y.+Jingauthor=Y.+Laiauthor=L.+Zhangauthor=Q.+Guoauthor=S.+Yuanauthor=J.+Zhangauthor=L.+Chenauthor=S.+Pengauthor=J.+Tian&title=Synthesis+and+anti-human+hepatocellular+carcinoma+activity+of+new+nitric+oxide-releasing+glycosyl+derivatives+of+oleanolic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DJing%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520anti-human%2520hepatocellular%2520carcinoma%2520activity%2520of%2520new%2520nitric%2520oxide-releasing%2520glycosyl%2520derivatives%2520of%2520oleanolic%2520acid%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26spage%3D632%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ling, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span> </span><span class="NLM_article-title">Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3251</span><span class="NLM_x">–</span> <span class="NLM_lpage">3259</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1014814" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3251-3259&author=Y.+Lingauthor=X.+Yeauthor=Z.+Zhangauthor=Y.+Zhangauthor=Y.+Laiauthor=H.+Jiauthor=S.+Pengauthor=J.+Tian&title=Novel+nitric+oxide-releasing+derivatives+of+farnesylthiosalicylic+acid%3A+synthesis+and+evaluation+of+antihepatocellular+carcinoma+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm1014814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1014814%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DNovel%2520nitric%2520oxide-releasing%2520derivatives%2520of%2520farnesylthiosalicylic%2520acid%253A%2520synthesis%2520and%2520evaluation%2520of%2520antihepatocellular%2520carcinoma%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3251%26epage%3D3259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Kuntz, K.; Uehling, D. E.; Waterson, A. G.; Emmitte, K. A.; Stevens, K.; Shotwell, J. B.; Smith, S. C.; Nailor, K. E.; Salovich, J. M.; Wilson, B. J.; Cheung, M.; Mook, R. A.; Baum, E. W.; Moorthy, G.</span><span> </span><span class="NLM_article-title">Preparation of imidazopyridines as inhibitors of IGF-1R and IR and one or both of EGFR and ErbB2 kinases for treating neoplasm</span>. U.S. Pat. Appl. Publ. US 20080300242,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+Kuntz&author=D.+E.+Uehling&author=A.+G.+Waterson&author=K.+A.+Emmitte&author=K.+Stevens&author=J.+B.+Shotwell&author=S.+C.+Smith&author=K.+E.+Nailor&author=J.+M.+Salovich&author=B.+J.+Wilson&author=M.+Cheung&author=R.+A.+Mook&author=E.+W.+Baum&author=G.+Moorthy&title=Preparation+of+imidazopyridines+as+inhibitors+of+IGF-1R+and+IR+and+one+or+both+of+EGFR+and+ErbB2+kinases+for+treating+neoplasm"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520imidazopyridines%2520as%2520inhibitors%2520of%2520IGF-1R%2520and%2520IR%2520and%2520one%2520or%2520both%2520of%2520EGFR%2520and%2520ErbB2%2520kinases%2520for%2520treating%2520neoplasm%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Jares-Erijman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jovin, T. M.</span><span> </span><span class="NLM_article-title">FRET imaging</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnbt896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=14595367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=1387-1395&author=E.+A.+Jares-Erijmanauthor=T.+M.+Jovin&title=FRET+imaging"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">FRET imaging</span></div><div class="casAuthors">Jares-Erijman, Elizabeth A.; Jovin, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1387-1395</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Foerster (or Fluorescence) Resonance Energy Transfer (FRET) is unique in generating fluorescence signals sensitive to mol. conformation, assocn., and sepn. in the 1-10 nm range.  We introduce a revised photophys. framework for the phenomenon and provide a systematic catalog of FRET techniques adapted to imaging systems, including new approaches proposed as suitable prospects for implementation.  Applications extending from a single mol. to live cells will benefit from multidimensional microscopy techniques, particularly those adapted for optical sectioning and incorporating new algorithms for resolving the component contributions to images of complex mol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTN4i2irXbCLVg90H21EOLACvtfcHk0lgGJmIF5FwF5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D&md5=01814592b10786fdb8f660c4a23dfa78</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnbt896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt896%26sid%3Dliteratum%253Aachs%26aulast%3DJares-Erijman%26aufirst%3DE.%2BA.%26aulast%3DJovin%26aufirst%3DT.%2BM.%26atitle%3DFRET%2520imaging%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D1387%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine<sup>790</sup> → methionine<sup>790</sup> mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Coneski, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfisch, M. H.</span><span> </span><span class="NLM_article-title">Nitric oxide release: part III. Measurement and reporting</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">3753</span><span class="NLM_x">–</span> <span class="NLM_lpage">3758</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=3753-3758&author=P.+N.+Coneskiauthor=M.+H.+Schoenfisch&title=Nitric+oxide+release%3A+part+III.+Measurement+and+reporting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConeski%26aufirst%3DP.%2BN.%26aulast%3DSchoenfisch%26aufirst%3DM.%2BH.%26atitle%3DNitric%2520oxide%2520release%253A%2520part%2520III.%2520Measurement%2520and%2520reporting%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2012%26volume%3D41%26spage%3D3753%26epage%3D3758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Fukumura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashiwagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">The role of nitric oxide in tumour progression</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnrc1910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=16794635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=521-534&author=D.+Fukumuraauthor=S.+Kashiwagiauthor=R.+K.+Jain&title=The+role+of+nitric+oxide+in+tumour+progression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The role of nitric oxide in tumour progression</span></div><div class="casAuthors">Fukumura, Dai; Kashiwagi, Satoshi; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">521-534</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) and nitric oxide synthases are ubiquitous in malignant tumors and are known to exert both pro- and anti-tumor effects.  We summarize our current understanding of the role of NO in tumor progression, esp. in relation to angiogenesis and vascular functions.  We also discuss potential strategies for cancer treatment that modulate NO prodn. and/or its downstream signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorTlzSMm-9dbVg90H21EOLACvtfcHk0liRp8Y8h1bZCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFehu7Y%253D&md5=ee546d1b8e37e216ef373374ba15209c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrc1910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1910%26sid%3Dliteratum%253Aachs%26aulast%3DFukumura%26aufirst%3DD.%26aulast%3DKashiwagi%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DThe%2520role%2520of%2520nitric%2520oxide%2520in%2520tumour%2520progression%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D521%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 42 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yilan Ju, Jintao Wu, Xi Yuan, Luqing Zhao, Ganlin Zhang, Chao Li, <span class="NLM_string-name hlFld-ContribAuthor">Renzhong Qiao</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (24)
                                     , 11372-11383. <a href="https://doi.org/10.1021/acs.jmedchem.8b01612" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01612%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BEvaluation%252Bof%252BPotent%252BEGFR%252BInhibitors%252Bthrough%252Bthe%252BIncorporation%252Bof%252BMacrocyclic%252BPolyamine%252BMoieties%252Binto%252Bthe%252B4-Anilinoquinazoline%252BScaffold%26aulast%3DJu%26aufirst%3DYilan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17102018%26date%3D14122018%26date%3D03122018%26volume%3D61%26issue%3D24%26spage%3D11372%26epage%3D11383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Patrick Kielty, Dennis A. Smith, Peter Cannon, Michael P. Carty, Michael Kennedy, Patrick McArdle, Richard J. Singer, <span class="NLM_string-name hlFld-ContribAuthor">Fawaz Aldabbagh</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Methylmagnesium Chloride Mediated Acetylations of Isosorbide: A Route to Powerful Nitric Oxide Donor Furoxans. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (10)
                                     , 3025-3029. <a href="https://doi.org/10.1021/acs.orglett.8b01060" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b01060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b01060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b01060%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DSelective%252BMethylmagnesium%252BChloride%252BMediated%252BAcetylations%252Bof%252BIsosorbide%25253A%252BA%252BRoute%252Bto%252BPowerful%252BNitric%252BOxide%252BDonor%252BFuroxans%26aulast%3DKielty%26aufirst%3DPatrick%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04042018%26date%3D26042018%26volume%3D20%26issue%3D10%26spage%3D3025%26epage%3D3029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Junjie  Fu</span>, and <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (18)
                                     , 7617-7635. <a href="https://doi.org/10.1021/acs.jmedchem.6b01672" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01672</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01672%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNitric%252BOxide%252BDonor-Based%252BCancer%252BTherapy%25253A%252BAdvances%252Band%252BProspects%26aulast%3DHuang%26aufirst%3DZhangjian%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D13112016%26date%3D23052017%26date%3D28092017%26date%3D15052017%26volume%3D60%26issue%3D18%26spage%3D7617%26epage%3D7635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoke  Gu</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Zhiguang  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Tang</span>, <span class="hlFld-ContribAuthor ">Rongfang  Xue</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Luo</span>, <span class="hlFld-ContribAuthor ">Sixun  Peng</span>, <span class="hlFld-ContribAuthor ">Hui  Peng</span>, <span class="hlFld-ContribAuthor ">Bin  Lu</span>, <span class="hlFld-ContribAuthor ">Jide  Tian</span>, and <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Potent Inhibition of Nitric Oxide-Releasing Bifendate Derivatives against Drug-Resistant K562/A02 Cells in Vitro and in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (3)
                                     , 928-940. <a href="https://doi.org/10.1021/acs.jmedchem.6b01075" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01075%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252BInhibition%252Bof%252BNitric%252BOxide-Releasing%252BBifendate%252BDerivatives%252Bagainst%252BDrug-Resistant%252BK562%25252FA02%252BCells%252Bin%252BVitro%252Band%252Bin%252BVivo%26aulast%3DGu%26aufirst%3DXiaoke%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D26072016%26date%3D18012017%26date%3D09022017%26date%3D09012017%26volume%3D60%26issue%3D3%26spage%3D928%26epage%3D940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6580-6594. <a href="https://doi.org/10.1021/acs.jmedchem.5b00840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChallenges%252Band%252BPerspectives%252Bon%252Bthe%252BDevelopment%252Bof%252BSmall-Molecule%252BEGFR%252BInhibitors%252Bagainst%252BT790M-Mediated%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D02062015%26date%3D26022016%26date%3D28072016%26date%3D16022016%26volume%3D59%26issue%3D14%26spage%3D6580%26epage%3D6594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenwen  Duan</span>, <span class="hlFld-ContribAuthor ">Jin  Li</span>, <span class="hlFld-ContribAuthor ">Elizabeth S.  Inks</span>, <span class="hlFld-ContribAuthor ">C. James  Chou</span>, <span class="hlFld-ContribAuthor ">Yuping  Jia</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Chu</span>, <span class="hlFld-ContribAuthor ">Xiaoyang  Li</span>, <span class="hlFld-ContribAuthor ">Wenfang  Xu</span>, and <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (10)
                                     , 4325-4338. <a href="https://doi.org/10.1021/acs.jmedchem.5b00317" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00317</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00317%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BAntitumor%252BEvaluation%252Bof%252BNovel%252BHistone%252BDeacetylase%252BInhibitors%252BEquipped%252Bwith%252Ba%252BPhenylsulfonylfuroxan%252BModule%252Bas%252Ba%252BNitric%252BOxide%252BDonor%26aulast%3DDuan%26aufirst%3DWenwen%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D25022015%26date%3D07052015%26date%3D28052015%26date%3D23042015%26volume%3D58%26issue%3D10%26spage%3D4325%26epage%3D4338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Ai</span>, <span class="hlFld-ContribAuthor ">Fenghua  Kang</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaowen  Xue</span>, <span class="hlFld-ContribAuthor ">Yisheng  Lai</span>, <span class="hlFld-ContribAuthor ">Sixun  Peng</span>, <span class="hlFld-ContribAuthor ">Jide  Tian</span>, and <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of CDDO–Amino Acid–Nitric Oxide Donor Trihybrids as Potential Antitumor Agents against Both Drug-Sensitive and Drug-Resistant Colon Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (5)
                                     , 2452-2464. <a href="https://doi.org/10.1021/jm5019302" title="DOI URL">https://doi.org/10.1021/jm5019302</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm5019302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm5019302%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252BCDDO%2525E2%252580%252593Amino%252BAcid%2525E2%252580%252593Nitric%252BOxide%252BDonor%252BTrihybrids%252Bas%252BPotential%252BAntitumor%252BAgents%252Bagainst%252BBoth%252BDrug-Sensitive%252Band%252BDrug-Resistant%252BColon%252BCancer%26aulast%3DAi%26aufirst%3DYong%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D13122014%26date%3D23022015%26date%3D12032015%26date%3D12022015%26volume%3D58%26issue%3D5%26spage%3D2452%26epage%3D2464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Ming  Liu</span>, <span class="hlFld-ContribAuthor ">Xiao-Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Yao-Qing  Huang</span>, <span class="hlFld-ContribAuthor ">Pan  Feng</span>, <span class="hlFld-ContribAuthor ">Ya-Lan  Guo</span>, <span class="hlFld-ContribAuthor ">Gong  Yang</span>, and <span class="hlFld-ContribAuthor ">Ying  Chen</span>  . </span><span class="cited-content_cbyCitation_article-title">Hybrids of Phenylsulfonylfuroxan and Coumarin as Potent Antitumor Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (22)
                                     , 9343-9356. <a href="https://doi.org/10.1021/jm500613m" title="DOI URL">https://doi.org/10.1021/jm500613m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500613m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500613m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHybrids%252Bof%252BPhenylsulfonylfuroxan%252Band%252BCoumarin%252Bas%252BPotent%252BAntitumor%252BAgents%26aulast%3DLiu%26aufirst%3DMing-Ming%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D19042014%26date%3D10112014%26date%3D26112014%26date%3D28102014%26volume%3D57%26issue%3D22%26spage%3D9343%26epage%3D9356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nairong  Yu</span>, <span class="hlFld-ContribAuthor ">Na  Li</span>, <span class="hlFld-ContribAuthor ">Kun  Wang</span>, <span class="hlFld-ContribAuthor ">Qi  Deng</span>, <span class="hlFld-ContribAuthor ">Zhichao  Lei</span>, <span class="hlFld-ContribAuthor ">Jianbo  Sun</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological activity evaluation of novel scopoletin-NO donor derivatives against MCF-7 human breast cancer in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113701. <a href="https://doi.org/10.1016/j.ejmech.2021.113701" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113701%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivity%252Bevaluation%252Bof%252Bnovel%252Bscopoletin-NO%252Bdonor%252Bderivatives%252Bagainst%252BMCF-7%252Bhuman%252Bbreast%252Bcancer%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%26aulast%3DYu%26aufirst%3DNairong%26date%3D2021%26volume%3D224%26spage%3D113701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuxia  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Yang</span>, <span class="hlFld-ContribAuthor ">Tingting  Meng</span>, <span class="hlFld-ContribAuthor ">Yajuan  Qin</span>, <span class="hlFld-ContribAuthor ">Tingyou  Li</span>, <span class="hlFld-ContribAuthor ">Junjie  Fu</span>, <span class="hlFld-ContribAuthor ">Jian  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Nitric oxide-donating and reactive oxygen species-responsive prochelators based on 8-hydroxyquinoline as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113153. <a href="https://doi.org/10.1016/j.ejmech.2021.113153" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113153%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNitric%252Boxide-donating%252Band%252Breactive%252Boxygen%252Bspecies-responsive%252Bprochelators%252Bbased%252Bon%252B8-hydroxyquinoline%252Bas%252Banticancer%252Bagents%26aulast%3DZhang%26aufirst%3DYuxia%26date%3D2021%26volume%3D212%26spage%3D113153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Huilan  Li</span>, <span class="hlFld-ContribAuthor ">Zhifeng  Li</span>, <span class="hlFld-ContribAuthor ">Yulin  Feng</span>, <span class="hlFld-ContribAuthor ">Yi  Jin</span>, <span class="hlFld-ContribAuthor ">Yanhua  Liu</span>, <span class="hlFld-ContribAuthor ">Mingdong  Li</span>, <span class="hlFld-ContribAuthor ">Ronghua  Liu</span>, <span class="hlFld-ContribAuthor ">Yuanying  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Improved antiproliferative activity of novel
              Pulsatilla
              saponin D/α-hederin derivatives containing nitric oxide donors. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (45)
                                     , 19532-19540. <a href="https://doi.org/10.1039/D0NJ02941F" title="DOI URL">https://doi.org/10.1039/D0NJ02941F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ02941F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ02941F%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DImproved%252Bantiproliferative%252Bactivity%252Bof%252Bnovel%252BPulsatilla%252Bsaponin%252BD%25252F%2525CE%2525B1-hederin%252Bderivatives%252Bcontaining%252Bnitric%252Boxide%252Bdonors%26aulast%3DYang%26aufirst%3DZunhua%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D45%26spage%3D19532%26epage%3D19540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhixian  Shi</span>, <span class="hlFld-ContribAuthor ">Na  Li</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Yujin  Wang</span>, <span class="hlFld-ContribAuthor ">Zhichao  Lei</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Jianbo  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Novel NO-releasing scopoletin derivatives induce cell death via mitochondrial apoptosis pathway and cell cycle arrest. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112386. <a href="https://doi.org/10.1016/j.ejmech.2020.112386" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112386%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BNO-releasing%252Bscopoletin%252Bderivatives%252Binduce%252Bcell%252Bdeath%252Bvia%252Bmitochondrial%252Bapoptosis%252Bpathway%252Band%252Bcell%252Bcycle%252Barrest%26aulast%3DShi%26aufirst%3DZhixian%26date%3D2020%26volume%3D200%26spage%3D112386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun  Han</span>, <span class="hlFld-ContribAuthor ">Jiahong  Ren</span>, <span class="hlFld-ContribAuthor ">Feng  Su</span>, <span class="hlFld-ContribAuthor ">Xiaoqin  Hu</span>, <span class="hlFld-ContribAuthor ">Mengyao  Li</span>, <span class="hlFld-ContribAuthor ">Zhijun  Wang</span>, <span class="hlFld-ContribAuthor ">Lintao  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (6)
                                     , 724-733. <a href="https://doi.org/10.2174/1871520620666200302113206" title="DOI URL">https://doi.org/10.2174/1871520620666200302113206</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520620666200302113206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520620666200302113206%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DHybrids%252Bof%252BQuinoline%252Band%252BAnilinopyrimidine%25253A%252BNovel%252BEGFRT790M%252BInhibitors%252Bwith%252BAntiproliferative%252BActivity%252Bagainst%252BNon-Small%252BCell%252BLung%252BCancer%252BCell%252BLines%26aulast%3DHan%26aufirst%3DChun%26date%3D2020%26volume%3D20%26issue%3D6%26spage%3D724%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julie  Schmitt</span>, <span class="hlFld-ContribAuthor ">Elliot  Goodfellow</span>, <span class="hlFld-ContribAuthor ">Shanlong  Huang</span>, <span class="hlFld-ContribAuthor ">Christopher  Williams</span>, <span class="hlFld-ContribAuthor ">Izabela N.F.  Gomes</span>, <span class="hlFld-ContribAuthor ">Marcela N.  Rosa</span>, <span class="hlFld-ContribAuthor ">Rui M.  Reis</span>, <span class="hlFld-ContribAuthor ">Richard  Yang</span>, <span class="hlFld-ContribAuthor ">Hatem M.  Titi</span>, <span class="hlFld-ContribAuthor ">Bertrand J.  Jean-Claude</span>. </span><span class="cited-content_cbyCitation_article-title">Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112185. <a href="https://doi.org/10.1016/j.ejmech.2020.112185" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112185%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComparative%252Banalysis%252Bof%252Bthe%252Bdual%252BEGFR-DNA%252Btargeting%252Band%252Bgrowth%252Binhibitory%252Bproperties%252Bof%252B6-mono-alkylamino-%252Band%252B6%25252C6-dialkylaminoquinazoline-based%252Btype%252BII%252Bcombi-molecules%26aulast%3DSchmitt%26aufirst%3DJulie%26date%3D2020%26volume%3D192%26spage%3D112185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Lin</span>, <span class="hlFld-ContribAuthor ">Panpan  Wang</span>, <span class="hlFld-ContribAuthor ">Zemin  Zhang</span>, <span class="hlFld-ContribAuthor ">Guozhen  Xue</span>, <span class="hlFld-ContribAuthor ">Daijun  Zha</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Xiuzhi  Xu</span>, <span class="hlFld-ContribAuthor ">Zhulai  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis and anti-proliferative activity evaluation of quinoxaline derivatives. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2020,</strong> <em>50 </em>
                                    (6)
                                     , 823-830. <a href="https://doi.org/10.1080/00397911.2020.1714054" title="DOI URL">https://doi.org/10.1080/00397911.2020.1714054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2020.1714054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2020.1714054%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DFacile%252Bsynthesis%252Band%252Banti-proliferative%252Bactivity%252Bevaluation%252Bof%252Bquinoxaline%252Bderivatives%26aulast%3DLin%26aufirst%3DJin%26date%3D2020%26date%3D2020%26volume%3D50%26issue%3D6%26spage%3D823%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingda  Zang</span>, <span class="hlFld-ContribAuthor ">Fangfang  Lai</span>, <span class="hlFld-ContribAuthor ">Junmin  Fu</span>, <span class="hlFld-ContribAuthor ">Chuangjun  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Ma</span>, <span class="hlFld-ContribAuthor ">Chengjuan  Chen</span>, <span class="hlFld-ContribAuthor ">Ke  Liu</span>, <span class="hlFld-ContribAuthor ">Tiantai  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Dongming  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>190 </em>, 112079. <a href="https://doi.org/10.1016/j.ejmech.2020.112079" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112079%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bnitric%252Boxide-releasing%252Bderivatives%252Bof%252Btriptolide%252Bas%252Bantitumor%252Band%252Banti-inflammatory%252Bagents%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%25252C%252Band%252Bnitric%252Boxide%252Brelease%252Bstudies%26aulast%3DZang%26aufirst%3DYingda%26date%3D2020%26volume%3D190%26spage%3D112079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Wan</span>, <span class="hlFld-ContribAuthor ">Yan  Deng</span>, <span class="hlFld-ContribAuthor ">Yaoqing  Huang</span>, <span class="hlFld-ContribAuthor ">Zhihui  Yu</span>, <span class="hlFld-ContribAuthor ">Chunli  Wang</span>, <span class="hlFld-ContribAuthor ">Ke  Wang</span>, <span class="hlFld-ContribAuthor ">Jibin  Dong</span>, <span class="hlFld-ContribAuthor ">Ying  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Antitumor Evaluation of Novel Hybrids of Phenylsulfonylfuroxan and Estradiol Derivatives. </span><span class="cited-content_cbyCitation_journal-name">ChemistryOpen</span><span> <strong>2020,</strong> <em>9 </em>
                                    (2)
                                     , 176-182. <a href="https://doi.org/10.1002/open.201900228" title="DOI URL">https://doi.org/10.1002/open.201900228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/open.201900228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fopen.201900228%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistryOpen%26atitle%3DSynthesis%252Band%252BAntitumor%252BEvaluation%252Bof%252BNovel%252BHybrids%252Bof%252BPhenylsulfonylfuroxan%252Band%252BEstradiol%252BDerivatives%26aulast%3DWan%26aufirst%3DQi%26date%3D2020%26date%3D2019%26volume%3D9%26issue%3D2%26spage%3D176%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hugo P.  Monteiro</span>, <span class="hlFld-ContribAuthor ">Elaine G.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Adriana K.C.  Amorim Reis</span>, <span class="hlFld-ContribAuthor ">Luiz S.  Longo</span>, <span class="hlFld-ContribAuthor ">Fernando T.  Ogata</span>, <span class="hlFld-ContribAuthor ">Ana I.S.  Moretti</span>, <span class="hlFld-ContribAuthor ">Paulo E.  da Costa</span>, <span class="hlFld-ContribAuthor ">Ana C.S.  Teodoro</span>, <span class="hlFld-ContribAuthor ">Maytê S.  Toledo</span>, <span class="hlFld-ContribAuthor ">Arnold  Stern</span>. </span><span class="cited-content_cbyCitation_article-title">Nitric oxide and interactions with reactive oxygen species in the development of melanoma, breast, and colon cancer: A redox signaling perspective. </span><span class="cited-content_cbyCitation_journal-name">Nitric Oxide</span><span> <strong>2019,</strong> <em>89 </em>, 1-13. <a href="https://doi.org/10.1016/j.niox.2019.04.009" title="DOI URL">https://doi.org/10.1016/j.niox.2019.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.niox.2019.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.niox.2019.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DNitric%2520Oxide%26atitle%3DNitric%252Boxide%252Band%252Binteractions%252Bwith%252Breactive%252Boxygen%252Bspecies%252Bin%252Bthe%252Bdevelopment%252Bof%252Bmelanoma%25252C%252Bbreast%25252C%252Band%252Bcolon%252Bcancer%25253A%252BA%252Bredox%252Bsignaling%252Bperspective%26aulast%3DMonteiro%26aufirst%3DHugo%2BP.%26date%3D2019%26volume%3D89%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haihong  Li</span>, <span class="hlFld-ContribAuthor ">Ke  Wang</span>, <span class="hlFld-ContribAuthor ">Qi  Wan</span>, <span class="hlFld-ContribAuthor ">Ying  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anti-tumor evaluation of novel steroidal glycoconjugate with furoxan derivatives. </span><span class="cited-content_cbyCitation_journal-name">Steroids</span><span> <strong>2019,</strong> <em>141 </em>, 81-95. <a href="https://doi.org/10.1016/j.steroids.2018.11.018" title="DOI URL">https://doi.org/10.1016/j.steroids.2018.11.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.steroids.2018.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.steroids.2018.11.018%26sid%3Dliteratum%253Aachs%26jtitle%3DSteroids%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banti-tumor%252Bevaluation%252Bof%252Bnovel%252Bsteroidal%252Bglycoconjugate%252Bwith%252Bfuroxan%252Bderivatives%26aulast%3DLi%26aufirst%3DHaihong%26date%3D2019%26volume%3D141%26spage%3D81%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  YAN</span>, <span class="hlFld-ContribAuthor ">Yu-Xuan  DAI</span>, <span class="hlFld-ContribAuthor ">Guo-Long  GU</span>, <span class="hlFld-ContribAuthor ">Miao-Bo  PAN</span>, <span class="hlFld-ContribAuthor ">Shuai-Cong  WU</span>, <span class="hlFld-ContribAuthor ">Yu  CAO</span>, <span class="hlFld-ContribAuthor ">Wen-Long  HUANG</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of novel nitric oxide releasing dehydroandrographolide derivatives. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Natural Medicines</span><span> <strong>2018,</strong> <em>16 </em>
                                    (10)
                                     , 782-790. <a href="https://doi.org/10.1016/S1875-5364(18)30118-3" title="DOI URL">https://doi.org/10.1016/S1875-5364(18)30118-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S1875-5364(18)30118-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS1875-5364%2818%2930118-3%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Natural%2520Medicines%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bnitric%252Boxide%252Breleasing%252Bdehydroandrographolide%252Bderivatives%26aulast%3DYAN%26aufirst%3DLin%26date%3D2018%26volume%3D16%26issue%3D10%26spage%3D782%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fenghua  Kang</span>, <span class="hlFld-ContribAuthor ">Yong  Ai</span>, <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of new hybrids from 2-cyano-3,12-dioxooleana- 9-dien-28-oic acid and O 2 -(2,4-dinitrophenyl) diazeniumdiolate for intervention of drug-resistant lung cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>149 </em>, 269-280. <a href="https://doi.org/10.1016/j.ejmech.2018.02.062" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.062%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnew%252Bhybrids%252Bfrom%252B2-cyano-3%25252C12-dioxooleana-%252B9-dien-28-oic%252Bacid%252Band%252BO%252B2%252B-%2525282%25252C4-dinitrophenyl%252529%252Bdiazeniumdiolate%252Bfor%252Bintervention%252Bof%252Bdrug-resistant%252Blung%252Bcancer%26aulast%3DKang%26aufirst%3DFenghua%26date%3D2018%26volume%3D149%26spage%3D269%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Na  Bao</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Ou</span>, <span class="hlFld-ContribAuthor ">Manyi  Xu</span>, <span class="hlFld-ContribAuthor ">Fuqin  Guan</span>, <span class="hlFld-ContribAuthor ">Wei  Shi</span>, <span class="hlFld-ContribAuthor ">Jianbo  Sun</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Novel NO-releasing plumbagin derivatives: Design, synthesis and evaluation of antiproliferative activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>137 </em>, 88-95. <a href="https://doi.org/10.1016/j.ejmech.2017.05.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BNO-releasing%252Bplumbagin%252Bderivatives%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bantiproliferative%252Bactivity%26aulast%3DBao%26aufirst%3DNa%26date%3D2017%26volume%3D137%26spage%3D88%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kangtao  Tian</span>, <span class="hlFld-ContribAuthor ">Fanxing  Xu</span>, <span class="hlFld-ContribAuthor ">Xiang  Gao</span>, <span class="hlFld-ContribAuthor ">Tong  Han</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Huaqi  Pan</span>, <span class="hlFld-ContribAuthor ">Linghe  Zang</span>, <span class="hlFld-ContribAuthor ">Dahong  Li</span>, <span class="hlFld-ContribAuthor ">Zhanlin  Li</span>, <span class="hlFld-ContribAuthor ">Takahiro  Uchita</span>, <span class="hlFld-ContribAuthor ">Ming  Gao</span>, <span class="hlFld-ContribAuthor ">Huiming  Hua</span>. </span><span class="cited-content_cbyCitation_article-title">Nitric oxide-releasing derivatives of brefeldin A as potent and highly selective anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>136 </em>, 131-143. <a href="https://doi.org/10.1016/j.ejmech.2017.05.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNitric%252Boxide-releasing%252Bderivatives%252Bof%252Bbrefeldin%252BA%252Bas%252Bpotent%252Band%252Bhighly%252Bselective%252Banticancer%252Bagents%26aulast%3DTian%26aufirst%3DKangtao%26date%3D2017%26volume%3D136%26spage%3D131%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Haiqing  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Jiang</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Hunjun  Sun</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>133 </em>, 329-339. <a href="https://doi.org/10.1016/j.ejmech.2017.03.083" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.03.083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.03.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.03.083%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bmorpholine-substituted%252Bdiphenylpyrimidine%252Bderivatives%252B%252528Mor-DPPYs%252529%252Bas%252Bpotent%252BEGFR%252BT790M%252Binhibitors%252Bwith%252Bimproved%252Bactivity%252Btoward%252Bthe%252Bgefitinib-resistant%252Bnon-small%252Bcell%252Blung%252Bcancers%252B%252528NSCLC%252529%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2017%26volume%3D133%26spage%3D329%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid L.  Fershtat</span>, <span class="hlFld-ContribAuthor ">Nina N.  Makhova</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Hybridization Tools in the Development of Furoxan-Based NO-Donor Prodrugs. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (9)
                                     , 622-638. <a href="https://doi.org/10.1002/cmdc.201700113" title="DOI URL">https://doi.org/10.1002/cmdc.201700113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700113%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DMolecular%252BHybridization%252BTools%252Bin%252Bthe%252BDevelopment%252Bof%252BFuroxan-Based%252BNO-Donor%252BProdrugs%26aulast%3DFershtat%26aufirst%3DLeonid%2BL.%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D9%26spage%3D622%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Haijun  Yang</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Lei  Li</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Yuhong  Zhen</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton’s tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (2)
                                     , 765-772. <a href="https://doi.org/10.1016/j.bmc.2016.11.054" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.11.054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.11.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.11.054%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bphosphoryl-substituted%252Bdiphenylpyrimidines%252B%252528Pho-DPPYs%252529%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%25253A%252BTargeted%252Btreatment%252Bof%252BB%252Blymphoblastic%252Bleukemia%252Bcell%252Blines%26aulast%3DGe%26aufirst%3DYang%26date%3D2017%26volume%3D25%26issue%3D2%26spage%3D765%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Zhao</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Menghua  Qu</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Zhen  Li</span>, <span class="hlFld-ContribAuthor ">Jinyong  Peng</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 444-455. <a href="https://doi.org/10.1016/j.ejmech.2016.11.047" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.11.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.11.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.11.047%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Bof%252Bdiphenylpyrimidine%252Bderivatives%252B%252528DPPYs%252529%252Bas%252Bpotent%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%252Bwith%252Bimproved%252Bactivity%252Btoward%252BB%252Bleukemia%252Bcell%252Blines%26aulast%3DZhao%26aufirst%3DDan%26date%3D2017%26volume%3D126%26spage%3D444%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Yue  Jin</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Jinyong  Peng</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (21)
                                     , 5505-5512. <a href="https://doi.org/10.1016/j.bmc.2016.09.001" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.09.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bazole-diphenylpyrimidine%252Bderivatives%252B%252528AzDPPYs%252529%252Bas%252Bpotent%252BT790M%252Bmutant%252Bform%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2016%26volume%3D24%26issue%3D21%26spage%3D5505%26epage%3D5512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dahong  Li</span>, <span class="hlFld-ContribAuthor ">Tong  Han</span>, <span class="hlFld-ContribAuthor ">Kangtao  Tian</span>, <span class="hlFld-ContribAuthor ">Shuang  Tang</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>, <span class="hlFld-ContribAuthor ">Xu  Hu</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhanlin  Li</span>, <span class="hlFld-ContribAuthor ">Huiming  Hua</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Novel nitric oxide-releasing spirolactone-type diterpenoid derivatives with in vitro synergistic anticancer activity as apoptosis inducer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (17)
                                     , 4191-4196. <a href="https://doi.org/10.1016/j.bmcl.2016.07.059" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.07.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.07.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.07.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252Bnitric%252Boxide-releasing%252Bspirolactone-type%252Bditerpenoid%252Bderivatives%252Bwith%252Bin%252Bvitro%252Bsynergistic%252Banticancer%252Bactivity%252Bas%252Bapoptosis%252Binducer%26aulast%3DLi%26aufirst%3DDahong%26date%3D2016%26volume%3D26%26issue%3D17%26spage%3D4191%26epage%3D4196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siyuan  Yin</span>, <span class="hlFld-ContribAuthor ">Chunming  Tang</span>, <span class="hlFld-ContribAuthor ">Bin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Zhang</span>, <span class="hlFld-ContribAuthor ">Liliang  Zhou</span>, <span class="hlFld-ContribAuthor ">Lingjing  Xue</span>, <span class="hlFld-ContribAuthor ">Can  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>120 </em>, 26-36. <a href="https://doi.org/10.1016/j.ejmech.2016.04.072" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.072%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252BEGFR%25252FHER2%252Bdual%252Binhibitors%252Bbearing%252Ba%252Boxazolo%25255B4%25252C5-g%25255Dquinazolin-2%2525281H%252529-one%252Bscaffold%26aulast%3DYin%26aufirst%3DSiyuan%26date%3D2016%26volume%3D120%26spage%3D26%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dahong  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Hu</span>, <span class="hlFld-ContribAuthor ">Tong  Han</span>, <span class="hlFld-ContribAuthor ">Jie  Liao</span>, <span class="hlFld-ContribAuthor ">Wei  Xiao</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>, <span class="hlFld-ContribAuthor ">Zhanlin  Li</span>, <span class="hlFld-ContribAuthor ">Zhenzhong  Wang</span>, <span class="hlFld-ContribAuthor ">Huiming  Hua</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">NO-Releasing Enmein-Type Diterpenoid Derivatives with Selective Antiproliferative Activity and Effects on Apoptosis-Related Proteins. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (9)
                                     , 1193. <a href="https://doi.org/10.3390/molecules21091193" title="DOI URL">https://doi.org/10.3390/molecules21091193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21091193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21091193%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNO-Releasing%252BEnmein-Type%252BDiterpenoid%252BDerivatives%252Bwith%252BSelective%252BAntiproliferative%252BActivity%252Band%252BEffects%252Bon%252BApoptosis-Related%252BProteins%26aulast%3DLi%26aufirst%3DDahong%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D9%26spage%3D1193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Zhao</span>, <span class="hlFld-ContribAuthor ">Kang-tao  Tian</span>, <span class="hlFld-ContribAuthor ">Ke-guang  Cheng</span>, <span class="hlFld-ContribAuthor ">Tong  Han</span>, <span class="hlFld-ContribAuthor ">Xu  Hu</span>, <span class="hlFld-ContribAuthor ">Da-hong  Li</span>, <span class="hlFld-ContribAuthor ">Zhan-lin  Li</span>, <span class="hlFld-ContribAuthor ">Hui-ming  Hua</span>. </span><span class="cited-content_cbyCitation_article-title">Antiproliferative activity and apoptosis inducing effects of nitric oxide donating derivatives of evodiamine. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (13)
                                     , 2971-2978. <a href="https://doi.org/10.1016/j.bmc.2016.05.001" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAntiproliferative%252Bactivity%252Band%252Bapoptosis%252Binducing%252Beffects%252Bof%252Bnitric%252Boxide%252Bdonating%252Bderivatives%252Bof%252Bevodiamine%26aulast%3DZhao%26aufirst%3DNan%26date%3D2016%26volume%3D24%26issue%3D13%26spage%3D2971%26epage%3D2978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dahong  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Hu</span>, <span class="hlFld-ContribAuthor ">Tong  Han</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhenzhong  Wang</span>, <span class="hlFld-ContribAuthor ">Keguang  Cheng</span>, <span class="hlFld-ContribAuthor ">Zhanlin  Li</span>, <span class="hlFld-ContribAuthor ">Huiming  Hua</span>, <span class="hlFld-ContribAuthor ">Wei  Xiao</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Biological Activity, and Apoptotic Properties of NO-Donor/Enmein-Type ent-Kauranoid Hybrids. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2016,</strong> <em>17 </em>
                                    (6)
                                     , 747. <a href="https://doi.org/10.3390/ijms17060747" title="DOI URL">https://doi.org/10.3390/ijms17060747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms17060747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms17060747%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DSynthesis%25252C%252BBiological%252BActivity%25252C%252Band%252BApoptotic%252BProperties%252Bof%252BNO-Donor%25252FEnmein-Type%252Bent-Kauranoid%252BHybrids%26aulast%3DLi%26aufirst%3DDahong%26date%3D2016%26date%3D2016%26volume%3D17%26issue%3D6%26spage%3D747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlan  Wang</span>, <span class="hlFld-ContribAuthor ">Guimin  Xia</span>, <span class="hlFld-ContribAuthor ">Xiujun  Liu</span>, <span class="hlFld-ContribAuthor ">Rui  Zhang</span>, <span class="hlFld-ContribAuthor ">Yun  Chai</span>, <span class="hlFld-ContribAuthor ">Jun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoning  Li</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Juxian  Wang</span>, <span class="hlFld-ContribAuthor ">Mingliang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (9)
                                     , 2355-2359. <a href="https://doi.org/10.1016/j.bmcl.2016.03.012" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.03.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.03.012%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252BATB-429%252Bderivatives%252Bcontaining%252Ba%252Bnitric%252Boxide-releasing%252Bmoiety%26aulast%3DWang%26aufirst%3DChunlan%26date%3D2016%26volume%3D26%26issue%3D9%26spage%3D2355%26epage%3D2359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiqing  Yu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Yue  Jin</span>, <span class="hlFld-ContribAuthor ">Xu  Han</span>, <span class="hlFld-ContribAuthor ">Yuhong  Zhen</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>110 </em>, 195-203. <a href="https://doi.org/10.1016/j.ejmech.2016.01.045" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.01.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.01.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.01.045%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B4-anilinoquinazoline%252Bderivatives%252Bfeaturing%252Ban%252B1-adamantyl%252Bmoiety%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bwith%252Benhanced%252Bactivity%252Bagainst%252BNSCLC%252Bcell%252Blines%26aulast%3DYu%26aufirst%3DHaiqing%26date%3D2016%26volume%3D110%26spage%3D195%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vadim  Bernard-Gauthier</span>, <span class="hlFld-ContribAuthor ">Justin  Bailey</span>, <span class="hlFld-ContribAuthor ">Sheldon  Berke</span>, <span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2015,</strong> <em>20 </em>
                                    (12)
                                     , 22000-22027. <a href="https://doi.org/10.3390/molecules201219816" title="DOI URL">https://doi.org/10.3390/molecules201219816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules201219816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules201219816%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Band%252BApplication%252Bof%252BRadiolabeled%252BKinase%252BInhibitors%252Bfor%252BPET%252BImaging%26aulast%3DBernard-Gauthier%26aufirst%3DVadim%26date%3D2015%26date%3D2015%26volume%3D20%26issue%3D12%26spage%3D22000%26epage%3D22027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debjit  Basu</span>, <span class="hlFld-ContribAuthor ">André  Richters</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (12)
                                     , 2767-2780. <a href="https://doi.org/10.1016/j.bmc.2015.04.038" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.04.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.04.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.04.038%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252Bcovalent-reversible%252Binhibitors%252Bto%252Bovercome%252Bdrug%252Bresistance%252Bin%252BEGFR%26aulast%3DBasu%26aufirst%3DDebjit%26date%3D2015%26volume%3D23%26issue%3D12%26spage%3D2767%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Luo</span>, <span class="hlFld-ContribAuthor ">Yongxia  Zhu</span>, <span class="hlFld-ContribAuthor ">Kai  Ran</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Ningyu  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Feng</span>, <span class="hlFld-ContribAuthor ">Jun  Zeng</span>, <span class="hlFld-ContribAuthor ">Lidan  Zhang</span>, <span class="hlFld-ContribAuthor ">Bing  He</span>, <span class="hlFld-ContribAuthor ">Tinghong  Ye</span>, <span class="hlFld-ContribAuthor ">Shirui  Zhu</span>, <span class="hlFld-ContribAuthor ">Xiaolong  Qiu</span>, <span class="hlFld-ContribAuthor ">Luoting  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of N-(4-phenylthiazol-2-yl)cinnamamide derivatives as novel potential anti-tumor agents. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2015,</strong> <em>6 </em>
                                    (6)
                                     , 1036-1042. <a href="https://doi.org/10.1039/C4MD00573B" title="DOI URL">https://doi.org/10.1039/C4MD00573B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4MD00573B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4MD00573B%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BN-%2525284-phenylthiazol-2-yl%252529cinnamamide%252Bderivatives%252Bas%252Bnovel%252Bpotential%252Banti-tumor%252Bagents%26aulast%3DLuo%26aufirst%3DYong%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D1036%26epage%3D1042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah Fernandes  Teixeira</span>, <span class="hlFld-ContribAuthor ">Ricardo  Alexandre de Azevedo</span>, <span class="hlFld-ContribAuthor ">Maria Alejandra Clavijo  Salomon</span>, <span class="hlFld-ContribAuthor ">Salomão Dória  Jorge</span>, <span class="hlFld-ContribAuthor ">Débora  Levy</span>, <span class="hlFld-ContribAuthor ">Sérgio Paulo  Bydlowski</span>, <span class="hlFld-ContribAuthor ">Cecília Pessoa  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Célia Regina  Pizzo</span>, <span class="hlFld-ContribAuthor ">José Alexandre Marzagão  Barbuto</span>, <span class="hlFld-ContribAuthor ">Adilson Kleber  Ferreira</span>. </span><span class="cited-content_cbyCitation_article-title">Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2014,</strong> <em>68 </em>
                                    (8)
                                     , 1015-1022. <a href="https://doi.org/10.1016/j.biopha.2014.09.007" title="DOI URL">https://doi.org/10.1016/j.biopha.2014.09.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2014.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2014.09.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DSynergistic%252Banti-tumor%252Beffects%252Bof%252Bthe%252Bcombination%252Bof%252Ba%252Bbenzofuroxan%252Bderivate%252Band%252Bsorafenib%252Bon%252BNCI-H460%252Bhuman%252Blarge%252Bcell%252Blung%252Bcarcinoma%252Bcells%26aulast%3DTeixeira%26aufirst%3DSarah%2BFernandes%26date%3D2014%26volume%3D68%26issue%3D8%26spage%3D1015%26epage%3D1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun  Han</span>, <span class="hlFld-ContribAuthor ">Ledong  Wan</span>, <span class="hlFld-ContribAuthor ">Hongbin  Ji</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Zhangjian  Huang</span>, <span class="hlFld-ContribAuthor ">Yisheng  Lai</span>, <span class="hlFld-ContribAuthor ">Sixun  Peng</span>, <span class="hlFld-ContribAuthor ">Yihua  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>77 </em>, 75-83. <a href="https://doi.org/10.1016/j.ejmech.2014.02.032" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.02.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.02.032%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252B2-anilinopyrimidines%252Bbearing%252B3-aminopropamides%252Bas%252Bpotential%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%26aulast%3DHan%26aufirst%3DChun%26date%3D2014%26volume%3D77%26spage%3D75%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shiliang  Tu</span>, <span class="hlFld-ContribAuthor ">Hang  Yuan</span>, <span class="hlFld-ContribAuthor ">Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Chengguang  Zhao</span>, <span class="hlFld-ContribAuthor ">Rui  Chai</span>, <span class="hlFld-ContribAuthor ">Hongfeng  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Nitro Oxide Donating N-Hydroxycinnamamide Derivatives as Histone Deacetylase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2014,</strong> <em>62 </em>
                                    (12)
                                     , 1185-1191. <a href="https://doi.org/10.1248/cpb.c14-00449" title="DOI URL">https://doi.org/10.1248/cpb.c14-00449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c14-00449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c14-00449%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNitro%252BOxide%252BDonating%252BN-Hydroxycinnamamide%252BDerivatives%252Bas%252BHistone%252BDeacetylase%252BInhibitors%26aulast%3DTu%26aufirst%3DShiliang%26date%3D2014%26volume%3D62%26issue%3D12%26spage%3D1185%26epage%3D1191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative reversible and irreversible EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of <b>12a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) piperazine, dioxane, reflux, overnight, 97%; (b) ethyl bromoacetate, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux, 4 h, 90%; (c) iron powder, NH<sub>4</sub>Cl, THF/H<sub>2</sub>O (1:1, v/v), reflux, 3 h, 99% for <b>4</b>, 80% for <b>7</b>; (d) 2,4,5-trichloropyrimidine, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 2 h, 95%; (e) acryloyl chloride, Et<sub>3</sub>N, anhydrous CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 1 h, 90%; (f) TFA, 2-BuOH, reflux, 3 h, 80%; (g) LiOH, THF/H<sub>2</sub>O (1:1, v/v), 0 °C, 1 h, 98%; (h) <b>11a</b>–<b>k</b>, DCC/DMAP, anhydrous CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight, 70%–85%.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of NO production by the target compounds on NSCLC cell proliferation. (A) Variable levels of NO (presented as nitrite) produced by the indicated compounds. H1975 and 16HBE cells were treated with individual compounds at 100 μM for 150 min, and the concentrations of nitrite in the cell lysates were determined by Griess assay. The individual values were determined by measuring the absorbance at 540 nm and calculated according to the standard curve. Data are expressed as the mean ± SD of each compound in individual types of cells from three experiments. Key: (**) <i>p</i> < 0.01, (***) <i>p</i> < 0.001 vs 16HBE group. (B) Effects of hemoglobin on the antiproliferative effect of <b>12k</b>. H1975 and HCC827 cells were pretreated with the indicated concentrations of hemoglobin (Hb) (0, 1, 5, 10, or 20 μM) for 1 h and treated with 1 μM <b>12k</b> for 24 h. The results are expressed as the percentage of cell growth inhibition relative to control cells. Data are the mean value ± SD obtained from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>12k</b> and <b>1</b> induced H1975 (A) and HCC827 (B) cell apoptosis in vitro. The cells were incubated with the indicated concentrations of <b>12k</b> or <b>1</b> for 24 h, and the cells were stained with 7-AAD and annexin-V, followed by flow cytometry analysis. The quantitative data are expressed as the mean ± SD of the percentages of apoptotic cells from three independent experiments. Key: (**) <i>p</i> < 0.01, (***) <i>p</i> < 0.001 vs <b>1</b> group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compounds <b>12k</b> and <b>1</b> inhibited the activation of EGFR and downstream signaling in H1975 NSCLC cells harboring EGFR L858R/T790M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/medium/jm-2013-00463q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vivo antitumor effect of compound <b>12k</b> in a human NSCLC (H1975) xenograft nude mouse model. The H1975 model was resistant to gefitinib and sensitive to <b>1</b>. Tumor volumes were measured every other day. Data are shown as the mean ± SD from each group of mice (<i>n</i> = 6). Statistical significance (<i>p</i> < 0.05) for antitumor efficacy, based upon tumor growth relative to the vehicle controls.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400463q/production/images/large/jm-2013-00463q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400463q&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Olayioye, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The ErbB signaling network: receptor heterodimerization in development and cancer</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3159</span><span class="NLM_x">–</span> <span class="NLM_lpage">3167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1093%2Femboj%2F19.13.3159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=10880430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=3159-3167&author=M.+A.+Olayioyeauthor=R.+M.+Neveauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+ErbB+signaling+network%3A+receptor+heterodimerization+in+development+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network: receptor heterodimerization in development and cancer</span></div><div class="casAuthors">Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3159-3167</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review, with ∼126 refs., on individual ErbB receptors and their signaling pot. and examples of specific ErbB heterodimers in signaling and development.  The authors particular emphasis is on their role in mammary gland biol. , an organ in which the ErbB family and its ligands are critically involved in development, differentiation and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03qEN815kibVg90H21EOLACvtfcHk0livXHrcD1CUbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1ajtLY%253D&md5=3e70478dda68f1cfd5ab5bdb910e96a2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F19.13.3159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F19.13.3159%26sid%3Dliteratum%253Aachs%26aulast%3DOlayioye%26aufirst%3DM.%2BA.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520ErbB%2520signaling%2520network%253A%2520receptor%2520heterodimerization%2520in%2520development%2520and%2520cancer%26jtitle%3DEMBO%2520J.%26date%3D2000%26volume%3D19%26spage%3D3159%26epage%3D3167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Mendelsohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor targeting in cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1053%2Fj.seminoncol.2006.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=16890793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2006&pages=369-385&author=J.+Mendelsohnauthor=J.+Baselga&title=Epidermal+growth+factor+receptor+targeting+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor targeting in cancer</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-385</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family that is abnormally activated in many epithelial tumors.  Several mechanisms lead to the receptor's aberrant activation that is obsd. in cancer, including receptor overexpression, mutation, ligand-dependent receptor dimerization, and ligand-independent activation.  Two classes of anti-EGFR agents are currently approved for the treatment of patients with cancer: cetuximab, a monoclonal antibody directed at the extracellular domain of the receptor, and gefitinib and erlotinib, oral, low-mol.-wt. (MW), ATP-competitive inhibitors of the receptor's tyrosine kinase.  Anti-EGFR monoclonal antibodies have demonstrated activity in the therapy of advanced colorectal carcinoma and in a variety of epithelial tumor types, including head and neck cancer and non-small cell lung cancer (NSCLC).  The development of low MW, anti-EGFR tyrosine kinase inhibitors (TKIs) has been focused until recently on NSCLC, although responses have been reported for other types of cancer.  Erlotinib was the only agent approved based on demonstrating improved survival, which was obsd. in patients with advanced NSCLC who previously had been treated with chemotherapy.  Recent major advances in the EGFR field include the discovery of EGFR somatic mutations in NSCLC that have important implications for biol., treatment, clin. trial design, and methods for mutation detection.  Clin. and survival benefits with anti-EGFR agents have been demonstrated in addnl. tumor types such as head and neck and pancreatic carcinomas.  New agents with clin. activity are entering the clinic and new combinatorial approaches with anti-EGFR agents are being explored.  Major efforts are, belatedly, attempting to identify mol. markers that can predict patients more likely to respond to anti-EGFR therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkawbwoHPfpLVg90H21EOLACvtfcHk0lhbPkv8l6NYIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersLk%253D&md5=68ddafac141c8351630137c8b28ca74e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2006.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2006.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520targeting%2520in%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2006%26volume%3D33%26spage%3D369%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lhbPkv8l6NYIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Le, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chetty, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor expression in anal canal carcinoma</span> <span class="citation_source-journal">Am. J. Clin. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1309%2FX4UADHVN317V2XMW" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15923158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVGnsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2005&pages=20-23&author=L.+H.+Leauthor=R.+Chettyauthor=M.+J.+Moore&title=Epidermal+growth+factor+receptor+expression+in+anal+canal+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor expression in anal canal carcinoma</span></div><div class="casAuthors">Le, Lyly H.; Chetty, Runjan; Moore, Malcolm J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-23</span>CODEN:
                <span class="NLM_cas:coden">AJCPAI</span>;
        ISSN:<span class="NLM_cas:issn">0002-9173</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Pathology</span>)
        </div><div class="casAbstract">Most anal canal carcinomas (ACCs) are squamous cell carcinomas (SCCs).  SCCs in other tumor sites strongly express epidermal growth factor receptors (EGFRs), the inhibition of which might result in favorable changes in tumor growth.  A review of the published scientific literature reveals no information regarding the expression of EGFR in ACCs.  Therefore, we obtained archived pathol. samples from ACC biopsies and examd. the frequency and level of expression of EGFR and other cell surface and cell cycle markers.  The 21 samples studied universally and strongly expressed EGFR and were neg. for HER-2.  Clin. studies of EGFR inhibitors in advanced ACC are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9-g7t4797grVg90H21EOLACvtfcHk0lhbPkv8l6NYIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVGnsbY%253D&md5=9e2173f3725ba21f7aab99bc68b15791</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1309%2FX4UADHVN317V2XMW&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1309%252FX4UADHVN317V2XMW%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DL.%2BH.%26aulast%3DChetty%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520expression%2520in%2520anal%2520canal%2520carcinoma%26jtitle%3DAm.%2520J.%2520Clin.%2520Pathol.%26date%3D2005%26volume%3D124%26spage%3D20%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiestler, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Deimling, A.</span><span> </span><span class="NLM_article-title">Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme</span> <span class="citation_source-journal">Brain Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">871</span><span class="NLM_x">–</span> <span class="NLM_lpage">875</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1111%2Fj.1750-3639.1997.tb00890.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=9217972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADyaK2sXks1Skurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=871-875&author=Y.+Hayashiauthor=K.+Uekiauthor=A.+Wahaauthor=O.+D.+Wiestlerauthor=D.+N.+Louisauthor=A.+von+Deimling&title=Association+of+EGFR+gene+amplification+and+CDKN2+%28p16%2FMTS1%29+gene+deletion+in+glioblastoma+multiforme"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Association of EGFR gene amplification and CDKN2 (p 16/MTS 1) gene deletion in glioblastoma multiforme</span></div><div class="casAuthors">Hayashi, Yutaka; Ueki, Keisuke; Waha, Andreas; Wiestler, Otmar D.; Louis, David N.; Von Deimling, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Brain Pathology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">871-875</span>CODEN:
                <span class="NLM_cas:coden">BRPAE7</span>;
        ISSN:<span class="NLM_cas:issn">1015-6305</span>.
    
            (<span class="NLM_cas:orgname">International Society of Neuropathology</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) can be divided into genetic subsets: approx. one-third of GBM, primarily in older adults, have EGFR amplification; another one-third, primarily in younger adults, have TP53 mutation.  The majority of GBM also have homozygous deletions of the CDKN2 (p16/MTS1) gene, resulting in cell cycle deregulation and elevated proliferation indexes.  We evaluated the relationship between CDKN2 deletions and the GBM subsets as defined by EGFR amplification or TP53 mutation in 70 GBM.  Twenty-eight cases (40%) had EGFR amplification, 21 (30%) had TP53 mutation, and 21 (30%) had neither change.  CDKN2 deletions were present in 36 (51%) GBM.  Of the 28 GBM with EGFR amplification, 20 (71%) had CDKN2 deletion (p = 0.0078).  The remaining 16 cases with CDKN2 loss were divided between GBM with TP53 mutations (6 cases) and GBM with neither EGFR amplification nor TP53 mutation (10 cases).  Thus, CDKN2 deletions occur twice as commonly in GBM with EGFR amplification (71%) than in GBM with TP53 mutation (29%).  CDKN2 deletions occurred in GBM from patients somewhat older than those patients with GBM lacking CDKN2 deletion (mean age 53 vs. 48 yr).  Specifically among GBM with EGFR amplification, those with CDKN2 deletions also occurred in patients slightly older than those few GBM without CDKN2 deletions (mean age 55 vs. 51 yr).  The presence of CDKN2 deletions in most GBM with EGFR amplification and in generally older patients may provide one explanation for the potentially more aggressive nature of such tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrsMa5kqhhG7Vg90H21EOLACvtfcHk0lhNJT5hOgzsxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXks1Skurs%253D&md5=b04bf59e302420b06a53bd6385bd7309</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1750-3639.1997.tb00890.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1750-3639.1997.tb00890.x%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DUeki%26aufirst%3DK.%26aulast%3DWaha%26aufirst%3DA.%26aulast%3DWiestler%26aufirst%3DO.%2BD.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26atitle%3DAssociation%2520of%2520EGFR%2520gene%2520amplification%2520and%2520CDKN2%2520%2528p16%252FMTS1%2529%2520gene%2520deletion%2520in%2520glioblastoma%2520multiforme%26jtitle%3DBrain%2520Pathol.%26date%3D1997%26volume%3D7%26spage%3D871%26epage%3D875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naishadham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer statistics, 2013</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.3322%2Fcaac.21166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=23335087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A280%3ADC%252BC3szgvFSqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=11-30&author=R.+Siegelauthor=D.+Naishadhamauthor=A.+Jemal&title=Cancer+statistics%2C+2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2013</span></div><div class="casAuthors">Siegel Rebecca; Naishadham Deepa; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics.  A total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013.  During the most recent 5 years for which there are data (2005-2009), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women.  Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 100,000 population) to 2009 (173.1 per 100,000 population).  Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate).  Over the past 10 years of data (2000-2009), the largest annual declines in death rates were for chronic myeloid leukemia (8.4%), cancers of the stomach (3.1%) and colorectum (3.0%), and non-Hodgkin lymphoma (3.0%).  The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of approximately 1.18 million deaths from cancer, with 152,900 of these deaths averted in 2009 alone.  Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA4Ff_lauq0IkFb3mqPUYDfW6udTcc2eZqdB2q_cgit7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szgvFSqsw%253D%253D&md5=1b89010b6bcfc5472f32879085ab4ccc</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21166%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DNaishadham%26aufirst%3DD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202013%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2013%26volume%3D63%26spage%3D11%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippman, S. M.</span><span> </span><span class="NLM_article-title">Lung cancer</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">–</span> <span class="NLM_lpage">1380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1056%2FNEJMra0802714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=18815398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKjt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1367-1380&author=R.+S.+Herbstauthor=J.+V.+Heymachauthor=S.+M.+Lippman&title=Lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular origins of cancer: lung cancer</span></div><div class="casAuthors">Herbst, Roy S.; Heymach, John V.; Lippman, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1367-1380</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The altered mol. genetics of non-small-cell lung cancer is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxvIgLl4BT2LVg90H21EOLACvtfcHk0lhNJT5hOgzsxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKjt7bM&md5=a5968124ab5b0807e9a1b89e5e2dad51</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0802714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0802714%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26atitle%3DLung%2520cancer%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D1367%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, N.</span><span> </span><span class="NLM_article-title">New driver mutations in non-small-cell lung cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1016%2FS1470-2045%2810%2970087-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=21277552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ns74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=175-180&author=W.+Paoauthor=N.+Girard&title=New+driver+mutations+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">New driver mutations in non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Girard, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-180</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Treatment decisions for patients with lung cancer have historically been based on tumor histol.  Some understanding of the mol. compn. of tumors has led to the development of targeted agents, for which initial findings are promising.  Clearer understanding of mutations in relevant genes and their effects on cancer cell proliferation and survival, is, therefore, of substantial interest.  We review current knowledge about mol. subsets in non-small-cell lung cancer that have been identified as potentially having clin. relevance to targeted therapies.  Since mutations in EGFR and KRAS have been extensively reviewed elsewhere, here, we discuss subsets defined by so-called driver mutations in ALK, HER2 (also known as ERBB2), BRAF, PIK3CA, AKT1, MAP2K1, and MET.  The adoption of treatment tailored according to the genetic make-up of individual tumors would involve a paradigm shift, but might lead to substantial therapeutic improvements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplMPwgmZjAT7Vg90H21EOLACvtfcHk0lhNJT5hOgzsxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ns74%253D&md5=3d590b884d4a9827e85781d65d17759f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970087-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970087-5%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DGirard%26aufirst%3DN.%26atitle%3DNew%2520driver%2520mutations%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26spage%3D175%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Suda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomizawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span> </span><span class="NLM_article-title">Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1007%2Fs10555-010-9209-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=20108024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVOjtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=49-60&author=K.+Sudaauthor=K.+Tomizawaauthor=T.+Mitsudomi&title=Biological+and+clinical+significance+of+KRAS+mutations+in+lung+cancer%3A+an+oncogenic+driver+that+contrasts+with+EGFR+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation</span></div><div class="casAuthors">Suda, Kenichi; Tomizawa, Kenji; Mitsudomi, Tetsuya</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-60</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  KRAS and epidermal growth factor receptor (EGFR) are the two most frequently mutated proto-oncogenes in adenocarcinoma of the lung.  The occurrence of these two oncogenic mutations is mutually exclusive, and they exhibit many contrasting characteristics such as clin. background, pathol. features of patients harboring each mutation, and prognostic or predictive implications.  Lung cancers harboring the EGFR mutations are remarkably sensitive to EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib.  This discovery has dramatically changed the clin. treatment of lung cancer in that it almost doubled the duration of survival for lung cancer patients with an EGFR mutation.  In this review, we describe the features of KRAS mutations in lung cancer and contrast these with the features of EGFR mutations.  Recent strategies to combat lung cancer harboring KRAS mutations are also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprCfWXTA1K8LVg90H21EOLACvtfcHk0li6n-nvPaxztQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVOjtL0%253D&md5=dfeb54c1b4a68e501ee652d4b0ab57dc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs10555-010-9209-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-010-9209-4%26sid%3Dliteratum%253Aachs%26aulast%3DSuda%26aufirst%3DK.%26aulast%3DTomizawa%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DBiological%2520and%2520clinical%2520significance%2520of%2520KRAS%2520mutations%2520in%2520lung%2520cancer%253A%2520an%2520oncogenic%2520driver%2520that%2520contrasts%2520with%2520EGFR%2520mutation%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2010%26volume%3D29%26spage%3D49%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Gately, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Flaherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K.</span><span> </span><span class="NLM_article-title">The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC</span> <span class="citation_source-journal">J. Clin. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1136%2Fjclinpath-2011-200275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=22039281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1Chsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2012&pages=1-7&author=K.+Gatelyauthor=J.+O%E2%80%99Flahertyauthor=F.+Cappuzzoauthor=R.+Pirkerauthor=K.+Kerrauthor=K.+O%E2%80%99Byrne&title=The+role+of+the+molecular+footprint+of+EGFR+in+tailoring+treatment+decisions+in+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC</span></div><div class="casAuthors">Gately, Kathy; O'Flaherty, John; Cappuzzo, Frederico; Pirker, Robert; Kerr, Keith; O'Byrne, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">JCPAAK</span>;
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of patients with non-small-cell lung cancer (NSCLC) present with advanced disease, with targeted therapies providing some improvement in clin. outcomes.  The epidermal growth factor receptor (EGFR) tyrosine kinase (TK) plays an important role in the pathogenesis of NSCLC.  Tyrosine kinase inhibitors (TKIs), which target the EGFR TK domain, have proven to be an effective treatment strategy; however, patient responses to treatment vary considerably.  Therefore, the identification of patients most likely to respond to treatment is essential to optimize the benefit of TKIs.  Tumor-assocd. activating mutations in EGFR can identify patients with NSCLC who are likely to have a good response to TKIs.  Nonetheless, the majority of patients relapse within a year of starting treatment.  Studies of tumors at relapse have demonstrated expression of a T790M mutation in exon 20 of the EGFR TK domain in approx. 50% of cases.  Although conferring resistance to reversible TKIs, these patients may remain sensitive to new-generation irreversible/panerb inhibitors.  A no. of techniques have been employed for genotypic assessment of tumor-assocd. DNA to identify EGFR mutations, each of which has advantages and disadvantages.  This review presents an overview of the current methodologies used to identify such mol. markers.  Recent developments in technol. may make the monitoring of changes in patients' tumor genotypes easier in clin. practice, which may enable patients' treatment regimens to be tailored during the course of their disease, potentially leading to improved patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocEi-NA6vfibVg90H21EOLACvtfcHk0li6n-nvPaxztQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1Chsbg%253D&md5=b19dd64dfc23bfbcaef4ea7f6a5bd3bc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1136%2Fjclinpath-2011-200275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjclinpath-2011-200275%26sid%3Dliteratum%253Aachs%26aulast%3DGately%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Flaherty%26aufirst%3DJ.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DPirker%26aufirst%3DR.%26aulast%3DKerr%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26atitle%3DThe%2520role%2520of%2520the%2520molecular%2520footprint%2520of%2520EGFR%2520in%2520tailoring%2520treatment%2520decisions%2520in%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D2012%26volume%3D65%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Sarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28Iressa%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0li6n-nvPaxztQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DSarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528Iressa%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Orio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neveu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theleman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P.</span><span> </span><span class="NLM_article-title">Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">Caner Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4838</span><span class="NLM_x">–</span> <span class="NLM_lpage">4848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=9354447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4838-4848&author=J.+D.+Moyerauthor=E.+G.+Barbacciauthor=K.+K.+Iwataauthor=L.+Arnoldauthor=B.+Bomanauthor=A.+Cunninghamauthor=C.+Di+Orioauthor=J.+Dotyauthor=M.+J.+Morinauthor=M.+P.+Moyerauthor=M.+Neveuauthor=V.+A.+Pollackauthor=L.+R.+Pustilnickauthor=M.+M.+Reynoldsauthor=D.+Sloanauthor=A.+Thelemanauthor=P.+Miller&title=Induction+of+apoptosis+and+cell+cycle+arrest+by+CP-358%2C774%2C+an+inhibitor+of+epidermal+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Moyer, James D.; Barbacci, Elsa G.; Iwata, Kenneth K.; Arnold, Lee; Boman, Bruce; Cunningham, Ann; Diorio, Catherine; Doty, Jonathan; Morin, Michael J.; Moyer, Mikel P.; Neveu, Mark; Pollack, Vincent A.; Pustilnik, Leslie R.; Reynolds, Margaret M.; Sloan, Don; Theleman, April; Miller, Penny</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4838-4848</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype.  CP-358774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.  This inhibition is selective for EGFR tyrosine kinase relative to other tyrosine kinases we have examd., both in assays of isolated kinases and whole cells.  At doses of 100 mg/kg, CP-358774 completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice.  CP-358774 inhibits the proliferation of DiFi human colon tumor cells at submicromolar concns. in cell culture and blocks cell cycle progression at the G1 phase.  This inhibitor produces a marked accumulation of retinoblastoma protein in its underphosphorylated form and accumulation of p27KIP1 in DiFi cells, which may contribute to the cell cycle block.  Inhibition of the EGFR also triggers apoptosis in these cells as detd. by formation of DNA fragments and other criteria.  These results indicate that CP-358774 has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation or survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghArQOnGlkbVg90H21EOLACvtfcHk0li4EfKqGzgLew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D&md5=0a6e9697bf290d8e7c44cbe2a125e0b1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DBoman%26aufirst%3DB.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DDi%2BOrio%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DM.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DNeveu%26aufirst%3DM.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DPustilnick%26aufirst%3DL.%2BR.%26aulast%3DReynolds%26aufirst%3DM.%2BM.%26aulast%3DSloan%26aufirst%3DD.%26aulast%3DTheleman%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DInduction%2520of%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520by%2520CP-358%252C774%252C%2520an%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DCaner%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4838%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">S16</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=S16-22&issue=Suppl+2&author=M.+Ladanyiauthor=W.+Pao&title=Lung+adenocarcinoma%3A+guiding+EGFR-targeted+therapy+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DLung%2520adenocarcinoma%253A%2520guiding%2520EGFR-targeted%2520therapy%2520and%2520beyond%26jtitle%3DMod.%2520Pathol.%26date%3D2008%26volume%3D21%26issue%3DSuppl%25202%26spage%3DS16%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0li4EfKqGzgLew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liK2EAC5ENCGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butts, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiappori, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dasse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheeran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, P. D.</span><span> </span><span class="NLM_article-title">Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3936</span><span class="NLM_x">–</span> <span class="NLM_lpage">3944</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=3936-3944&author=P.+A.+Janneauthor=J.+von+Pawelauthor=R.+B.+Cohenauthor=L.+Crinoauthor=C.+A.+Buttsauthor=S.+S.+Olsonauthor=I.+A.+Eisemanauthor=A.+A.+Chiapporiauthor=B.+Y.+Yeapauthor=P.+F.+Lenehanauthor=K.+Dasseauthor=M.+Sheeranauthor=P.+D.+Bonomi&title=Multicenter%2C+randomized%2C+phase+II+trial+of+CI-1033%2C+an+irreversible+pan-ERBB+inhibitor%2C+for+previously+treated+advanced+non+small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DR.%2BB.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DButts%26aufirst%3DC.%2BA.%26aulast%3DOlson%26aufirst%3DS.%2BS.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DChiappori%26aufirst%3DA.%2BA.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DDasse%26aufirst%3DK.%26aulast%3DSheeran%26aufirst%3DM.%26aulast%3DBonomi%26aufirst%3DP.%2BD.%26atitle%3DMulticenter%252C%2520randomized%252C%2520phase%2520II%2520trial%2520of%2520CI-1033%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520for%2520previously%2520treated%2520advanced%2520non%2520small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D3936%26epage%3D3944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nokihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarashina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">891</span><span class="NLM_x">–</span> <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1007%2Fs00280-011-1738-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=22071596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVCku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=891-899&author=H.+Murakamiauthor=T.+Tamuraauthor=T.+Takahashiauthor=H.+Nokiharaauthor=T.+Naitoauthor=Y.+Nakamuraauthor=K.+Nishioauthor=Y.+Sekiauthor=A.+Sarashinaauthor=M.+Shahidiauthor=N.+Yamamoto&title=Phase+I+study+of+continuous+afatinib+%28BIBW+2992%29+in+patients+with+advanced+non-small+cell+lung+cancer+after+prior+chemotherapy%2Ferlotinib%2Fgefitinib+%28LUX-Lung+4%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)</span></div><div class="casAuthors">Murakami, H.; Tamura, T.; Takahashi, T.; Nokihara, H.; Naito, T.; Nakamura, Y.; Nishio, K.; Seki, Y.; Sarashina, A.; Shahidi, M.; Yamamoto, N.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose This Phase I study detd. the max.-tolerated dose (MTD) of afatinib (Afatinib is an investigational compd. and its safety and efficacy have not yet been established) (BIBW 2992; trade name not yet approved by FDA), an irreversible inhibitor of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor (HER)1 and 2, up to a dose of 50 mg/day in advanced non-small cell lung cancer (NSCLC), to establish the recommended dose for Phase II.  Methods Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily.  The MTD was detd. based on dose-limiting toxicities (DLTs); other assessments included safety, pharmacokinetic profile, antitumor activity according to response evaluation criteria in solid tumors and EGFR/HER1 mutation anal. where possible.  Results Twelve evaluable patients were treated at doses of 20-50 mg/day.  One DLT was obsd. at 50 mg/day in Course 1 (Grade 3 mucositis).  The most frequent drug-related adverse events were diarrhoea, dry skin, stomatitis, rash, paronychia and anorexia; most were Grade 1 or 2.  Six out of 12 patients had tumor size redns.; durable stable disease was achieved in three patients including one with EGFR/HER1 exon 19 and T790 M mutations.  Peak plasma concns. of afatinib were reached 3-4 h after administration and declined with a half-life of 30-40 h.  Afatinib 50 mg/day was well tolerated with an acceptable safety profile during Phase I. Conclusion Recommended dose for Phase II was defined as 50 mg/day for Japanese patients; the same as for non-Japanese patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW-SUAjXGY-7Vg90H21EOLACvtfcHk0liK2EAC5ENCGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVCku7c%253D&md5=154c8fe17cadb847db769258c29e6643</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs00280-011-1738-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-011-1738-1%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DSarashina%26aufirst%3DA.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DPhase%2520I%2520study%2520of%2520continuous%2520afatinib%2520%2528BIBW%25202992%2529%2520in%2520patients%2520with%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520after%2520prior%2520chemotherapy%252Ferlotinib%252Fgefitinib%2520%2528LUX-Lung%25204%2529%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D69%26spage%3D891%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ananthakrishnan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J. C.</span><span> </span><span class="NLM_article-title">Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3076</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1200%2FJCO.2009.27.9414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=20479403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=3076-3083&author=L.+V.+Sequistauthor=B.+Besseauthor=T.+J.+Lynchauthor=V.+A.+Millerauthor=K.+K.+Wongauthor=B.+Gitlitzauthor=K.+Eatonauthor=C.+Zacharchukauthor=A.+Freymanauthor=C.+Powellauthor=R.+Ananthakrishnanauthor=S.+Quinnauthor=J.+C.+Soria&title=Neratinib%2C+an+irreversible+pan-ErbB+receptor+tyrosine+kinase+inhibitor%3A+results+of+a+phase+II+trial+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Neratinib, an irreversible Pan-ErbB, receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Sequist, Lecia V.; Besse, Benjamin; Lynch, Thomas J.; Miller, Vincent A.; Wong, Kwok K.; Gitlitz, Barbara; Eaton, Keith; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3076-3083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations.  Resistance emerges after 9 to 12 mo, primarily mediated by the T790M resistance mutation.  We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.  Patients with advanced NSCLC underwent EGFR sequencing of available tumor tissue at enrollment.  Those with ≥ 12 wk of prior TKI therapy were placed in arm A if they were EGFR mutation pos. or arm B if they were wild-type.  Arm C included TKI-naive patients with adenocarcinoma and light smoking histories (≤ 20 pack-years).  All patients received daily oral neratinib, initially at 320 mg but subsequently reduced to 240 mg because of excessive diarrhea.  The primary end point was objective response rate (RR).  167 Patients were treated: 91 in arm A, 48 in arm B, and 28 in arm C.  Diarrhea was the most common toxicity; grade 3 incidence was 50% at 320 mg but improved to 25% after dose redn.  The RR was 3% in arm A and zero in arms B and C.  No patients with known T790M responded.  Notably, three of four patients with an exon 18 G719X EGFR mutation had a partial response and the fourth had stable disease lasting 40 wk.  Neratinib had low activity in patients with prior benefit from TKIs and in TKI-naive patients, potentially because of insufficient bioavailability from diarrhea-imposed dose limitation.  Responses were seen in patients with the rare G719X EGFR mutation, highlighting the importance of obtaining comprehensive genetic information on trials of targeted agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Z3gsvbWbOrVg90H21EOLACvtfcHk0lhhbeItPrZy1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlaju7c%253D&md5=460e088e58919bbfcf8c153772f157b0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.27.9414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.27.9414%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGitlitz%26aufirst%3DB.%26aulast%3DEaton%26aufirst%3DK.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DFreyman%26aufirst%3DA.%26aulast%3DPowell%26aufirst%3DC.%26aulast%3DAnanthakrishnan%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DNeratinib%252C%2520an%2520irreversible%2520pan-ErbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D3076%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seog Heo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbot, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span> </span><span class="NLM_article-title">Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3337</span><span class="NLM_x">–</span> <span class="NLM_lpage">3344</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1200%2FJCO.2011.40.9433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=22753918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3337-3344&author=S.+S.+Ramalingamauthor=F.+Blackhallauthor=M.+Krzakowskiauthor=C.+H.+Barriosauthor=K.+Parkauthor=I.+Boverauthor=D.+Seog+Heoauthor=R.+Rosellauthor=D.+C.+Talbotauthor=R.+Frankauthor=S.+P.+Letrentauthor=A.+Ruiz-Garciaauthor=I.+Taylorauthor=J.+Q.+Liangauthor=A.+K.+Campbellauthor=J.+O%E2%80%99Connellauthor=M.+Boyer&title=Randomized+phase+II+study+of+dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-human+epidermal+growth+factor+receptor+inhibitor%2C+versus+erlotinib+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of dacomitinib (PF-00299804), and irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Blackhall, Fiona; Krzakowski, Maciej; Barrios, Carlos H.; Park, Keunchil; Bover, Isabel; Heo, Dae Seog; Rosell, Rafael; Talbot, Denis C.; Frank, Richard; Letrent, Stephen P.; Ruiz-Garcia, Ana; Taylor, Ian; Liang, Jane Q.; Campbell, Alicyn K.; O'Connell, Joseph; Boyer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3337-3344</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR1/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).  Patients and Methods Patients with NSCLC, Eastern Cooperative Oncol. Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily.  Results One hundred eighty-eight patients were randomly assigned.  Treatment arms were balanced for most clin. and mol. characteristics.  Median progression-free survival (PFS; primary end point) was 2.86 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (hazard ratio [HR] = 0.66; 95% CI, 0.47 to 0.91; two-sided P = .012); in patients with KRAS wild-type tumors, median PFS was 3.71 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (HR = 0.55; 95% CI, 0.35 to 0.85; two-sided P = .006); and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 mo for patients treated with dacomitinib and 1.84 mo for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37 to 0.99; two-sided P = .043).  Median overall survival was 9.53 mo for patients treated with dacomitinib and 7.44 mo for patients treated with erlotinib (HR = 0.80; 95% CI, 0.56 to 1.13; two-sided P = .205).  Adverse event-related discontinuations were uncommon in both arms.  Common treatment-related adverse events were dermatol. and gastrointestinal, predominantly grade 1 to 2, and more frequent with dacomitinib.  Conclusion Dacomitinib demonstrated significantly improved PFS vs. erlotinib, with acceptable toxicity.  PFS benefit was obsd. in most clin. and mol. subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHl-bReesXsbVg90H21EOLACvtfcHk0lhhbeItPrZy1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK&md5=bdc76102e0ae37fb3f5307c285f952d4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.9433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.9433%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DKrzakowski%26aufirst%3DM.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DSeog%2BHeo%26aufirst%3DD.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTalbot%26aufirst%3DD.%2BC.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DLetrent%26aufirst%3DS.%2BP.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DJ.%2BQ.%26aulast%3DCampbell%26aufirst%3DA.%2BK.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DM.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-human%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520versus%2520erlotinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3337%26epage%3D3344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">S146</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=S146-149&author=G.+J.+Riely&title=Second-generation+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DSecond-generation%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2008%26volume%3D3%26spage%3DS146%26epage%3D149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lhhbeItPrZy1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+J.+Zhouauthor=D.+Ercanauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0ljiOaIPv4I2Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0ljiOaIPv4I2Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Fukumura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashiwagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">The role of nitric oxide in tumour progression</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnrc1910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=16794635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=521-534&author=D.+Fukumuraauthor=S.+Kashiwagiauthor=R.+K.+Jain&title=The+role+of+nitric+oxide+in+tumour+progression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The role of nitric oxide in tumour progression</span></div><div class="casAuthors">Fukumura, Dai; Kashiwagi, Satoshi; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">521-534</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) and nitric oxide synthases are ubiquitous in malignant tumors and are known to exert both pro- and anti-tumor effects.  We summarize our current understanding of the role of NO in tumor progression, esp. in relation to angiogenesis and vascular functions.  We also discuss potential strategies for cancer treatment that modulate NO prodn. and/or its downstream signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorTlzSMm-9dbVg90H21EOLACvtfcHk0ljiOaIPv4I2Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFehu7Y%253D&md5=ee546d1b8e37e216ef373374ba15209c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc1910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1910%26sid%3Dliteratum%253Aachs%26aulast%3DFukumura%26aufirst%3DD.%26aulast%3DKashiwagi%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DThe%2520role%2520of%2520nitric%2520oxide%2520in%2520tumour%2520progression%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D521%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Bonavida, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baritaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huerta-Yepez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.</span><span> </span><span class="NLM_article-title">Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases</span> <span class="citation_source-journal">Nitric Oxide</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=152-157&author=B.+Bonavidaauthor=S.+Baritakiauthor=S.+Huerta-Yepezauthor=M.+I.+Vegaauthor=D.+Chatterjeeauthor=K.+Yeung&title=Novel+therapeutic+applications+of+nitric+oxide+donors+in+cancer%3A+roles+in+chemo-+and+immunosensitization+to+apoptosis+and+inhibition+of+metastases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonavida%26aufirst%3DB.%26aulast%3DBaritaki%26aufirst%3DS.%26aulast%3DHuerta-Yepez%26aufirst%3DS.%26aulast%3DVega%26aufirst%3DM.%2BI.%26aulast%3DChatterjee%26aufirst%3DD.%26aulast%3DYeung%26aufirst%3DK.%26atitle%3DNovel%2520therapeutic%2520applications%2520of%2520nitric%2520oxide%2520donors%2520in%2520cancer%253A%2520roles%2520in%2520chemo-%2520and%2520immunosensitization%2520to%2520apoptosis%2520and%2520inhibition%2520of%2520metastases%26jtitle%3DNitric%2520Oxide%26date%3D2008%26volume%3D19%26spage%3D152%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Riganti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miraglia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viarisio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costamagna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pescarmona, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghigo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosia, A.</span><span> </span><span class="NLM_article-title">Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">525</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15695394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1KqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=516-525&author=C.+Rigantiauthor=E.+Miragliaauthor=D.+Viarisioauthor=C.+Costamagnaauthor=G.+Pescarmonaauthor=D.+Ghigoauthor=A.+Bosia&title=Nitric+oxide+reverts+the+resistance+to+doxorubicin+in+human+colon+cancer+cells+by+inhibiting+the+drug+efflux"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux</span></div><div class="casAuthors">Riganti, Chiara; Miraglia, Erica; Viarisio, Daniele; Costamagna, Costanzo; Pescarmona, Gianpiero; Ghigo, Dario; Bosia, Amalia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">516-525</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is a phenomenon by which cancer cells evade the cytotoxic effects of chemotherapeutic agents.  It may occur through different mechanisms, but it often correlates with the overexpression of integral membrane transporters, such as P-glycoprotein (Pgp) and MDR-assocd. proteins (MRPs), with resulting decrease of drug accumulation and cellular death.  Doxorubicin is a substrate of Pgp; it has been suggested that its ability to induce synthesis of nitric oxide (NO) could explain, at least in part, its cytotoxic effects.  Culturing the human epithelial colon cell line HT29 in the presence of doxorubicin, we obtained a doxorubicin-resistant (HT29-dx) cell population: these cells accumulated less intracellular doxorubicin, were less sensitive to the cytotoxic effects of doxorubicin and cisplatin, overexpressed Pgp and MRP3, and exhibited a lower NO prodn. (both under basal conditions and after doxorubicin stimulation).  The resistance to doxorubicin could be reversed when HT29-dx cells were incubated with inducers of NO synthesis (cytokines mix, atorvastatin).  Some NO donors increased the drug accumulation in HT29-dx cells in a guanosine-3':5'-cyclic monophosphate-independent way; this effect was assocd. with a marked redn. of doxorubicin efflux rate in HT29 and HT29-dx cells, and tyrosine nitration in the MRP3 protein.  Our results suggest that onset of MDR and impairment of NO synthesis are related; this finding could point to a new strategy to reverse doxorubicin resistance in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTu2bqm5O1DbVg90H21EOLACvtfcHk0lhG2ZjKeWV25Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1KqtQ%253D%253D&md5=e0e7757d954680c9b9eb3470a1758da6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiganti%26aufirst%3DC.%26aulast%3DMiraglia%26aufirst%3DE.%26aulast%3DViarisio%26aufirst%3DD.%26aulast%3DCostamagna%26aufirst%3DC.%26aulast%3DPescarmona%26aufirst%3DG.%26aulast%3DGhigo%26aufirst%3DD.%26aulast%3DBosia%26aufirst%3DA.%26atitle%3DNitric%2520oxide%2520reverts%2520the%2520resistance%2520to%2520doxorubicin%2520in%2520human%2520colon%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520drug%2520efflux%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D516%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Sullivan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, C. H.</span><span> </span><span class="NLM_article-title">Chemosensitization of cancer by nitric oxide</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1113</span><span class="NLM_x">–</span> <span class="NLM_lpage">1123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.2174%2F138161208784246225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=18473858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslKrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1113-1123&author=R.+Sullivanauthor=C.+H.+Graham&title=Chemosensitization+of+cancer+by+nitric+oxide"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Chemosensitization of cancer by nitric oxide</span></div><div class="casAuthors">Sullivan, Richard; Graham, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1113-1123</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent evidence from exptl. and clin. studies links the development of intratumoral hypoxia and oxidative stress with malignant progression.  Cellular adaptation induced by these environmental stresses is also assocd. with the emergence of drug resistant populations.  This adaptation is most likely a multifactorial process involving coordination of various stress-induced signaling pathways, including those regulated by hypoxia-inducible factor-1 (HIF-1) and nuclear factor κB (NF-κB) together with their down-stream targets linked to resistance mechanisms.  Exptl. data suggest that treatment of human cancer cells with nitric oxide (NO) and NO mimetic agents can effectively restore the sensitivity of resistant populations to the cytotoxic effects of chemotherapeutics both in vitro and in vivo.  Furthermore, preliminary results from Phase II clin. trials evaluating NO as an adjuvant to chemotherapy are promising.  The present review highlights the significance of intratumoral hypoxia and oxidative stress in the emergence of multidrug resistance, and summarizes the latest data demonstrating the chemosensitizing ability of NO.  To date, the specific mechanisms through which NO restores sensitivity to anticancer agents are not clearly understood.  However, the data suggest that chemosensitization is likely to involve NO-mediated activities assocd. with both prevention and inhibition of cellular drug resistance mechanisms.  Potential mechanisms contributing to the chemosensitizing activity of NO include vascular changes that promote increased blood delivery and tumor oxygenation, antioxidant effects and down-regulation of the glutathione detoxification/redox buffering system, inhibition of key transcription factors such as HIF-1 and NF-κB, as well as inhibition of drug efflux transporters and DNA repair enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgKEY49it3dbVg90H21EOLACvtfcHk0ljLmYxfXNe0KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslKrsrw%253D&md5=e0a4aa6a7c684d5e8cc68e2c88dffe09</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138161208784246225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161208784246225%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DR.%26aulast%3DGraham%26aufirst%3DC.%2BH.%26atitle%3DChemosensitization%2520of%2520cancer%2520by%2520nitric%2520oxide%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2008%26volume%3D14%26spage%3D1113%26epage%3D1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Nakanishi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toi, M.</span><span> </span><span class="NLM_article-title">Nuclear factor-κB inhibitors as sensitizers to anticancer drugs</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnrc1588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15803156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=297-309&author=C.+Nakanishiauthor=M.+Toi&title=Nuclear+factor-%CE%BAB+inhibitors+as+sensitizers+to+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear factor-κB inhibitors as sensitizers to anticancer drugs</span></div><div class="casAuthors">Nakanishi, Chikashi; Toi, Masakazu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-309</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytotoxicity of chemotherapeutic agents is attributed to apoptosis.  Acquired resistance to the effects of chemotherapy has emerged as a significant impediment to effective cancer therapy.  One feature that cytotoxic treatments of cancer have in common is their activation of the transcription factor nuclear factor-κB (NF-κB), which regulates cell survival.  NF-κB activation suppresses the apoptotic potential of chemotherapeutic agents and contributes to resistance.  What evidence is there that inhibitors of NF-κB might promote apoptosis in cancer cells and can NF-κB inhibitors be used to overcome resistance to chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsXlm8lIyTbVg90H21EOLACvtfcHk0ljLmYxfXNe0KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7Y%253D&md5=4449832c63d81112812502b97d2fdaea</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnrc1588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1588%26sid%3Dliteratum%253Aachs%26aulast%3DNakanishi%26aufirst%3DC.%26aulast%3DToi%26aufirst%3DM.%26atitle%3DNuclear%2520factor-%25CE%25BAB%2520inhibitors%2520as%2520sensitizers%2520to%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D297%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Chang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billiar, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ha, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. M.</span><span> </span><span class="NLM_article-title">Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of IκB</span> <span class="citation_source-journal">Exp. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Femm.2004.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=15365250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVWmu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=311-324&author=K.+Changauthor=S.+J.+Leeauthor=I.+Cheongauthor=T.+R.+Billiarauthor=H.+T.+Chungauthor=J.+A.+Hanauthor=Y.+G.+Kwonauthor=K.+S.+Haauthor=Y.+M.+Kim&title=Nitric+oxide+suppresses+inducible+nitric+oxide+synthase+expression+by+inhibiting+post-translational+modification+of+I%CE%BAB"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of IκB</span></div><div class="casAuthors">Chang, Kwang; Lee, Seon-Jin; Cheong, Ilyoung; Billiar, Timothy R.; Chung, Hun-Taeg; Han, Jeong-A.; Kwon, Young-Guen; Ha, Kwon-Soo; Kim, Young-Myeong</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-324</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1226-3613</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Medical Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The expression of inducible nitric oxide synthase (iNOS) is a crit. factor in both normal physiol. functions and the pathogenesis of disease.  This study was undertaken to det. the mol. mechanism by which nitric oxide (NO) exerts neg. feedback regulation on iNOS gene expression.  Isolated rat hepatocytes stimulated with cytokines exhibited a marked increase in NO prodn. as well as iNOS mRNA and protein levels, which were significantly reduced by pretreatment of the NO donors S-nitroso-N-acetyl-D,L-penicillamine (SNAP) and V-PYRRO/NO.  This effect of SNAP was inhibited when NO was scavenged using red blood cells.  Pretreatment with oxidized SNAP, 8-Br-cGMP, NO2-, or NO3- did not suppress the cytokine-induced NO prodn.  Moreover, LPS/IFN-γ-stimulated RAW264.7 cells, which produce endogenous NO, expressed lower levels of iNOS, IL-1β, IL-6 and TNF-α mRNAs, without changes in their mRNA half-lives, than those in the presence of the iNOS inhibitor NG-monomethyl-L-arginine.  The iNOS gene transcription rate exhibited an 18-fold increase after cytokine stimulation, which was significantly inhibited by SNAP pretreatment.  SNAP also blocked cytokine-induced increase in NF-κB activation, iNOS promoter activity, nuclear translocation of cytosolic NF-κB p65 subunit, and IκBα degrdn., which correlated with its inhibitory effect on phosphorylation and ubiquitination of IκB.  These data indicate that NO down-regulates iNOS gene expression and NO prodn. by inhibiting the post-translational processes of IκBα thereby preventing NF-κB activation.  These results identify a novel neg. feedback mechanism whereby NO down-regulates iNOS gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5HdSQePfzd7Vg90H21EOLACvtfcHk0ljLmYxfXNe0KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVWmu7o%253D&md5=3ee24e7eb89b28c3900285b5ae5d2dec</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Femm.2004.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femm.2004.42%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DCheong%26aufirst%3DI.%26aulast%3DBilliar%26aufirst%3DT.%2BR.%26aulast%3DChung%26aufirst%3DH.%2BT.%26aulast%3DHan%26aufirst%3DJ.%2BA.%26aulast%3DKwon%26aufirst%3DY.%2BG.%26aulast%3DHa%26aufirst%3DK.%2BS.%26aulast%3DKim%26aufirst%3DY.%2BM.%26atitle%3DNitric%2520oxide%2520suppresses%2520inducible%2520nitric%2520oxide%2520synthase%2520expression%2520by%2520inhibiting%2520post-translational%2520modification%2520of%2520I%25CE%25BAB%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2004%26volume%3D36%26spage%3D311%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Bivona, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieronymus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">471</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=471&publication_year=2011&pages=523-526&author=T.+G.+Bivonaauthor=H.+Hieronymusauthor=J.+Parkerauthor=K.+Changauthor=M.+Taronauthor=R.+Rosellauthor=P.+Moonsamyauthor=K.+Dahlmanauthor=V.+A.+Millerauthor=C.+Costaauthor=G.+Hannonauthor=C.+L.+Sawyers&title=FAS+and+NF-%CE%BAB+signalling+modulate+dependence+of+lung+cancers+on+mutant+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DHieronymus%26aufirst%3DH.%26aulast%3DParker%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DK.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DDahlman%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DHannon%26aufirst%3DG.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DFAS%2520and%2520NF-%25CE%25BAB%2520signalling%2520modulate%2520dependence%2520of%2520lung%2520cancers%2520on%2520mutant%2520EGFR%26jtitle%3DNature%26date%3D2011%26volume%3D471%26spage%3D523%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Aguirre, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boiani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerecetto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pintos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymondo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arredondo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacheco, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basombrio, M. A.</span><span> </span><span class="NLM_article-title">Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies</span> <span class="citation_source-journal">Pharmazie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2006&pages=54-59&author=G.+Aguirreauthor=M.+Boianiauthor=H.+Cerecettoauthor=M.+Fernandezauthor=M.+Gonzalezauthor=E.+Leonauthor=C.+Pintosauthor=S.+Raymondoauthor=C.+Arredondoauthor=J.+P.+Pachecoauthor=M.+A.+Basombrio&title=Furoxan+derivatives+as+cytotoxic+agents%3A+preliminary+in+vivo+antitumoral+activity+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAguirre%26aufirst%3DG.%26aulast%3DBoiani%26aufirst%3DM.%26aulast%3DCerecetto%26aufirst%3DH.%26aulast%3DFernandez%26aufirst%3DM.%26aulast%3DGonzalez%26aufirst%3DM.%26aulast%3DLeon%26aufirst%3DE.%26aulast%3DPintos%26aufirst%3DC.%26aulast%3DRaymondo%26aufirst%3DS.%26aulast%3DArredondo%26aufirst%3DC.%26aulast%3DPacheco%26aufirst%3DJ.%2BP.%26aulast%3DBasombrio%26aufirst%3DM.%2BA.%26atitle%3DFuroxan%2520derivatives%2520as%2520cytotoxic%2520agents%253A%2520preliminary%2520in%2520vivo%2520antitumoral%2520activity%2520studies%26jtitle%3DPharmazie%26date%3D2006%26volume%3D61%26spage%3D54%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span> </span><span class="NLM_article-title">Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4834</span><span class="NLM_x">–</span> <span class="NLM_lpage">4838</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800167u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4834-4838&author=L.+Chenauthor=Y.+Zhangauthor=X.+Kongauthor=E.+Lanauthor=Z.+Huangauthor=S.+Pengauthor=D.+L.+Kaufmanauthor=J.+Tian&title=Design%2C+synthesis%2C+and+antihepatocellular+carcinoma+activity+of+nitric+oxide+releasing+derivatives+of+oleanolic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm800167u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800167u%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DLan%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DKaufman%26aufirst%3DD.%2BL.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520antihepatocellular%2520carcinoma%2520activity%2520of%2520nitric%2520oxide%2520releasing%2520derivatives%2520of%2520oleanolic%2520acid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4834%26epage%3D4838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span> </span><span class="NLM_article-title">Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">632</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=632-639&author=Z.+Huangauthor=Y.+Zhangauthor=L.+Zhaoauthor=Y.+Jingauthor=Y.+Laiauthor=L.+Zhangauthor=Q.+Guoauthor=S.+Yuanauthor=J.+Zhangauthor=L.+Chenauthor=S.+Pengauthor=J.+Tian&title=Synthesis+and+anti-human+hepatocellular+carcinoma+activity+of+new+nitric+oxide-releasing+glycosyl+derivatives+of+oleanolic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DJing%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520anti-human%2520hepatocellular%2520carcinoma%2520activity%2520of%2520new%2520nitric%2520oxide-releasing%2520glycosyl%2520derivatives%2520of%2520oleanolic%2520acid%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26spage%3D632%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ling, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span> </span><span class="NLM_article-title">Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3251</span><span class="NLM_x">–</span> <span class="NLM_lpage">3259</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1014814" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3251-3259&author=Y.+Lingauthor=X.+Yeauthor=Z.+Zhangauthor=Y.+Zhangauthor=Y.+Laiauthor=H.+Jiauthor=S.+Pengauthor=J.+Tian&title=Novel+nitric+oxide-releasing+derivatives+of+farnesylthiosalicylic+acid%3A+synthesis+and+evaluation+of+antihepatocellular+carcinoma+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm1014814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1014814%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26atitle%3DNovel%2520nitric%2520oxide-releasing%2520derivatives%2520of%2520farnesylthiosalicylic%2520acid%253A%2520synthesis%2520and%2520evaluation%2520of%2520antihepatocellular%2520carcinoma%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3251%26epage%3D3259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Kuntz, K.; Uehling, D. E.; Waterson, A. G.; Emmitte, K. A.; Stevens, K.; Shotwell, J. B.; Smith, S. C.; Nailor, K. E.; Salovich, J. M.; Wilson, B. J.; Cheung, M.; Mook, R. A.; Baum, E. W.; Moorthy, G.</span><span> </span><span class="NLM_article-title">Preparation of imidazopyridines as inhibitors of IGF-1R and IR and one or both of EGFR and ErbB2 kinases for treating neoplasm</span>. U.S. Pat. Appl. Publ. US 20080300242,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+Kuntz&author=D.+E.+Uehling&author=A.+G.+Waterson&author=K.+A.+Emmitte&author=K.+Stevens&author=J.+B.+Shotwell&author=S.+C.+Smith&author=K.+E.+Nailor&author=J.+M.+Salovich&author=B.+J.+Wilson&author=M.+Cheung&author=R.+A.+Mook&author=E.+W.+Baum&author=G.+Moorthy&title=Preparation+of+imidazopyridines+as+inhibitors+of+IGF-1R+and+IR+and+one+or+both+of+EGFR+and+ErbB2+kinases+for+treating+neoplasm"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520imidazopyridines%2520as%2520inhibitors%2520of%2520IGF-1R%2520and%2520IR%2520and%2520one%2520or%2520both%2520of%2520EGFR%2520and%2520ErbB2%2520kinases%2520for%2520treating%2520neoplasm%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Jares-Erijman, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jovin, T. M.</span><span> </span><span class="NLM_article-title">FRET imaging</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnbt896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=14595367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=1387-1395&author=E.+A.+Jares-Erijmanauthor=T.+M.+Jovin&title=FRET+imaging"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">FRET imaging</span></div><div class="casAuthors">Jares-Erijman, Elizabeth A.; Jovin, Thomas M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1387-1395</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Foerster (or Fluorescence) Resonance Energy Transfer (FRET) is unique in generating fluorescence signals sensitive to mol. conformation, assocn., and sepn. in the 1-10 nm range.  We introduce a revised photophys. framework for the phenomenon and provide a systematic catalog of FRET techniques adapted to imaging systems, including new approaches proposed as suitable prospects for implementation.  Applications extending from a single mol. to live cells will benefit from multidimensional microscopy techniques, particularly those adapted for optical sectioning and incorporating new algorithms for resolving the component contributions to images of complex mol. systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTN4i2irXbCLVg90H21EOLACvtfcHk0ljFiHaSI-GfpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosFOksbo%253D&md5=01814592b10786fdb8f660c4a23dfa78</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnbt896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt896%26sid%3Dliteratum%253Aachs%26aulast%3DJares-Erijman%26aufirst%3DE.%2BA.%26aulast%3DJovin%26aufirst%3DT.%2BM.%26atitle%3DFRET%2520imaging%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D1387%26epage%3D1395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine<sup>790</sup> → methionine<sup>790</sup> mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Coneski, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenfisch, M. H.</span><span> </span><span class="NLM_article-title">Nitric oxide release: part III. Measurement and reporting</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">3753</span><span class="NLM_x">–</span> <span class="NLM_lpage">3758</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=3753-3758&author=P.+N.+Coneskiauthor=M.+H.+Schoenfisch&title=Nitric+oxide+release%3A+part+III.+Measurement+and+reporting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConeski%26aufirst%3DP.%2BN.%26aulast%3DSchoenfisch%26aufirst%3DM.%2BH.%26atitle%3DNitric%2520oxide%2520release%253A%2520part%2520III.%2520Measurement%2520and%2520reporting%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2012%26volume%3D41%26spage%3D3753%26epage%3D3758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Fukumura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashiwagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">The role of nitric oxide in tumour progression</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">534</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm400463q&amp;key=10.1038%2Fnrc1910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm400463q&amp;key=16794635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm400463q&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFehu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=521-534&author=D.+Fukumuraauthor=S.+Kashiwagiauthor=R.+K.+Jain&title=The+role+of+nitric+oxide+in+tumour+progression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The role of nitric oxide in tumour progression</span></div><div class="casAuthors">Fukumura, Dai; Kashiwagi, Satoshi; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">521-534</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) and nitric oxide synthases are ubiquitous in malignant tumors and are known to exert both pro- and anti-tumor effects.  We summarize our current understanding of the role of NO in tumor progression, esp. in relation to angiogenesis and vascular functions.  We also discuss potential strategies for cancer treatment that modulate NO prodn. and/or its downstream signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorTlzSMm-9dbVg90H21EOLACvtfcHk0liMozTbkcOi0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFehu7Y%253D&md5=ee546d1b8e37e216ef373374ba15209c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrc1910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1910%26sid%3Dliteratum%253Aachs%26aulast%3DFukumura%26aufirst%3DD.%26aulast%3DKashiwagi%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DThe%2520role%2520of%2520nitric%2520oxide%2520in%2520tumour%2520progression%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D521%26epage%3D534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i42"><a href="/doi/suppl/10.1021/jm400463q">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_43058"></div></div></div></div></div><hr /></hr><p class="last">Description of the induction of apoptosis in H460 cells and compound purity measured by HPLC. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400463q/suppl_file/jm400463q_si_001.pdf">jm400463q_si_001.pdf (548.13 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400463q&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm400463q%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-11%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400463q" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a64c85f683cac","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
